Greetings

You have in your hands, or at your fingertips, the first edition of the American Academy of Pediatrics clinical practice guideline for evaluation and management of children and adolescents with overweight and obesity. Putting together this guideline was no small task, and the Academy is grateful to the efforts of all the professionals who contributed to the production of this document. This work is a true testament to their passion and dedication to combatting childhood and adolescent overweight and obesity.

The Subcommittee responsible for developing this guideline comprises a diverse group of professionals from a variety of disciplines representing both governmental entities and private institutions. Experts all, they are united by a common desire to provide the finest, most effective care and treatment to children and adolescents with overweight and obesity. Over the course of several months, the members of the Subcommittee reviewed the technical reports produced from the study review, then worked in concert to develop the Key Action Statements and Expert Consensus Recommendations contained within this guideline. These were crafted with meticulous care by the Subcommittee members, to align with current literature and to place appropriate emphasis on each statement.

While representing such a broad spectrum of perspectives, the members of this committee are all keenly aware of the multitude of barriers to treatment that patients and their families face. These barriers impact not only their access to treatment, but their ability to follow prescribed treatment plans. Whereas some patients are able to adapt the lifestyle changes and habitualize elements of their prescribed treatment plans, so many others struggle to do so for a wide variety of reasons. The members of the Subcommittee understand all of this. To assist with optimizing health equity and overcoming these barriers, guidance on a number of multilevel factors related to barriers to treatment have been included in this guideline. During the course of their work, members of the Subcommittee acknowledged that, although so much has been learned to advance the treatment of children and adolescents with overweight and obesity, there is still so much we have yet to learn.

to discover. The Subcommittee recognizes the importance that future studies will play in advancing our knowledge and understanding of this chronic disease, knowledge and understanding that will lead to the development of new and more effective treatments. Specific discussion about the needs for future research are included in the guideline.

It is the fervent hope of every member of the Subcommittee that this guideline and the resources that accompany it will provide you with a more complete understanding of the issues, factors, and needs of patients combating overweight and obesity, as well as successful treatment options to assist them in their battle. This guideline and the resources that accompany it are not only for you, they are because of you, and all that you do to care for each and every patient as if they were the most important one. Because, as we all know, they are.

Be well,
Doug Lunsford, Family Representative

I. INTRODUCTION

The current and long-term health of 14.4 million children and adolescents is affected by obesity, making it one of the most common pediatric chronic diseases. Long stigmatized as a reversible consequence of personal choices, obesity has complex genetic, physiologic, socioeconomic, and environmental contributors. As the environment has become increasingly obesogenic, access to evidence-based treatment has become even more crucial.

A significant milestone in the fight to counter misperceptions about obesity and its causes occurred in 1998, when the National Institutes of Health (NIH) designated obesity as a chronic disease. The NIH made a further commitment to necessary research in the “Strategic Plan for NIH Obesity Research,” released by the NIH Obesity Task Force in 2011. In 2013, on the basis of accumulating evidence, the American Medical Association recognized obesity as a complex, chronic disease that requires medical attention.

The scientific and medical community’s understanding of obesity is constantly evolving. Increased understanding of the impact of social determinants of health (SDOHS, see Definition of Terms section) on the chronic disease of obesity—along with heightened appreciation of the impact of the chronicity and severity of obesity comorbidities—has enabled broader and deeper understanding of the complexity of both obesity risk and treatment. Multiple randomized controlled trials and comparative effectiveness studies have yielded effective treatment strategies, demonstrating that, despite the complex nature of this disease, obesity treatment can be successful.

The knowledge and skills to treat childhood obesity have become necessities for clinical teams in pediatric primary and subspecialty care. For more than 2 decades, the American Academy of Pediatrics (AAP) and its members have had the opportunity to collaborate with multiple scientific and professional organizations to improve the clinical care of children with overweight and obesity. Notable milestones include the 1998 “Expert Committee Recommendations,” the 2007 “Expert Committee Recommendations,” the creation of the AAP Section on Obesity and founding of the Institute for Healthy Childhood Weight, both in 2013; and the Institute’s “Algorithm for the Assessment and Management of Childhood Obesity” in 2016.

This is the AAP’s first clinical practice guideline (CPG) outlining evidence-based evaluation and treatment of children and adolescents with overweight and obesity.

This guideline does not cover the prevention of obesity, which will be addressed in a forthcoming AAP policy statement.

The CPG also does not include guidance for overweight and obesity evaluation and treatment of children younger than 2 years. Children under the age of 2 were not part of the inclusion criteria for the evidence review, because it is difficult to practically define and measure excess adiposity in this age group. The CPG also does not discuss primary obesity prevention, as no studies reporting results of obesity prevention interventions met the inclusion criteria for the evidence review.

Nonetheless, the topics of obesity prevention and evaluation and treatment of children younger than 2 years are very important to reduce this threat to children’s
current and future health. Future CPGs may include these topics; in the meantime, information that may assist pediatricians and other pediatric health care providers (PHCPs) is included on the AAP Institution for Healthy Childhood Weight’s Web site (aap.org/obesitycpg). Further information on the CPG’s methodology and the writing committee’s approach is covered in subsequent sections.

The CPG contains Key Action Statements (KASs), recommendations based on evidence from randomized controlled and comparative effectiveness trials as well as high-quality longitudinal and epidemiologic studies. The CPG writing Subcommittee uses the term “pediatricians and other pediatric health care providers” to include both pediatric primary and specialty care physicians and other medical providers as well as allied health care professionals, since all will encounter and can intervene with children with overweight, obesity, and obesity-related comorbidities. An algorithm with these KASs is provided in Appendix 1.

The KASs are supplemented by Consensus Recommendations that are based on expert opinion and address issues that were not part of the supporting technical reports (TRs). These consensus recommendations are supported by AAP-endorsed guidelines, clinical guidelines, and/or position statements from professional societies in the field and an extensive literature review.

This CPG stands on the shoulders of the pediatricians, other PHCPs, clinical researchers, and other stakeholders who collaborated to create the previous Expert Recommendations, which have been valued sources of guidance for health care professionals, clinical systems, parents, and other key stakeholders. It is our hope that this CPG will further advance the equitable care of children and adolescents with this chronic disease.

II. APPROACH

Childhood obesity results from a multifactorial set of socioecological, environmental, and genetic influences that act on children and families. Individuals exposed to adversity can have alterations in immunologic, metabolic, and epigenetic processes that increase risk for obesity by altering energy regulation.17–19 These influences tend to be more prevalent among children who have experienced negative environmental and SDoHs, such as racism.20 Overweight and obesity are more common in children who live in poverty,21,22 children who live in underresourced communities,23 in families that have immigrated,24 or in children who experience discrimination or stigma.25–32 As such, obesity does not affect all population groups equally.33 This fact highlights the importance of understanding the role of SDoHs as well as the social context of children and their families in the etiology and treatment of overweight and obesity.

Children with overweight and obesity benefit from health behavior and lifestyle treatment, which is a child-focused, family-centered, coordinated approach to care, coordinated by a patient-centered medical home, and may involve pediatricians, other pediatric health care providers (such as registered dietitian nutritionists [RDNs], psychologists, nurses, exercise specialists, and social workers), families, schools, communities, and health policy.35 Obesity is long-lasting and has persistent and negative health effects, attributable morbidity and mortality, and social and economic consequences that can impact a child’s quality of life.36–39 Because obesity is a chronic disease with escalating effects over time, a life course approach to identification and treatment should begin as early as possible and continue longitudinally through childhood, adolescence, and young adulthood, with transition into adult care.36,39–41

A. Health Equity Considerations

It is not uncommon for the differences in disease prevalence and outcomes among population groups to be described in terms of ethnicity, race, gender, and/or age and for these differences to be referred to as “disparities.”42 Disparity, however, only defines differences between groups without referring to inequities that cause these differences among populations (ie, “economic, civil-political, cultural, or environmental conditions that are required to generate parity and equality”42). Precisely because of the intertwining of inequities throughout the life course, health disparities can be found from maternal pregnancy outcomes through adolescence and, as such, can have an inevitable impact on childhood obesity.

This distinction between health disparities and inequities is particularly important when considering chronic disease, because: (1) obesity risk factors are embedded in the socioecological and environmental fabric of children’s lives; and (2) there is a danger of stigmatizing children with obesity and their families on the basis of race and ethnicity, age, and gender based on the disparities of outcome—with failure to recognize the systemic challenges that cause and maintain inequities.43,44

Inequities are often associated with each other45 and result in disparities in obesity risk and outcomes across the socioecological...
spectrum. Importantly, they represent neighborhood-, community-, and population-level factors that can be changed. Inequities that promote obesity in childhood can have a longitudinal effect leading to disparities in adult health and contributing to adult obesity and chronic disease.

The AAP is dedicated to reducing health disparities and increasing health equity for all children and adolescents. Attainment of these goals requires addressing inequities in available resources and systemic barriers to quality health care services for children with obesity. Inequalities in poverty, education, and address the social, economic, and environmental determinants of the chronic disease spectrum. Importantly, these factors may adversely affect quality of care, prevent patients with overweight and obesity from seeking medical care, and contribute to worsened morbidity and mortality, independent of excess adiposity.

C. Weight Bias and Stigma Considerations

Individuals with overweight and obesity experience weight stigma, victimization, teasing, and bullying, which contribute to binge eating, social isolation, avoidance of health care services, and decreased physical activity. Importantly, internalized weight bias has been associated with a negative impact on mental health. Collectively, these factors may adversely affect quality of care, prevent patients with overweight and obesity from seeking medical care, and contribute to worsened morbidity and mortality, independent of excess adiposity.

Pediatricians and other PHCPs have been—and remain—a source of weight bias. They first need to uncover and address their own attitudes regarding children with obesity. Understanding weight stigma and bias, and learning how to reduce it in the clinical setting, sets the stage for productive discussions and improved relationships between families and pediatricians or other PHCPs. Acknowledging the multitude of genetic and environmental factors that contribute to the complexity of obesity is an important mitigator in reducing weight stigma. Additional actions that reduce weight stigma include having appropriately sized office furniture, using appropriate capacity medical equipment, ensuring that aesthetic and/or instructional images posted in the office are inclusive, and avoiding stigmatizing language. Accordingly, the CPG utilizes person-first language (ie, using the term “child with obesity, rather than “obese child”) to avoid labeling the child. This practice is consistent with recommendations from the AAP and other national organizations, including the Academy of Nutrition and Dietetics, the Obesity Society, and the Obesity Action Coalition.

D. Adverse Childhood Experiences

Adverse childhood experiences (ACEs) are negative experiences caused by situations or events in the lives of children and adolescents that can pose threats to their current and future physical and mental health. These experiences range from family turmoil and violence to financial hardship, loss of a parent, divorce, abuse, and parental mental illness— to name a few. ACEs have been associated with obesity, both in adulthood and in childhood. Children and adolescents who live in poverty have a higher likelihood of experiencing ACEs, but risk for ACEs occurs at every income level. These experiences are written to inform pediatricians and other PHCPs about the standard practice of structuring health care services, and decreased physical activity. Importantly, internalized weight bias has been associated with a negative impact on mental health. Collectively, these factors may adversely affect quality of care, prevent patients with overweight and obesity from seeking medical care, and contribute to worsened morbidity and mortality, independent of excess adiposity.

Approach Summary

The recommendations in the CPG are child-centric and not specific to a particular health care setting and are written to inform pediatricians and other PHCPs about the standard
of care for evaluating and treating children with overweight and obesity and related comorbidities. To reflect the pediatrician’s and PHCP’s individual relationship with the child and family, the Subcommittee refers to “evaluation” (eg, for comorbidities) rather than “screening.” It is anticipated that a pediatrician’s or other PHCP’s setting, training, and expertise may moderate how elements of the CPG are implemented. Helpful resources can be found in accompanying implementation materials.

Understanding the underlying genetic, biological, environmental, and social determinants that pose risk for obesity is the bedrock of all evaluation and intervention. Allowing the family to have a safe space to understand and process the complexity of obesity and its chronicity requires tact, empathy, and humility. Achieving this goal enables the patient and family to gain the knowledge and understanding needed to recognize risk factors in their environment and behaviors, to honor cultural preferences, and to institute changes independently as well as under the guidance of a trusted and well-trained advocate—such as pediatricians and other PHCPs.

Finally, to emphasize important goals of treatment—both improved weight status and reduction or elimination of comorbidities—the Subcommittee uses the term intensive health behavior and lifestyle treatment (IHBLT) rather than "intensive lifestyle or behavioral modification" or "weight management." Additional definitions are listed in the next section.

III. DEFINITION OF TERMS

BMI: BMI is a measure used to screen for excess body adiposity; it is calculated by dividing a person’s weight in kilograms by the square of height in meters. For children and teens, BMI interpretation is age- and sex-specific. A child’s BMI category (eg, healthy weight, overweight) is determined using an age- and sex-specific percentile for BMI rather than the BMI cut-points used for adult categories.72

Capacity-building: "Building individual competencies and technical expertise, strengthening organizational capacities, and enabling supportive structural environments" to maintain or improve health services delivery.74

Children with special health care needs: Children with special health care needs are those who have, or who are at increased risk for, a chronic physical, developmental, behavioral, or emotional condition and who also require health and related services of a type or amount beyond that required by children generally.74

Chronic care model: The chronic care model identifies essential elements of a health care system that encourage high-quality chronic disease care: the community; the health system; self-management support; delivery system design; decision support, and clinical information systems.75

Chronic disease: The Centers for Disease Control and Prevention (CDC) defines chronic diseases broadly as "conditions that last 1 year or more and require ongoing medical attention or limit activities of daily living or both."76 Obesity is a chronic disease that results in altered anatomy, physiology, and metabolism—all of which adversely affect the physical and mental health trajectory of children and adolescents.77 The Obesity Medicine Association defines obesity as a "chronic, relapsing, multifactorial, neurobehavioral disease, wherein an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass physical forces, resulting in adverse metabolic, biomechanical, and psychosocial health consequences."78

Comprehensive obesity treatment: Comprehensive obesity treatment (COT) (Fig 1) includes79,80:

- Providing intensive, longitudinal treatment in the medical home
- Evaluating and monitoring child or adolescent for obesity-related medical and psychological comorbidities
- Identifying and addressing social drivers of health
- Using nonstigmatizing approaches to clinical treatment that honor unique individual qualities of each child and family
- Using motivational interviewing that addresses nutrition, physical activity, and health behavior change using evidence-based targets for weight reduction and health promotion
- Setting collaborative treatment goals not limited to BMI stabilization or reduction; including goals which reflect improvement or resolution of comorbidities, quality of life, self-image, and other goals related to holistic care
- Integrating weight management components and strategies across appropriate disciplines, which can include intensive health behavior and lifestyle treatment, with pharmacotherapy and metabolic and bariatric surgery if indicated
- Tailoring treatment to the ongoing and changing needs of the individual child or adolescent, and the family and community context

Comprehensive patient history: A comprehensive patient history includes a review of systems; family history; history of present illness;
and appropriate nutritional, physical activity, and psychosocial history.

**Family-based treatment:** Family-based treatment centers on the role of family at each stage of child development, includes consideration of the family’s critical role in supporting child health, and understands the unique contextual elements that affect the patient and family and influence treatment.

**Intensive health behavior and lifestyle treatment:** IHBLT educates and supports families in nutrition and physical activity changes that improve weight status and comorbidities and promote long-term health. IHBLT is most often effective when it occurs face-to-face, engages the whole family, and delivers at least 26 hours of nutrition, physical activity, and behavior change lessons over 3 to 12 months. IHBLT is foundational to COT and should continue longitudinally. It should be provided in conjunction with pharmacotherapy and metabolic and bariatric surgery if these treatments are indicated. IHBLT may be available in the form of a defined program and may be offered in pediatrician and other PHCP offices, medical centers or health systems, or in partnership with community organizations.

**Longitudinal care:** Care provided by a group of health care professionals who monitor a patient’s weight and other health indicators over a length of time sufficient to be associated with health improvements. Longitudinal care is continuous and coordinated and should include a plan for transition into adulthood.

**Overweight and obesity:** Overweight is defined as a BMI at or above the 85th percentile and below the 95th percentile for children and teens of the same age and sex. Obesity is defined as a BMI at or above the 95th percentile for children and teens of the same age and sex.

**Pediatricians and other pediatric health care providers:** For the purpose of this CPG, pediatricians and other pediatric health care providers refers to a qualified primary or tertiary care medical provider operating within their scope of practice and providing clinical care to children and adolescents. Examples include physicians, nurse practitioners, and physician assistants. (This document also refers to dietitians, licensed psychologists, exercise specialists, and other health care professionals who are not practicing medicine in the same manner.)

**Pediatric medical home:** The "pediatric medical home" delivers accessible, continuous, comprehensive, patient- and family-centered, coordinated, compassionate, and culturally effective health care. In this venue, well-trained pediatric physicians known to the child and family deliver or direct primary medical care.

**Pediatric obesity specialist or clinician with expertise:** Pediatric obesity specialists and clinicians with expertise are health care professionals with additional training in pediatric obesity medicine. Training may take the form of certification programs specific to obesity, fellowship, or a focus during specialty training, such as within endocrinology or gastroenterology specialty training. It may also take the form of an informal apprenticeship combined with professional workshops. For the purposes of this document, such training occurs within the context of recognized health care professional organizations.

**Person-first language:** According to the CDC, person-first language emphasizes the individual, not their disabilities. Hence, this CPG describes "children with obesity" or "adolescents with overweight," not "obese children" and/or "overweight adolescents."

**Severe obesity:** The expanded definition of “severe obesity” includes Class 2 and Class 3 obesity.

- Class 2 obesity (≥120% to <140% of the 95th percentile) or a BMI ≥ 35 kg/m² to <40 kg/m², whichever is lower based on age and sex
- Class 3 obesity (≥140% of the 95th percentile) or BMI ≥ 40 kg/m², whichever is lower based on age and sex

**Social determinants of health (SDoHs):** SDoHs are the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks. SDoHs can be grouped into 5 domains: economic stability, education access and quality, neighborhood and built environment, and social and community context.

**Treatment intensification:** Treatment intensification occurs through increased frequency of contact, increased length of treatment, or other means of increasing the dose of treatment. Treatment intensification could include additional health care professionals and/or additional methods, such as physical therapy, psychotherapy, medical nutrition therapy, pharmacotherapy, or metabolic and bariatric surgery.

**IV. METHODOLOGY**

**A. Subcommittee Process and Support**

In 2017, the CDC supported the AAP’s Institute for Healthy Child
Weight (the Institute) to conduct an evidence review of obesity treatment and obesity-related comorbidities. The Institute identified a methodologist and convened an evidence review committee consisting of pediatricians and researchers with expertise in pediatric obesity etiologies, diagnosis, and management. This committee, which met regularly in 2018 to 2019, followed established methods (elaborated on below) to create 2 TRs, which capture the evidence review committee’s findings and detail the search criteria, systematic review process, and research history. One TR is on overweight and obesity treatment (https://doi.org/10.1542/peds.2022-060643) and the second is on overweight and obesity comorbidities (https://doi.org/10.1542/peds.2022-060643).

The Subcommittee members were identified by the AAP and met virtually thereafter. Members were assigned sections and met virtually to complete their sections. Sections were reviewed by the chair or cochair and outstanding issues were resolved by group consensus. The parent member was an at-large member of all the writing groups and reviewed each section. Members’ potential conflicts of interest were identified and considered; no conflicts prevented Subcommittee members from participating in the CPG development process.

B. Scope of the Review

This review was designed to answer 2 overarching key questions (KQs). KQ1 was: “What are effective clinically based treatments for pediatric obesity?” KQ2 was: “What is the risk of comorbidities among children with obesity?”

The Subcommittee developed this focus based on the needs of pediatricians and other PHCPs and the evidence required to inform the future development of clinical practice guidelines. The review did not attempt to address treatment strategies for comorbidities (eg, hypertension [HTN], sleep apnea, type 2 diabetes mellitus [T2DM]), as other guidelines and reviews are available to guide such treatment.86–90

B.1. Rationale for KQ1: Intervention Studies

Pediatricians and other PHCPs are a trusted source of health information for parents, including on issues related to nutrition and physical activity, which are key components of obesity prevention and treatment. To meet this need, pediatricians and other PHCPs need to know the strategies that have high-quality evidence for effectiveness in preventing and treating obesity. Additionally, pediatricians and other PHCPs need guidance on which treatments are effective for their population and how to leverage available resources for obesity treatment efforts.

B.2. Rationale for KQ2: Comorbidity Studies

Previous recommendations have included assessments of comorbidities, including HTN, dyslipidemia, glucose, fatty liver disease, and others. It is not clear whether these assessments would lead to improved treatment strategies or outcomes. Additionally, it is not clear whether conducting these assessments would result in an adverse outcome. We examined specific conditions that were previously recommended or that would reasonably require screening: dyslipidemia, HTN, diabetes, fatty liver disease, depression, sleep apnea, and asthma. This is not intended to be a comprehensive list of all conditions comorbid with obesity but represents those most common and for which screening is potentially helpful.

C. Search Strategy

The Evidence Review Subcommittee searched PubMed and CENTRAL (for trials). The initial search was on April 6, 2018, and an additional search was conducted to update the review, covering the time period April 7, 2018 through February 15, 2020. Both searches followed the same procedures, which are described below.

The Subcommittee combined the searches for both KQ1 and KQ2 because of their significant overlap to more efficiently review studies. Because the focus was on interventions that are relevant to primary care, the Subcommittee did not search other discipline-specific databases, such as ERIC or PsycInfo.

The Subcommittee searched for studies of children or adolescents, with a focus on overweight, obesity, or weight status; involving pediatricians, other pediatric health care providers, health care, or other treatment or screening (KQ1); and
examining common comorbidities (KQ2). For both questions, the Subcommittee limited only using key words, not filters, to ensure the inclusion of the newest studies that had not yet been fully indexed. No date limits were placed on searches. In practice, this meant the Subcommittee reviewed studies from 1950 to 2020, although fewer than 2% of the studies were from before 1980.

The complete search strategies are included in Appendix 2 of the accompanying TRs (https://doi.org/10.1542/peds.2022-060642 and https://doi.org/10.1542/peds.2022-060643).

D. Inclusion Criteria

D.1. Inclusion Criteria Common to All Studies

All studies were required to include children ages 2 to 18 years. Studies could also include young adults up to age 25, if this population was stratified from older adult participants, as long as children younger than 18 years were also included in the study. Children could have other conditions (eg, asthma), as long as these conditions were not known to cause obesity, or be taking medications (eg, steroids) other than those known to be significantly obesogenic. Conditions known to cause obesity, such as Prader-Willi syndrome, obesogenic medication (eg, antipsychotics), or known genetic mutations associated with obesity (eg, melanocortin 4 receptor [MC4R]) were excluded.

All studies had to originate from Organization for Economic Cooperation and Development member countries and be available in English.

The race distribution of the samples is reported in the accompanying technical report evidence overview (Appendix 5 in TRs [https://doi.org/10.1542/peds.2022-060642 and https://doi.org/10.1542/peds.2022-060643]) to assist in interpretation of evidence within a health equity framework. The technical report authors notated in the “special populations” section of Appendix 5 when each study specifically focused on a lower-resourced population, as well as race and ethnicity distributions for all studies.

D.2. Inclusion Criteria for KQ1 (Intervention Studies)

The primary aim of the intervention studies had to be examination of an obesity prevention (intended for children of any weight status) or treatment (intended for children with overweight or obesity) intervention. The primary intended outcome had to be obesity, broadly defined, and not an obesity comorbidity. Studies of obesity interventions that reported other outcomes were included.

Interventions could involve any approach, including screening, counseling, medically managed weight loss, pharmaceutical treatment, or surgery. Regardless of the intervention components, there had to be some level of outpatient clinical involvement in the treatment (ie, not just referral to an outside program), such as screening or a clinic follow-up appointment. Interventions that occurred completely outside the scope of health care were excluded. For example, school-based obesity prevention programs or community-based activity programs with no pediatrician or other pediatric health care provider involvement were excluded.

The Subcommittee did not limit the search by study design but did report experimental and nonexperimental studies separately. Although nonexperimental designs were included, all studies had to have a relevant comparison group to be included in the TR on interventions (https://doi.org/10.1542/peds.2022-060642).

D.3. Inclusion Criteria for KQ2 (Comorbidity Studies)

The Subcommittee included studies that had a primary aim of comparing comorbidities among those with and without obesity or by severity of obesity. Obesity and the comorbidity had to be measured contemporaneously to reflect the practice of clinical screening. Obesity had to be categorized using a BMI-based measure into accepted categories (ie, healthy weight, overweight, class 1 obesity, class 2 obesity, class 3 obesity). These categories could be based on percentiles or z-scores and could use the distributions relevant to the studied population (eg, World Health Organization [WHO] or the CDC).91,92

All studies had to include 1 or more of the following comorbidities: lipids, blood pressure (BP), HTN, liver function, glucose metabolism, obstructive sleep apnea (OSA), asthma, or depression. These were chosen based on known associations with weight and potential for screening in the primary care setting.

The complete inclusion criteria are included in Appendix 3 of the accompanying TR on comorbidities (https://doi.org/10.1542/peds.2022-060643).

E. Review Process

The Subcommittee used Covidence to manage the review process (https://www.covidence.org/). Covidence is a program for online collaboration and management of systematic reviews. All abstracts were reviewed by 2 independent reviewers on the Subcommittee, who assessed the study’s inclusion in the full-text
review process. All conflicts were discussed and resolved. Articles excluded at this stage were assigned an exclusion reason, with a hierarchy, which is shown in Appendix 4 of the accompanying TRs (https://doi.org/10.1542/peds.2022-060642 and https://doi.org/10.1542/peds.2022-060643).

F. Data Extraction and Quality Assessment

All articles deemed to meet criteria for full text inclusion were categorized into different data extraction strategies. Randomized trials were given a quality assessment using the Cochrane Risk of Bias tool. The Subcommittee decided not to limit studies based on the study quality, because many of them did not reach “high-quality” status (ie, at low risk of bias for most or all domains in the Cochrane Risk of Bias Assessment) using any of the tools. This occurred largely because studies consisted primarily of behavioral interventions without the possibility of blinding.

All studies, regardless of group, were fully extracted by 2 reviewers, and conflicts were discussed and resolved. Intervention studies were categorized into 5 groups for data extraction.

F.1. Group 1 Extraction

Group 1 articles included randomized trials of diet or “lifestyle” interventions. Extraction of these articles included: sponsorship or funder, design, population information, provider type, detailed intervention strategies and intensity, and BMI-based outcomes. The Subcommittee also identified outcomes other than BMI, including lipids, glucose metabolism, BP, other laboratory values, other obesity measures, psychosocial outcomes, mental health, behaviors, and other outcomes (primarily parent BMI and child cardiovascular fitness).

The Subcommittee categorized the intensity of interventions in a manner consistent with the US Preventive Services Task Force (USPSTF) to allow for comparisons with its findings, into interventions with a dose (number of hours) of <5 hours; 5 to 25 hours; 26 to 51 hours; and 52 or more hours. All interventions occurred over less than 1 year. The Subcommittee conducted quality assessment for group 1 articles.

F.2. Group 2 Extraction

Group 2 articles included randomized controlled trials of pharmaceutical treatments. Similar information as above was extracted, using a brief description of the

FIGURE 1

Treatment experience of obesity as a chronic disease (this figure illustrates how longitudinal care is important to help address this chronicity and to address and buffer the social and contextual factors that influence a person’s health).

Longitudinal Non-Stigmatizing Care Coordinated Patient Centered Treatment Across Lifespan
Shared decision making with patient and family
Culturally competent care
Treatment coordinated in the medical home
Transition planning

Patient & Family & PCP/PHCP Partnership

Structural and Contextual Factors That Impede and Influence Health and Treatment
Access to Care
Weight Bias and Stigma
Obesogenic Environments
Adverse Child Experiences
Racism
Health Inequalities

Treatment intensity & support vary to address relapsing & remitting nature of obesity as a chronic disease
treatment and no categorization of intensity. These articles also received a quality assessment.

F.3. Groups 3 Through 5 Extraction

i) Groups 3 Through 5 Articles
Group 3 articles included nonrandomized comparative studies of diet and “lifestyle” treatments, group 4 articles included nonrandomized comparative studies of pharmaceutical treatment, and group 5 articles included any surgical studies.

Because of small numbers, the Subcommittee combined randomized and nonrandomized surgical studies. Brief treatment descriptions and BMI-related outcome data were extracted from these, but the Cochrane Risk of Bias tool was not used because these were observational designs.

F.4. KQ2 Extraction (Comorbidity Studies)

All studies were extracted by 2 reviewers who reported prevalence of comorbidities or mean values of laboratory parameters by weight classification. The Subcommittee included healthy weight, overweight, class 1 obesity, class 2 obesity, and class 3 obesity.

Because all classes of obesity severity were not always reported in the studies, these classes may include higher groups. For example, reporting of ≥95th percentile would only be considered class 1 obesity, although children at higher levels may be included. (See the TR for a detailed description of the KQ1 extraction procedures.)

G. Data Synthesis and Analysis

The Subcommittee’s primary method of data synthesis was narrative. To allow broad inclusion, the Subcommittee did not limit to specific designs or measures that would facilitate meta-analysis. The Subcommittee has reported on studies in each group based on their type and design and has reported findings for outcomes other than BMI.

The AAP policy statement, “Classifying Recommendations for Clinical Practice Guidelines,” was followed in designating aggregate evidence quality levels for the available evidence (Fig 2).93 The AAP policy statement is consistent with the grading recommendations advanced by the University of Oxford Centre for Evidence-Based Medicine.

Evidence grades were determined based on the grading matrix in Fig 2. Although we included both trials and observational studies in the technical reports, they are reviewed separately. Study design was considered in the aggregate evidence quality grades, as indicated by the matrix. We did not explicitly use risk of bias scores, but this information was available and used in the Subcommittee’s final assessment.

The Subcommittee reached consensus on the evidence, which was then used to develop the clinical practice guideline’s KASs. When the scientific evidence was at least “good” in quality and demonstrated a preponderance of benefits over harms, the KAS provides a “strong recommendation” or “recommendation.” Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present; clinicians are prudent to follow a recommendation but are advised to remain alert to new information and be sensitive to patient preferences (Fig 2).

Integrating evidence quality appraisal with an assessment of the anticipated balance between benefits and harms leads to a designation of a strong recommendation, recommendation, option, or no recommendation. Once the evidence level was determined, an evidence grade was assigned. AAP policy stipulates that the evidence
supporting each KAS be prospectively identified, appraised, and summarized, and an explicit link between quality levels and the grade of recommendation must be defined.

Possible grades of recommendations range from “A” to “D,” with “A” being the highest:

- Grade A: consistent level A studies;
- Grade B: consistent level B or extrapolations from level A studies;
- Grade C: level C studies or extrapolations from level B or level C studies;
- Grade D: level D evidence or troublingly inconsistent or inconclusive studies of any level; and

Level X: not an explicit level of evidence as outlined by the Centre for Evidence-Based Medicine. This level is reserved for interventions that are unethical or impossible to test in a controlled or scientific fashion and for which the preponderance of benefit or harm is overwhelming, precluding rigorous investigation.

When it was not possible to identify sufficient evidence, recommendations are based on the consensus opinion of the Subcommittee members.

VI. EPIDEMIOLOGY OF CHILDHOOD AND ADOLESCENT OBESITY

A. Prevalence of Childhood Obesity

Obesity is a common, complex, and often persistent chronic disease associated with serious health and social consequences. Childhood obesity is typically defined as having a BMI of ≥95th percentile for age and sex. Severe obesity is defined as BMI ≥ 120% of the 95th percentile for age and sex. The percentage of US children and adolescents affected by obesity has more than tripled from 5% in 1963 to 1965 to 19% in 2017 to 2018. In 2017 to 2018, the rise in obesity prevalence slowed in children younger than 6 years of age, but increases continued among certain populations, including adolescents and non-Hispanic Black and Mexican American youth. A predictive epidemiologic model estimates that if 2017 obesity trends hold, 57% of children aged 2 to 19 years will have obesity by the time they are 35 years of age, in 2050.

Obesity prevalence increases with increasing age. For example, in 2015 to 2016, the prevalence of obesity in children aged 2 to 5 years, 6 to 11 years, and 12 to 19 years was 13.9%, 18.4%, and 20.6%, respectively. Among children younger than 6 years, there were no significant trends in obesity from 1999 to 2018 for those 2 through 5 years of age. For children 6 through 11 years of age, significant trends in obesity show an increased prevalence from 15.8% in 1999 to 2002 to 19.3% in 2015 to 2018. Similarly, among adolescents 12 through 19 years, trends show increased obesity in the same time period from 16.0% to 20.9%. The proportion of children and youth 2 to 19 years of age with severe obesity increased from 4.9% in 1999 to 2000 to 7.9% in 2015 to 2016. The prevalence of severe obesity in youth 12 to 19 years of age in 2015 to 2018 was 7.6%.

The COVID-19 pandemic has significantly affected the lives and routines of children and adolescents. In 1 analysis, the pandemic period was associated with a doubling in the rate of BMI increase compared with the prepandemic period. Obesity prevention and management efforts should routinely include health care provider screening for BMI, food security, and social determinants of health and increased access to evidence-based pediatric weight management programs and food assistance resources to mitigate such effects in the future.

Disparities exist among children and youth with obesity, including, but not limited to, lower level of parental education, lower income, less access to healthier food options and safe and affordable physical activity opportunities, and higher incidence of ACEs. For example, among 5345 children 6 to 9 years of age, those whose parents had lower levels of education had a greater odds of having obesity compared with children whose parents had higher levels of education (odds ratio: 1.78; 95% confidence interval [CI]: 1.36 to 2.32). A cross-sectional analysis of 111,799 children in Massachusetts at the school district level showed that for every 1 percentage point increase in the proportion of children with low SES, there was a 1.17 percentage point increase in the prevalence of obesity. Furthermore, children with disabilities, including those with intellectual disabilities, are at higher risk for developing obesity than their peers without disabilities.

Finally, among 43,864 children and adolescents aged 10 to 17 years old, the presence of 2 or more early ACEs was associated with an increased odds of obesity later in childhood and adolescence (odds ratio: 1.21; 95% CI: 1.02 to 1.44). Together, these disparities highlight the burden of obesity in children from families of lower SES and the need to provide strategies to minimize these inequities.

Disparities also exist in obesity prevalence across ethnic and racial groups. In 2015 to 2018, non-Hispanic Black children and Mexican American youth 6 to 11 years of age had a higher prevalence of obesity compared with non-Hispanic white children (22.7% and 28.2% vs 15.5%, respectively). An analysis of the Indian Health Services National Data Warehouse showed that in 2015, the prevalence of overweight...
and obesity in American Indian and Alaska Native (AI/AN) children and adolescents was 18.5% and 29.7%, respectively.104

Among children 2 to 5 years of age from lower-income families enrolled in the Special Supplemental Nutrition Program for Women, Infants, and Children program, recent analyses indicate a modest but significant decline in obesity prevalence from 2010 (15.9%) to 2018 (14.4%).106 Among these children, obesity prevalence ranged across states from 8.5% to 20.2%; disparities persisted by race and ethnicity despite changes in prevalence over time.105

In addition, children and youth with special health care needs (CYSHCN) have a higher prevalence of obesity and lower levels of physical activity compared with children having typical growth and development.106–108 Among CYSHCN, a metaanalysis of studies of adolescents with intellectual disabilities found a pooled odds ratio of obesity of 1.80 compared with adolescents with typical development.102

B. Impact of Obesity in Childhood

Children with obesity commonly become adolescents and adults with obesity; severe obesity during adolescence increases the risk for severe obesity during young adulthood.109,110 BMI levels strongly track throughout childhood and adolescence and are predictive of high adult BMI.110

Obesity puts children and adolescents at risk for serious short- and long-term adverse health outcomes later in life, including cardiovascular disease, including HTN; dyslipidemia; insulin resistance; T2DM; and nonalcoholic fatty liver disease (NAFLD).111–113 Additionally, prediabetes in youth with obesity, compared with youth with normal weight, has been associated with elevated systolic blood pressure and low-density lipoprotein, and lower insulin sensitivity.114

In addition to physical and metabolic consequences, obesity in childhood and adolescence is associated with poor psychological and emotional health, increased stress, depressive symptoms, and low self-esteem.115 Several studies have determined that children of some racial and ethnic groups have a greater prevalence of comorbidities associated with childhood obesity, including HTN, T2DM, hypercholesterolemia, and depression, compared with non-Hispanic white children.116–120

KAS 1. Pediatricians and other PHCPs should measure height and wt, calculate BMI, and assess BMI percentile using age- and sex-specific CDC growth charts or growth charts for children with severe obesity at least annually for all children 2 to 18 y of age to screen for overweight (BMI ≥ 85th percentile to <95th percentile), obesity (BMI ≥ 95th percentile), and severe obesity (BMI ≥ 120% of the 95th percentile for age and sex).

Aggregate Evidence Quality

| Benefits | Easy to use; reproducible; improved identification of severe obesity; and improved ability to monitor improvements in weight status of youth with severe obesity. |
| Risks, harms, costs | Screening tool with both false negatives and false positives; may misclassify some populations; development, implementation, and use of separate growth charts for severe obesity requires identification of severe obesity (electronic health record decision prompts can support this); use of severe obesity growth charts may confer stigma associated with obesity; interpretation and explanation for families may be challenging. |
| Benefit-harm assessment | Benefit outweighs harm. |
| Intentional vagueness | Growth charts based on reference populations; need to screen or assess adiposity for children among specific populations (eg, CYSHCN); provider education on use and interpretation of charts; training requirements. |
| Role of patient preference | Patient and family inclusion and discussion is critical to shared decision-making. |
| Exclusions | >21 y |
| Strength | Moderate |
| Key references | 73, 123–130 |

Obesity in childhood and adolescence is associated with health care utilization and costs. For example, the most common primary conditions that cooccur with a secondary diagnosis of obesity and may increase costs and utilization include pregnancy, mood disorders, asthma, and diabetes.121 A modeling study has estimated that the total lifetime medical costs for 10-year-olds with lifelong obesity to be in the range of $9.4 to $14 billion for that cohort alone.122

Tracking obesity across the lifespan underscores the importance of primary and secondary prevention and treatment efforts early in life. These efforts include evaluating for obesity using BMI; identifying children at high risk and adolescents; providing or referring to evidence-based obesity treatments for children, youth, and their families; and addressing SDoHs.

VII. Diagnosis and Measurement

Although KAS 1 was not explicitly studied and referenced by the TR, most of the TR studies implicitly included measurement of height and weight and calculation and plotting of BMI as part of the study procedures. Thus, the concept of appropriate measurement, calculation, charting, and tracking is...
A. Use of BMI as a Screening and Diagnosis Tool

The gold standard measurement of body composition—dual-energy x-ray absorptiometry—to identify, locate, and quantify body fat, and can be expensive and difficult to implement. In clinical practice, BMI is frequently used as both a screening and diagnostic tool for detecting excess body fat because it is easy to use and inexpensive. BMI is a validated proxy measure of underlying adiposity that is replicable and can track weight status in children and adolescents.38,131,132 Because of its ease of use, BMI is also frequently used to follow a child or adolescent’s weight trajectory over time. The CDC BMI growth curves are frequently used to visualize BMI trajectory over time. Furthermore, BMI is often used to evaluate the success or impact of interventions to improve weight status.

For most individuals, BMI is generally well-correlated with direct measures of body fat, including skinfold thickness measurements, bioelectrical impedance, densitometry, and dual-energy x-ray absorptiometry.131,133–139

BMI has limitations, however, including high specificity and low sensitivity for detecting excess adiposity.132 BMI does not directly measure body composition and fat content and may under- or overdetect excess adiposity in certain racial and ethnic groups.140,141 Finally, children and adolescents who have high fat-free mass may have a high BMI and, as a result, be incorrectly classified as having overweight or obesity.142

The CDC’s 2000 Growth Charts are based on NHANES data from the 1960s through the early 1990s and include age- and sex-specific BMI-for-age charts.143 The CDC Growth Charts provide a historical comparison of children’s weight status relative to a time before the current obesity epidemic during that healthier growth patterns predominated; thus, percentiles on the Growth Charts do not equate to the current population distribution of BMI. The CDC Growth Charts are recommended for clinically tracking BMI patterns among US children and adolescents aged 2 to 18 years; although the CDC Growth Charts can be used for adolescents aged 19 to 21 years, in practice, most pediatricians and other PHCPs transition to adult BMI calculation and categorization for patients older than 18 years.143

“Overweight” is defined as a BMI at or above the 85th percentile and below the 95th percentile for age and sex; “obesity” is defined as a BMI at or above the 95th percentile for age and sex. “Severe obesity” is defined as a BMI equal to or more than 120% above the 95th percentile, which approximates the 99th percentile. The CDC Growth Charts were not intended to track growth of children with extremely high BMI values. Because of limited data on children and adolescents above the 97th percentile in the reference population, higher percentile curves could not be generated. Caution was recommended in extrapolation of percentiles beyond the 97th percentile, as this may generate unusual or unexpected results.144 In older adolescents, the adult cut-off of a BMI equal to or greater than 30 kg/m² can be used to define obesity if this value is less than the 95th percentile BMI for age and sex. Conversion of BMI percentiles to z-scores (a statistical measure that describes a value’s relationship to a population mean) derived from the CDC Growth Charts have historically been used for assessing longitudinal change in adiposity over time among children and adolescents with obesity.127 The change in z-score, however, may not accurately detect meaningful changes in weight status or comorbidity risk over time, particularly for children and adolescents with severe obesity caused by compression of z-scores corresponding to extremely high BMI values into a very narrow range.145 Consequently, investigators have proposed and described various alternative options, including using the degree to which, expressed in percentage, a particular BMI percentile was above the 95th percentile, or the median, for age and sex (referred to as percentage above the 95th percentile, or percentage above the median, respectively).

The “extended” method for calculating BMI z-scores and percentiles at extremely high BMI values was developed to address these limitations. This method incorporates data on children and adolescents with obesity from more recent NHANES surveys to better characterize the BMI distribution above the 95th percentile while retaining the 2000 CDC Growth Chart BMI distribution below the 95th percentile.

The CDC and the AAP recommend that weight status in children up to 2 years of age be tracked using the WHO’s weight-for-length, age-, and sex-specific charts.146,147 Specialized growth charts for children and adolescents with certain conditions, such as trisomy 21, can provide useful growth reference information for special populations. These charts may, however, be limited, for example, by the small sample sizes used in developing them, which may not be representative of all children and youth with trisomy 21.148

B. The Clinical Utility of BMI

BMI is a useful evaluation measure to clinically identify children with overweight and obesity for appropriate
Following comprehensive systematic reviews, the USPSTF issued a Grade B recommendation that pediatricians and other PHCPs screen children and adolescents aged 6 years or older annually for obesity—defined by BMI percentile—and offer, or refer children and adolescents to, a comprehensive, intensive, family-based behavioral treatment to improve weight status.\(^2^9\) (A “comprehensive, intensive behavioral treatment” was defined as a treatment of 26 hours or more over a period of 2 to 12 months.) (See Evaluation and Treatment sections.)

Furthermore, the AAP’s Bright Futures recommendations, which are based on systematic reviews and expert panels, offer prevention guidelines including annual assessment of BMI alongside dietary nutrition and physical activity counseling for children and adolescents starting at 2 years old\(^12^7,15^3\) (Appendix 2).

Appendix 2 describes the USPSTF recommendations, Bright Futures recommendations, and the recommendations reflected in this CPG’s KAS 1. All 3 sources recommend annual screening for excess weight using BMI, with the USPSTF beginning at 6 years old and both Bright Futures and this CPG beginning at age 2 years. For children or adolescents with a BMI \(\geq 95\text{th percentile}\) for age and sex, the USPSTF provides recommendations for primary care providers to offer, or refer them to, a comprehensive, family-based weight management intervention. Bright Futures recommends that primary care providers screen for excess weight and provide dietary nutrition and physical activity counseling for all children and adolescents with either overweight or obesity (BMI \(\geq 85\text{th and <95th percentile}\) for age and sex), Bright Futures also provides implementation tips and guidance for pediatricians and other PHCPs including, for example, providing counseling using motivational interviewing. Bright Futures offers guidance to states by offering a framework for meeting national performance standards under Title V. Finally, Bright Futures suggests how communities and families can support healthier lifestyles and prevention. This CPG recommends referral to evidence-based weight management interventions for all children 2 years and older who have a BMI \(\geq 95\text{th percentile}\) for age and sex (see KAS 1, above).

The practice of annual BMI measurement at well-child visits is recommended and central to the management and tracking of overweight and obesity in children.\(^12^7,15^3,15^4\) Limitations to this approach include missed opportunities to track and manage weight changes that occur in less than a 12-month period.\(^12^7,15^3\) However, other visit opportunities can be used to assess BMI outside the well-child visit.\(^15^3\) This CPG’s KAS on evaluation, based on the evidence described above, and in concordance with USPSTF and the Bright Futures recommendations, continues to highlight the critical importance of annual evaluation for excess weight and the provision of, or referral to, evidence-based interventions, as indicated, to promote the health and well-being of all children and adolescents.

C. Communication of BMI and Weight Status to Children and Parents

Despite its limitations, BMI is currently the most appropriate clinical tool to screen for excess adiposity and make the clinical diagnosis of overweight or obesity. Thus, the BMI must be communicated to the patient and family, as it guides next steps for comprehensive evaluation and treatment of obesity and related comorbidities. Weight-related discussions can be uncomfortable for clinicians who want to avoid stigmatizing children because of their shape or size. Avoiding this discussion may, however, cause delays or barriers to patients receiving evidence-based care. In addition, obesity stigma can result in patient avoidance of health care and disruption of clinician-patient relationships. There is evidence that having conversations about obesity can facilitate effective treatment.\(^15^5–15^7\)

Three key factors can facilitate a nonstigmatizing conversation about weight with patients and families:

1. Ask permission to discuss the patient’s BMI and/or weight.
2. Avoid labeling by using person-first language (“Child with obesity”; not “obese child” or “my patient is affected by obesity; not “my patient is obese”).\(^15^8\)
3. Use words that are perceived as neutral by parents, adolescents, and children. In several studies inclusive of diverse racial, ethnic, and rural and urban populations, preferred words include: “unhealthy weight, gaining too much weight for age, height, or health, demasiado peso para su salud (too much weight for his or her health).” Words perceived as most offensive include: “obese, morbidly obese, large, fat, overweight, chubby, or sobrepeso (overweight).”\(^15^6\)

Recognize that discussing BMI with children, adolescents, and families, even when using nonstigmatizing language and preferred terms, can
elicit strong emotional responses including sadness or anger. Acknowledging and validating those responses, while keeping the focus on the child’s health, can help to strengthen the relationship between the pediatrician or other PHCP and patient and family to support ongoing care.159

**VIII. RISK FACTORS FOR CHILD AND ADOLESCENT OVERWEIGHT AND OBESITY**

Obesity is a chronic disease that has a multifactorial etiology. Risk factors for overweight and obesity—many of which are SDoHs—include broader policies and systems factors; institutional or organizational (ie, school); neighborhood and community; and family, socioeconomic, environmental, ecological, genetic, and biological factors (Table 1).21,160 These individual, social, and contextual risk factors often overlap and/or influence one another and can operate longitudinally throughout childhood and adolescence, initiating weight gain and escalating existing obesity. Children and their families interact with their environment at all of these levels and have a unique and “insider’s” point of view that needs to be understood in delivering culturally sensitive care.161

Pediatricians and other PHCPs need to be aware of the risk factors for pediatric obesity to provide early anticipatory guidance for obesity prevention, monitor their patients closely, and intervene early when weight trajectory increases.

**Consensus Recommendation**

The CPG authors recommend pediatricians and other pediatric health care providers:

- perform initial and longitudinal assessment of individual, structural, and contextual risk factors to provide individualized and tailored treatment of the child or adolescent with overweight or obesity.

**A. Policy Factors**

The larger macroenvironment—including societal attitudes and beliefs, government policies, food industry practices, and the educational and health care systems—can influence obesity risk.162 It is difficult to make or sustain healthy behavior changes in an obesogenic environment that promotes high-energy intake, unhealthy dietary choices, and sedentary behavior.

**A.1. Marketing of Unhealthy Foods**

Marketing of unhealthy food and beverages directed at children tends to negatively impact their dietary choices and behaviors.163–166 Foods and beverages embedded in entertainment media have been shown to influence eating behavior choices of children and also increase consumption of foods during or after exposure to the embedded foods.167

A systematic review and meta-analysis showed that even short exposure to unhealthy food and beverage marketing targeted to children resulted in increased dietary intake and behavior during and after the exposure.168 Both younger children and male children (sex assigned at birth) tend to be more susceptible to the food and beverage marketing,168 and because of their stage of cognitive development, younger children are more likely to be susceptible to advertising and interpret it as factual.169,170

Currently, marketing to children targets highly palatable relatively inexpensive energy-dense foods and beverages.166 This marketing occurs via television, websites, online games, at supermarkets, and outside schools.166 Children are, unfortunately, frequently exposed to foods of low nutritional values from advertisements; therefore, it is not surprising that they have preferential increase in consumption of foods of low nutritional value.167

**A.2. Underresourced Communities**

Underresourced communities are settings in which obesity risk factors can predominate over health-promoting factors. Children and families in these settings may be unable to access fresh fruits and vegetables and safe physical activity spaces and may suffer from food insecurity.170–172 Limitations in transportation, cost, affordability, and availability may reduce access to health care and obesity treatment. Families may be struggling with poverty, access to healthy foods, lack of social supports, racism, and/or immigration status. Understanding these contextual factors that impact each child and family is crucial in being able to provide compassionate and effective obesity treatment.

**A.2.a. Socioeconomic Status**

Obesity has been shown to disproportionately affect children and adolescents who have low SES.173–175 Even though the prevalence of obesity has been stabilizing among US children overall, the rates continue to increase among children with low SES.173,176 According to the Children’s Defense Fund, the poverty rate among US children is alarmingly high.177

A longitudinal analysis of predominantly non-Hispanic white children in the United States found that low SES before 2 years of age was associated with higher obesity risk by adolescence in both boys and girls; this analysis also indicated that the effect of early poverty endures later in life.178 Similarly, another study found that low SES in
early childhood had a long-term impact on overweight and obesity.\textsuperscript{179} This study found that the risk of experiencing overweight or obesity in adulthood was not altered by either upward or downward mobility of poverty after early childhood,\textsuperscript{179} indicating the long-term effect of poverty-related stress in early childhood.

Low SES may also be associated with higher risk for obesity by increasing the child’s experience with toxic stress. In addition, poverty may limit access to healthy foods and opportunities for physical activity.\textsuperscript{180–182} Another study of a large dataset of children followed longitudinally from 9 months of age to kindergarten entry showed that SES played a major role in BMI z-score gaps in Hispanic children, whereas rapidity of weight gain in the first 9 months “accounted for much of the disparity between white children and children” of other races and ethnicities (other than Hispanic children).\textsuperscript{180}

**A.2.b. Children in Families That Have Immigrated**

For decades, researchers have believed that despite poverty and other negative SES factors, recently arrived immigrants are healthier than their US-born counterparts. Recent studies, however, have examined large datasets in novel ways and now call this idea into question when it comes to children in families that have immigrated.\textsuperscript{183}

As families who have immigrated try to adjust to a new culture, they may adopt Americanized foodways, which are high in fat, sugar, and salt. This tendency could be heightened by children’s exposure to media advertising these foods and high-energy snacks and by reduced physical activity.\textsuperscript{184,185}

Patterns of childhood overweight and obesity among families that have immigrated vary substantially by both ethnicity and generational status. Immigrants to the United States generally originate from countries that have a lower prevalence of obesity, but as families acculturate to US eating and activity patterns, rates of obesity may increase. One study found that second-generation Hispanic immigrants were 55% more likely to have obesity than nonimmigrant white children, whereas first-generation Asian immigrants had a 63% lower risk of having obesity.\textsuperscript{180}

Several studies have indicated different patterns of developing obesity in Mexican-origin populations among adults and children. Obesity among adults of Mexican origin in the United States has been associated with longer stays in the United States and with being born in the United States versus Mexico, which are 2 proxies for acculturation. This pattern differs in children, in whom “significantly higher obesity prevalence has been observed for first-generation young adult males (ages 18–24) and adolescent females (ages 12–17).”\textsuperscript{186}

In addition, in some cultures, larger body sizes may be preferred as an indication of health and wealth.\textsuperscript{187} This cultural factor may make it more difficult for parents to understand the gravity of their children’s overweight or obesity. For this and many other reasons, it is vital to ensure that children and families who have immigrated and who are native-born have access to culturally competent health care.\textsuperscript{188}

**A.3. Food Insecurity**

The literature positing an association between food insecurity and overweight and obesity in children has been inconsistent when looking at general child populations. Children living in households with food insecurity have been found, however, to have higher BMI z-scores and waist circumference measurement and a greater likelihood of having overweight or obesity.\textsuperscript{189} The correlation between food insecurity and obesity has been found to be higher in adolescents, who may have had more exposure to food insecurity over their life-course.\textsuperscript{190} Female children appear to more at risk for obesity in food-insecure environments, compared with male children.\textsuperscript{191}

Food insecurity is highly associated with poverty, and the cost of fruits and vegetables\textsuperscript{192} and fast food have been found to influence consumption in low-income families\textsuperscript{193,194} and to be positively related to overweight in children.\textsuperscript{195} Associations between consuming more sugar from sugar-sweetened beverages, and less frequency of eating breakfast and eating dinner with family have also been noted in families with food insecurity.\textsuperscript{190,196} Family dynamics around feeding may change in situations of food insecurity and include pressure to eat as well as monitoring and restrictive eating practices.\textsuperscript{191,197} Experiences of food insecurity are stressful for children and families and may add to the burden of chronic stress, which can result in altered eating patterns in the direction of either restricting intake or increasing consumption of energy-dense foods.\textsuperscript{190,196}

The AAP and Food Research and Action Center’s toolkit, *Screen and Intervene: A Toolkit for Pediatricians to Address Food Insecurity*, is designed to help pediatricians identify and address childhood food insecurity (available at https://frac.
The Toolkit assists pediatricians and other PHCPs to:
(1) better identify children living in households struggling with food insecurity; (2) sensitively address the topic; (3) connect patients and their families to federal nutrition programs and community resources; and (4) advocate for greater food security and improved overall health of children and their families. The toolkit also includes the "Hunger Vital Sign," a simple, validated 2-question tool that can be used in the clinical setting to evaluate for food insecurity (see link to toolkit above).

### B. Neighborhood and Community Environment Influences or Contributors to Obesity

Environmental factors play an important role in obesity prevalence. Families’ dietary and physical activity opportunities and practices (mentioned above) are influenced by their neighborhoods (Table 1).

#### B.1. School Environment

Children spend most of their time in school. Therefore, schools play an important role in influencing children’s food choices and physical activity level and, ultimately, their body weight. For example, the presence of fast foods, vending machines, and/or sweetened beverages in schools may negatively influence children’s food choices.\(^{198}\)

Systematic reviews have shown an association between fast food outlets and convenience stores located near schools and obesity in children.\(^{199,200}\) When analyzed by subgroups, a positive association has been seen between fast-food outlets and proximity to schools among Hispanic, Black, and white children. Although the association was seen for all grade levels, the effect was larger in younger grades.\(^{199}\) This review also reported a stronger association between fast-food outlets and grocery stores located near schools and obesity in socioeconomically underresourced neighborhoods.

#### B.2 Lack of Fresh Food Access

A neighborhood’s food environment has been shown to have mixed association with children’s BMI. Although some studies have shown that a 1.6-km distance or shorter from a home to a supermarket is associated with a lower BMI,\(^{201}\) other studies have found that the greater the number of supermarkets located near a child’s home, the higher the child’s BMI.\(^{202}\) Similarly,
a systematic review reported mixed association, with some studies showing a negative association between supermarket accessibility and childhood and adolescent obesity, and other studies either showing a positive effect or no association.  

Some of the differences were attributed to variations in assessment measures and lack of adjustment for confounding variables. Hence, it is not only the presence of supermarkets that is important, but also other factors that may impact dietary choices—such as the type of foods stocked, pricing, etc. Some, but not all, studies have reported a positive association between neighborhood poverty and childhood and adolescent obesity.  

It has been suggested that lack of access to fresh fruits and vegetables may be a risk factor for childhood and adolescent obesity, as it may lead to an increased reliance on, and consumption of, unhealthy foods. The data for this association have been inconsistent, however. A recent systematic review showed that, although there was a negative association between access to fresh fruits and vegetables and healthy eating behavior, the association between access to fresh fruits and vegetables and overweight and obesity was inconclusive.  

B.3. Presence of Fast-food Restaurants  
Fast-food restaurants generally serve relatively low-priced and calorie-rich fast foods with high levels of saturated fat, simple carbohydrates, sugar, and sodium. Because of their easy availability, taste, and marketing strategies, fast foods tend to be popular with children and adolescents.  

Fast-food consumption has been associated with weight gain. Some, but not all, studies have shown an association between access to fast-food restaurants and pediatric obesity. A meta-analysis and recent systematic review showed a mixed association between access to fast-food restaurants and weight-related behaviors and weight status in children and adolescents. This association was shown to be stronger in populations with lower SES.  

B.4. Access to Safe Physical Activity  
A child’s environment may influence the amount of physical activity they get. For example, living in an urban environment that lacks safe walkable and/or green spaces in which children can play may result in decreased physical activity levels. Greater exposure to green space has been shown to be associated with higher levels of physical activity and lower risk of obesity.  

A recent systematic review of the literature on the influence of the built environment and childhood obesity found significant association between childhood obesity and traffic air pollution and indicators of walkability (which included intersection density and presence and amount of park area in the neighborhood).  

In addition to green spaces, other aspects of the environment—including safety—are important in these spaces’ use. A study of low-income preschool children in New York City reported an association of lower obesity risk in neighborhoods with trees alongside the streets and a positive association between obesity and higher homicide rates in the neighborhood.  

B.5. Environmental Health  
Exposure to environmental hazards during the prenatal period, infancy, and childhood can have impacts on the health and well-being of children. Endocrine-disrupting chemicals (EDC) can cross the placental barrier and affect the fetus. There are some data that show an association between prenatal exposure to bisphenol A and polyfluoroalkyl and childhood obesity.  

In the postnatal and infancy period exposure may occur through breastfeeding, inhalation, ingestion, or absorption through the skin. Children get exposed to chemicals that are used in household products including cleaning agents, food packaging, pesticides, fabrics, upholstery, etc. Leaching of chemical products (eg, bisphenols, phthalates, parabens, and other EDCs) has been reported in baby feeding bottles, clothing, diaper creams, etc. Exposure to EDCs during early childhood can affect programming of several systems, including endocrine and metabolic systems, which may affect BMI, cardiovascular, and metabolic outcomes later in life.  

C. Family and Home Environment Factors  
The family’s dietary preferences and lifestyle habits have a crucial role in influencing the child’s weight. Parenting feeding practices and modeling of eating behavior and the type and quantities of foods and beverages in the home have been reported to be important influences in children’s appetitive behaviors and food preferences.  

C.1. Parenting Feeding Styles  
Parenting styles differ and may have an impact on a child’s risk for obesity. Four types of parent feeding styles have been described: authoritative (responsive and warm with high expectations); authoritarian (not responsive but with high expectations); permissive or indulgent (responsive and warm but lenient with few rules); and negligent (not responsive with few rules). The 4 parenting styles discussed were initially defined by Baumrind (1966) and later expanded by Maccoby and Martin (1983). (Restrictive feeding
was not included as 1 of the parenting styles.)

Authoritative feeding, where parents respond to the child’s cues of hunger and satiety, is considered to be protective against excessive weight gain. Children from authoritative parenting homes have been shown to eat more healthy foods, be more physically active, and have healthier BMI, compared with children raised in homes with authoritarian, permissive or indulgent, or negligent parenting styles.220,221

One possible mechanism of parenting style’s influence on a child’s weight status is thought to be from interference in the child’s ability to self-regulate their dietary intake. An authoritarian parent, for example, may not respond to a child’s cues for energy intake, resulting in poor ability on the part of the child to self-regulate their own energy intake, and a higher likelihood of overindulging when presented with an opportunity to eat.222,223

A large cross-sectional study showed that, among preschool- and school-aged children, authoritarian or negligent parenting is associated with a higher risk of obesity,224 whereas authoritative parenting was associated with healthy BMI.221

Among preschoolers, the effect of the parenting feeding style was found to be modulated by poverty, with the effect only being seen among children who were not living in poverty.224

C.2. Family Home Environment Organization

A systematic review of associations between the organization of the family home environment and childhood obesity found that greater organization of the home environment, which included practices such as having family routines and setting limits, was inversely associated with obesity.225 This relationship was present for younger and older children. Most but not all of the 32 studies included in the review controlled for sociodemographic factors.

C.3. Sugar-Sweetened Beverages

A systematic review of 20 prospective cohort studies and randomized controlled trials from 2013 to 2015 found that sugar-sweetened beverages (SSBs) were positively associated with obesity in children in all but 1 study (96%).226 Based on this review and others demonstrating a link between SSB and multiple other medical and dental diseases, the AAP published a policy statement on SSBs in 2019, calling for broad implementation of policies restricting SSB consumption in children and adolescents.227

C.4. Portion Sizes

Much of the research on the influence of portion size on children’s intake has been performed in laboratory settings providing a single meal to preschool-aged children. A comprehensive review of this research reported that children who serve or are served larger portions of commonly liked energy-dense foods typically consume larger amounts but cautioned that long-term studies of the effects of larger portions over time on a number of variables, including body weight, are lacking.228

C.5. Snacking Behavior

A recent systematic review of body fat and consumption of ultra-processed foods (defined as snacks, fast foods, junk foods, and convenience foods) in children and adolescents found a positive association but noted that longer-term studies examining the association of these foods and obesity are needed.229

C.6. Dining Out and Family Meals

Eating outside of the home has been shown to be associated with higher energy intake in both children and adults.230,231 In the United States, food eaten outside the home is characterized by higher fat content, larger portions, and greater energy intake.230

In a systematic review of pediatric and adult studies, eating at fast-food establishments was associated with much higher weight gain, compared with eating at other types of restaurants.231

Take-away food has also been associated with high BMI.231 Hence, eating outside of the home—irrespective of the type of restaurant establishment visited—is associated with higher risk of weight or BMI gain. Conversely, 2 meta-analyses found that increased frequency of eating family meals was associated with lower risk of childhood obesity.232,233

C.7. Screen Time

Some, but not all, studies report an association between screen time duration, childhood adiposity,234–236 and adult BMI.237 Some studies have shown a dose-response effect of screen time and childhood adiposity,235 with screen time greater than 2 hours per day being positively associated with higher risk of overweight or obesity.236 A recent meta-analysis reported 42% greater risk of overweight or obesity with more than 2 hours per day of television (TV) compared with 2 or fewer hours.238

There is evidence to support the association between screen time and consumption of unhealthy diet and high energy intake.235 The appearance or depiction of food items while engaging in screen time may affect a child’s dietary behavior. A systematic review examining food
choice and intake showed that food included in entertainment media affects eating behaviors of children.\textsuperscript{167} Children and adolescents are more exposed to food and beverage advertisements when watching TV.\textsuperscript{239} Additionally, increase in screen time may displace physical activity and interfere with sleep.\textsuperscript{235,240}

Although “screen time” includes TV, computer, video or videogames, mobile phones, and other digital devices, the majority of the studies published examined the effect of TV viewing.\textsuperscript{235} Male children and adolescents tend to spend more time on media screen devices and other Internet technology than female children and adolescents do.\textsuperscript{236}

\textbf{C.8. Sedentary Behavior}

The association between sedentary behavior and adiposity has been shown to range from small to inconsistent.\textsuperscript{241} Studies examining the effect of sedentary behavior alone on weight using accelerometer measures have shown no association between sedentary behavior and obesity. Teasing out the effects of sedentary behavior alone in treatment studies may be challenging, as this is often confounded with other behaviors such as physical activity, screen time, or increased intake of unhealthy foods.\textsuperscript{241}

\textbf{C.9. Sleep Duration}

Short sleep duration is associated with higher risk of obesity in children.\textsuperscript{242–244} A meta-analysis of prospective cohort studies demonstrated a dose-response inverse association between sleep duration and risk of childhood overweight and obesity.\textsuperscript{244} Children 13 years and younger with short sleep duration (~10 hours) had a 76% increased risk of overweight or obesity compared with their counterparts with longer sleep duration (12.2 hours).

Sleep restriction may be associated with increased calorie consumption.\textsuperscript{245,246} Additionally, fatigue and decreased physical activity has also been associated with short sleep duration. It is unclear whether the inverse association between sleep and adiposity is causal or a consequence of hormonal or metabolic disturbance.\textsuperscript{247} Although the exact mechanism for this association is unknown, some of the consequences of short sleep duration include hormonal and metabolic alterations—such as increased ghrelin and decreased leptin—which may lead to increased hunger.\textsuperscript{242}

\textbf{C.10. Environmental Smoke Exposure}

Children exposed to environmental tobacco smoke (ETS) have been found to have higher BMI compared with their nonexposed counterparts, according to a systematic review of ETS exposure and growth outcomes in children up to 8 years of age.\textsuperscript{248} A number of studies have documented an association between ACEs and the development of overweight and obesity. ACEs impact occurs via toxic stress, which occurs “when a child experiences strong, frequent, and/or prolonged adversity—such as physical or emotional abuse, chronic neglect, caregiver substance abuse or mental illness, exposure to violence, and/or the accumulated burdens of family economic hardship—without adequate adult support.”\textsuperscript{252,253}

ACEs include a history of physical, emotional, or sexual abuse; exposure to domestic violence; household dysfunction from parental divorce or substance abuse; economic insecurity; mental illness; and/or loss of a parent because of death or incarceration.\textsuperscript{69,254–257} A US study found that cumulative ACEs doubled the risk of children having overweight or obesity, compared with their counterparts with no history of ACEs.\textsuperscript{258} Unresolved stress and emotional issues may result in maladaptive coping strategies—such as binge eating, eating in the absence of hunger, impulsive eating, and poor sleep hygiene—which may result in further weight gain.

Poverty and associated toxic stresses in utero and early childhood have been suggested to initiate neuroendocrine and/or metabolic adaptations that produce biological phenotypes and obesogenic behaviors that lead to obesity.\textsuperscript{259,260} These effects may persist throughout the lifetime.\textsuperscript{260}
D. Individual-Level Influences or Contributors to Obesity

D.1. Genetic Factors

Heritability studies suggest that there is a 40% to 70% genetic contribution to an individual’s obesity risk.261–263 Genome-wide association studies have identified 32 loci of significance to obesity predisposition.264 Genetic causes of obesity include both common and rare genetic variants that involve impairment of gene expression or function.264

TABLE 2 Genetic Syndromes Associated With Obesity

| Genetic Syndrome | Polygenic causes of obesity are by far the most common, and single gene defects are rarer causes of obesity. For example, MC4R, a heterozygous mutation, is the most common form of monogenic obesity and accounts for only 2% to 5% of severe obesity in children.265,266 Polygenetic inheritance refers to a single inherited phenotypic trait that is controlled by 2 or more different genes. Polygenic variants, on their own, have little effect on an individual’s phenotype. The phenotypic effect manifests only in the presence of, or in combination with, other predisposing factors. Children with genetic causes of obesity may present with characteristic clinical features that have historically included findings such as short stature, dysmorphic features, developmental delay, skeletal defects, deafness, retinal changes, or intellectual disability. It is important to note that more recently discovered genetic |

<table>
<thead>
<tr>
<th>Genetic Syndrome</th>
<th>Monogenetic disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>MC4R deficiency</td>
<td>Increased lean body mass, accelerated linear growth. Hyperinsulinemia. May have lower blood pressure.</td>
</tr>
<tr>
<td>POMC deficiency</td>
<td>Accelerated childhood growth. Adrenocorticotropic hormone deficiency, mild hypothyroidism.</td>
</tr>
<tr>
<td>Proprotein subtilisin or kexin type 1 deficiency</td>
<td>Failure to thrive in early infancy. Hypoglycemia, adrenocorticotropic hormone deficiency, mild hypothyroidism.</td>
</tr>
<tr>
<td>SRC1 deficiency</td>
<td>Impaired leptin-induced POMC expression.</td>
</tr>
<tr>
<td>Syndromic forms of obesity</td>
<td></td>
</tr>
<tr>
<td>SH2B1 deficiency</td>
<td>Hyperinsulinemia, delayed speech and language development, aggressive behavior.</td>
</tr>
<tr>
<td>16p11.2 microdeletion syndrome</td>
<td>Developmental delay, intellectual disability, autism spectrum disorder, impaired communication, and socialization skills.</td>
</tr>
<tr>
<td>Brain derived neurotrophic factor deficiency</td>
<td>Hyperphagia, impaired short-term memory, hyperactivity, learning disability. Patients with Wilms tumor-aniridia (WAGR syndrome) have subset of deletions on chromosome 11p.12 including brain derived neurotrophic factor locus.</td>
</tr>
<tr>
<td>Albright’s hereditary osteodystrophy</td>
<td>Short stature, round face, brachydactyly, subcutaneous ossifications. Some patients may have mild developmental delay. If inherited from the mother, may be associated with pseudohypoparathyroidism type 1a.</td>
</tr>
<tr>
<td>Cohen syndrome</td>
<td>Hypotonia, intellectual disability, distinctive facial features with prominent upper central teeth, broad nasal tip, smooth or shortened philtrum, thick hair and eyebrows, long eyelashes, retinal dystrophy, acquired microcephaly, joint hyperextensibility.</td>
</tr>
<tr>
<td>Beckwith-Wiedemann syndrome</td>
<td>Macrosomia, macroglossia, hemihyperplasia, anterior abdominal wall defects, visceromegaly, neonatal hypoglycemia, embryonal tumors, renal anomalies. Genetic alteration in chromosome 11p15.5.</td>
</tr>
</tbody>
</table>

Adapted from Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.268
disorders associated with obesity are not necessarily characterized by these findings in childhood; for instance, short stature is not a hallmark of leptin deficiency in children. Table 2 lists selected monogenetic causes and syndromes associated with obesity.

Early onset of severe obesity and the presence of hyperphagia are the 2 clinical characteristics that distinguish genetic disorders of obesity. "Early onset" refers to the presence of obesity before age 5. As noted previously, "severe obesity" is defined as BMI ≥ 120% of the 95th percentile for age and sex. "Hyperphagia" is the presence of insatiable hunger in which the individual’s time to satiation is long, the individual’s duration of satiation is shorter, the individual’s feelings of hunger are prolonged, and the individual has a severe preoccupation with food and experiences distress if denied food.267

D.1.c. Epigenetic Factors

Epigenetic factors can result in alterations in gene expression without alteration in genetic code. These epigenetic factors may modify the interaction of environmental and individual factors in promoting weight gain.269 One of the critical periods in the establishment of the epigenome is considered to be during embryonic development.270 Prepregnancy maternal or paternal obesity, for example, may influence epigenetic changes during subsequent pregnancy, increasing the risk of overweight or obesity in the offspring.269 Other risk factors during pregnancy—such as gestational diabetes or maternal excessive weight gain—may result in epigenetic changes and increase the risk of obesity in the offspring.

D.2. Prenatal Risk Factors

The perinatal environment plays an important role in a child’s later development of overweight or obesity. The mechanisms by which the fetal environment predisposes to the development of obesity are complex and poorly understood. They probably include gene-environment interactions or epigenetic changes attributable to several environmental factors, including maternal diet, physical activity, and/or other environmental contaminants.271,272

Preterm infants have a greater likelihood of developing childhood obesity.273–275 Although the exact mechanisms for this association are uncertain, several risk factors have been postulated, including feeding patterns leading to accelerated weight gain in preterm infants.273

D.2.a. Parental Obesity

Parental weight is a strong predictor of pediatric obesity. Children are at greatest risk of developing obesity as an adult if at least 1 of their parents has obesity.276 A meta-analysis reported an increased risk of adolescent excess adiposity if either parent had overweight or obesity; the risk increased if both parents had obesity.277 Contributors to this association include genetic, environmental, and behavioral factors or the interaction of these factors, resulting in intergenerational transmission of adiposity.

Maternal BMI is a stronger predictor of childhood and adolescent obesity, compared with paternal obesity.247 Maternal obesity more than doubles the risk of adult obesity (see below). Paternal obesity has been associated with childhood and adolescent obesity and has an additive effect to maternal obesity.278

D.2.b. Maternal Weight Gain

Prepregnancy adiposity and weight gain during pregnancy are associated with neonatal, infancy, and childhood adiposity.247 The known effect of maternal weight on the offspring led the Institute of Medicine (IOM) to recommend different ranges for weight gain during pregnancy, varying from 12.5 to 18 kg for underweight women to 5 to 9 kg for women with obesity (BMI > 30 kg/m²).279 Yet, between 1997 and 2007, almost half of US individuals gained more than the weight recommended by the IOM.280

Excess maternal adiposity has been suggested to affect fetal metabolic programming and make the offspring more vulnerable to the obesogenic environment and increase the risk of obesity. This effect was illustrated in metabolic and bariatric surgery studies, in which children born to mothers with obesity after gastric bypass surgery had lower prevalence of macrosomia and severe obesity at adolescence, compared with their siblings born before the mothers’ surgery.247 Fetal or infant macrosomia and gestational diabetes are some of the complications associated with maternal obesity and serve as risk factors for later onset of obesity and T2DM in the offspring.281

The exact mechanism by which maternal obesity predisposes to adverse outcomes in the offspring is unclear. It has been suggested that the pathways that are affected control the central regulation of appetite and insulin sensitivity and cardiovascular regulation.280 Alteration of the fetal hypothalamic-pituitary-adrenal axis function has been implicated in programming the metabolic syndrome of the offspring of mothers with obesity.282
D.2.c. Gestational Diabetes
Infants and children of mothers with gestational diabetes mellitus (GDM) have higher fat mass and BMI than their counterparts whose mothers did not have GDM.\textsuperscript{283} Adjusting for maternal BMI and other potential confounders, GDM was shown to be associated with childhood obesity with odds ratio of 1.6 to 2.8.\textsuperscript{284,285} The odds of developing higher waist circumference (≥95th and percentile) in children of mothers with GDM was also found to be higher after controlling for potential confounders (OR, 1.55; 95% CI, 1.03–2.35).\textsuperscript{285} Sibling studies controlling for shared genetics and environment have shown higher BMIs in offspring exposed to diabetes in utero compared with their unexposed siblings.\textsuperscript{286}

Although the exact mechanisms of the effect of GDM are not fully understood, it has been postulated that the effect may be mediated through insulin. Pregnant women with GDM have higher insulin resistance compared with pregnant women without GDM.\textsuperscript{287,288} It has been suggested that maternal insulin resistance and hyperglycemia causes fetal hyperinsulinemia, resulting in excessive fetal growth with associated macrosomia and increased adiposity.\textsuperscript{289} Maternal hypertriglyceridemia from insulin resistance has also been thought to lead to increased adiposity and birth size even when glucose levels are well-controlled.\textsuperscript{290} Additionally, maternal diabetes is associated with increased leptin synthesis in the offspring.\textsuperscript{290} Epigenetic changes in infants of mothers with GDM is another suggested mechanism, affecting gene expression regulation body fat accumulation or other related metabolic pathways.\textsuperscript{291}

D.2.d. Maternal Smoking
Exposure to ETS has been shown to increase the prevalence of childhood and adolescent obesity.\textsuperscript{292–294} A systematic review and meta-analysis reported an association between prenatal ETS and childhood and adolescent obesity; children exposed to ETS in utero had about 1.9 times greater risk of developing obesity, compared with their nonexposed counterparts.\textsuperscript{295} Prenatal exposure to the risk from tobacco smoke can occur both directly from smoking mothers and indirectly through ETS, although maternal smoking was found to more strongly predict obesity.

Children exposed to smoking in utero have a dose-dependent increased risk of developing overweight and obesity.\textsuperscript{296}

D.3. Postnatal Risk Factors
As with the prenatal environment, the postnatal environment is important to the later development of overweight and obesity. In addition to epigenetic mechanisms, behavioral habits begin to get set at an early age. Acceptance of foods, availability of high calorie foods, establishment of the microbiome, and early eating habits are only a few of the proposed mechanisms for postnatal factors to influence later weight status.\textsuperscript{297}

D.3.a. Birth Weight
Several studies have shown a U-shaped or J-shaped distribution between birth weight and adult BMI.\textsuperscript{247} Infants with both low (<2500 g) and high (>4000 g) birth weight have been shown to have higher risk of obesity, compared with infants with birth weight between 2500 and 4000 g.\textsuperscript{298} A high BMI and central adiposity are more prevalent among low-birth weight infants.\textsuperscript{299} Maternal prepregnancy weight and nutritional status are strong predictors of neonatal outcomes, with underweight prepregnancy increasing the risk of preterm birth and small-for-gestational-age neonates.\textsuperscript{300} Maternal pregnancy overweight and obesity are significantly associated with large-for-gestational-age babies.\textsuperscript{300}

D.3.b. Early Breastfeeding Cessation and Formula Feeding
Some, but not all, studies have reported decreased risk of childhood and adolescent obesity in breastfed infants.\textsuperscript{247} The majority of evidence is derived from observational studies and may include confounding effects.\textsuperscript{247} Some studies have reported that, compared with bottle-fed infants, breastfed infants are better able to regulate their energy intake and have lower risk of childhood excess weight gain.\textsuperscript{301} Other studies have also shown that body weight gain is slower in breastfed infants.\textsuperscript{247}

Breastfeeding has been found to be inversely associated with overweight risk in the first year of life, independent of maternal BMI and SES. Breastfeeding cessation before 6 months was associated with an increased risk of rapid weight gain and overweight by 12 months of age, compared with exclusive breastfeeding.\textsuperscript{302}

A systematic review of feeding practices associated with rapid infant weight gain found that certain practices (such as overfeeding, inappropriately concentrating formula, placing infants in bed with a bottle, or adding cereal to a bottle) may lead to rapid infant weight gain.\textsuperscript{303} In addition, infants fed high-protein formulas are at greater risk of elevated BMI later in childhood.\textsuperscript{247,304}

D.3.c. Rapid Weight Gain During Infancy and Early Childhood
In resource-abundant countries, rapid weight gain in infancy and
during the first 2 years of life is associated with higher risk of obesity both in later childhood and in adulthood.247,305 A systematic review and meta-analysis found that children who experienced rapid weight gain from birth to age 2 were up to 3.6 times more likely to have overweight or obesity in childhood or adulthood, with the relationship being stronger between rapid infant weight gain and childhood overweight or obesity.306 Therefore, rapid weight gain in infancy and early childhood can be viewed both as a risk factor for later excess weight gain and also as a signal, as mentioned previously, for pediatricians and other PHCPs to look for other underlying risk factors and causes for excess weight gain. For instance, early introduction (at younger than 4 months of age) of complementary foods has been found to increase the risk of childhood obesity in several systematic reviews.307,308

D.3.d. Early Use of Antibiotics

Literature on antibiotic exposure in early life (<2 years) is mixed, with some suggestion that it may slightly increase the risk of childhood and adolescent obesity.309-312 The association is stronger with repeated antibiotic exposure,313,314 exposure within the first 6 months of infancy,314 and broad-spectrum antibiotic use.310 With similar antibiotic exposure, boys appear to be more susceptible to weight gain than girls.295 Gut microbiota is usually established during the first years of life; it is hypothesized that the effect of antibiotics is mediated through the alteration of the gut microbiome, which plays a role in energy balance.

D.4. Childhood Risk Factors

Various medical conditions that present in childhood and adolescence are associated with the development and progression of overweight and obesity. Similarly, certain behaviors established in childhood and adolescence can increase the risk of later development of overweight and obesity.

D.4.a. Endocrine Disorders

Endocrine disorders account for less than 1% of all the causes of pediatric obesity. These disorders can be associated with endogenous or exogenous glucocorticoid excess (eg, Cushing syndrome, use of corticosteroid medications). Short stature or growth failure and abnormally high BMI may result from pseudohypoparathyroidism type 1a, growth hormone deficiency, or hypothyroidism.268,315

D.4.b. Children and Youth With Special Health Care Needs Impacting Nutrition and Physical Activity

D.4.b.1 Children With Developmental and Physical Disabilities

A survey of data from NHANES, the National Health Interview Survey, and the National Survey of Children’s Health found that children with disabilities were from 27% to 59% more at risk for obesity than children without disabilities.316

In addition to factors experienced by children without disabilities, factors that affect children with disabilities that have been implicated in their greater obesity risk are: more difficulty breastfeeding,317 disrupted appetite regulation,318 weight-gain promoting medications,319,320 food selectivity and sensitivity issues,321 behavioral disorders,322 physical activity limitations,323 and use of food rewards.316 A lack of adaptive physical education or sports,324 and specialized supervision and instruction324 also play a role in increasing obesity risk.

Furthermore, it is important to consider that children with disabilities are at a disadvantage when it comes to obesity treatment strategies that are tailored to their needs. For example, most community or school weight management, nutrition or physical activity interventions are not readily adapted for children with disabilities. Therefore, many children with disabilities do not have the support or strategies that they need to address excess weight. Finally, children may face bullying or stigmatization and bias in school. They may also receive unhealthy incentives as rewards from caregivers increasing their risk for obesity. These systemic trends and biases make providing adequate care for children with disabilities extremely difficult.

D.4.b.2 Children With Autism Spectrum Disorder

Children and youth with autism spectrum disorder (ASD) have a higher risk of developing overweight or obesity. In the United States, children and adolescents 2 to 18 years of age with ASD have a 43.7% greater risk of obesity compared with their counterparts without ASD.325 Although the exact mechanisms through which ASD increases the risk for excess weight gain is unknown, a recent meta-analysis of international studies showed that positive moderators to this association include children of certain races and ethnicities, female biological sex, increased age, and living in the United States.325 This meta-analysis did not control for other risk factors for obesity, however, such as use of antipsychotic medications, food intake challenges, or limited physical activity. Hence, the variable of race could be reflective of a negative SDoH.

Several etiological factors have been postulated to contribute to the
association between ASD and obesity, including: genetic variants (eg, 16p11.2 deletion and microdeletion 11p14.1), prenatal exposure to certain infections or medications, pre and postnatal exposure to toxins, maternal obesity, intrauterine growth restriction and preterm birth, food selectivity, and physical limitations.

D.4.b.3 Children With Myelomeningocele
Several studies report increased rates of obesity of children with myelomeningocele, with children having more severe disease tending to have higher BMIs. Children and adolescents with myelomeningocele have increased total body fat and lower energy expenditure, compared with children without myelomeningocele. Risk factors for obesity in this population include limited ambulation, sedentary lifestyle, decreased lean body mass, and reduced resting energy expenditure. In addition, children with myelomeningocele may be less likely to have routine weight and height, and primary care providers’ discussions may be lacking with respect to addressing healthy lifestyles.

D.4.c. Attention-Deficit/Hyperactivity Disorder
A systematic review and meta-analysis showed significant association between attention-deficit/hyperactivity disorder (ADHD) and obesity among unmedicated individuals with ADHD—but not among medicated individuals. The prevalence of obesity was found to be 40% higher among children and adolescents with ADHD, compared with those without ADHD. This association is not affected by gender or by study setting, country, or quality. Causality between ADHD and obesity could not be inferred from this meta-analysis, because the studies were cross-sectional; however, some prospective studies have shown that ADHD precedes the diagnosis of obesity.

Some of the known symptoms of ADHD may contribute to weight gain. For example, binge eating, which is a manifestation of impulsivity in individuals with ADHD, may result in increased energy intake. Inattentiveness, another symptom of ADHD, may lead to lack of planning, of following through on a plan, resulting in missed meals or the consumption of unhealthy meals and snacks. Other psychiatric comorbidities that are often associated with ADHD—such as depression, anxiety, and circadian rhythm disturbances—may also be risk factors for obesity.

Dopamine plays an important role in some of the addictive behaviors of ADHD and obesity. Functional MRI studies have identified shared neuropsychiatric circuits that are associated with reward, response inhibition, and emotional regulation in obesity, ADHD, and abnormal eating behavior.

D.4.d. Weight-Promoting Appetitive Traits
Differences in children’s appetitive traits manifest as early as infancy (for example, sucking behavior) and may become more pronounced when children get exposed to an obesogenic food environment. Although the exact reasons why some children have better control of their energy intake is unknown, interaction between genetic predisposition and children’s early environment may explain some of the individual differences in appetite traits. Parent feeding style, as discussed, has been shown to be of importance.

Systematic review and meta-analysis of adult data showed a positive association between eating quickly and higher BMI, and in longitudinal studies, faster eating rate was associated with excess weight gain. Similarly, 2 cross-sectional pediatric studies have reported a positive association between eating fast and childhood and adolescent obesity.

Eating quickly has been suggested to result in greater energy intake.

A recent American Heart Association policy statement on caregiver influences on young children’s eating behaviors synthesized appetitive traits consistently associated with child adiposity. In addition to more rapid eating pace, these traits include eating in the absence of hunger, high enjoyment of food, low responsiveness to satiety, and low level of restrained eating.

D.4.e. Medication Use
Medications within many categories have been associated with weight gain. The magnitude of risk associated with medication use is not fully known; therefore, there is an urgent need for more research in this area as well as mediating strategies.

Medications implicated include glucocorticoids, sulfonyleureas, insulin, thiazolidinediones, antipsychotics, tricyclic antidepressants, and antiepileptic drugs. In particular, second-generation antipsychotics (ie, risperidone, clozapine, quetiapine, and aripiprazole) can lead to rapid weight gain and comorbidities such as prediabetes, diabetes, and dyslipidemia.

A recent review discusses the more commonly prescribed medications in children and adolescents with obesity and comorbidities, and offers suggestions on alternative therapeutic agents (Table 3).
TABLE 3 Selected Examples of Commonly Prescribed Medications and Weight Gain in Pediatric Practice

<table>
<thead>
<tr>
<th>Medication</th>
<th>Obesogenic Medications</th>
<th>Nonobesogenic Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergies and asthma management</td>
<td>• antihistamines</td>
<td>• inhaled nasal steroids</td>
</tr>
<tr>
<td></td>
<td>• steroids (systemic)</td>
<td>• montelukast</td>
</tr>
<tr>
<td></td>
<td>• amitriptyline</td>
<td>• bupropion</td>
</tr>
<tr>
<td></td>
<td>• nortriptyline</td>
<td>• imipramine HCL</td>
</tr>
<tr>
<td></td>
<td>• paroxetine</td>
<td>• buspiron</td>
</tr>
<tr>
<td></td>
<td>• sertraline</td>
<td>• trimipramine maleate</td>
</tr>
<tr>
<td>Antidepressants</td>
<td></td>
<td>• cilatopram</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• protriptyline HCL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• desipramine HCL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• trazadone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• venlafaxine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• doxepin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• escitalopram</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• fluoxetine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• fluvaxetine</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>• carbamazepine</td>
<td>• felbamate</td>
</tr>
<tr>
<td></td>
<td>• gabapentin</td>
<td>• lamotrigine</td>
</tr>
<tr>
<td></td>
<td>• pregabalin</td>
<td>• levetiracetam</td>
</tr>
<tr>
<td></td>
<td>• valproate</td>
<td>• phenytoin</td>
</tr>
<tr>
<td></td>
<td>• vigabatrin</td>
<td>• topiramate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• zonisamide</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>• amisulpride</td>
<td>• molindone</td>
</tr>
<tr>
<td></td>
<td>• clozapine</td>
<td>• pimozide</td>
</tr>
<tr>
<td></td>
<td>• haloperidol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• mirtazapine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• olanzapine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• perphenazine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• quetiapine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• risperidone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• sertindole</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• thiopridazine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• ziprasidone</td>
<td></td>
</tr>
<tr>
<td>Anxiolytics</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• flurazepam</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Migraine management</td>
<td>• alprazolam</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• lorazepam</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• amitriptyline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• atenolol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• divalproex sodium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• fluoxetine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• gabapentin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• imipramine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• nortriptyline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• pizotifen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• propranolol</td>
<td></td>
</tr>
<tr>
<td>Mood stabilizers and antimania</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• carbamazepine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• gabapentin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• lithium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• valproate</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychostimulants</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• amphetamine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• methylphenidate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• dextroamphetamine sulfate</td>
<td></td>
</tr>
</tbody>
</table>

This is not an exhaustive list; it is included as an example of medications that may result in weight gain and possible alternatives.

D.4.f. Depression

Children with obesity are more likely to have anxiety and depressive symptoms compared with their peers of healthy weight. It is not clear whether obesity is a risk factor for these symptoms. Some earlier research reported bidirectional associations between obesity and depression and anxiety. Limitations of some of the studies included small samples; self-reported data on anthropometry; assessment of symptoms based on self-administered questionnaires; and not controlling for potential confounders, such as family history, neuropsychiatric disorders, and SES. A more recent study showed that obesity was a risk factor for anxiety and depression among children and adolescent after adjusting for SES, neuropsychiatric disorders, and family history of anxiety or depression.

The association between obesity and depression and anxiety may be attributable to interactions and shared pathophysiological mechanisms between these conditions. Some of the shared risk factors include genetic, physiologic, and environmental factors. Obesity is associated with subclinical inflammation and oxidative stress, which have been shown to be important etiological factors for depression, and this has been suggested as possible common link between obesity and depression. Other factors that can potentially impact the association between obesity and anxiety and depression include sleep disturbance, unhealthy diet, physical activity, and injury bullying of children or bullying of children.

IX. EVALUATION OF THE PEDIATRIC PATIENT WITH OVERWEIGHT OR OBESITY

A. Evaluation of Patients With Overweight or Obesity

This evaluation is an important part of COT (see COT section in the Treatment section). As with all chronic diseases, a complete history, review of systems (RoS), and physical examination are important for treatment. Specific elements of both history and physical relating to obesity are of special importance. Evaluation of the patient and family’s readiness to change behavior is critical to effectively
KAS 2. Pediatricians and other PHCPs should evaluate children 2 to 18 y of age with overweight (BMI ≥ 85th percentile to <95th percentile) and obesity (BMI ≥ 95th percentile) for obesity-related comorbidities by using a comprehensive patient history, mental and behavioral health screening, SDoH evaluation, physical examination, and diagnostic studies.

<table>
<thead>
<tr>
<th>Aggregate Evidence Quality</th>
<th>Grade B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefits</td>
<td>Early detection and treatment can reduce future serious sequelae, detection of comorbidity may motivate treatment engagement.</td>
</tr>
<tr>
<td>Risks, harm, costs</td>
<td>Increased anxiety, overtesting, time needed for counseling, potential false-negative or false-positive tests, costs of tests.</td>
</tr>
<tr>
<td>Benefit-harm assessment</td>
<td>Potential to identify and manage comorbidities that have short and long term serious sequelae exceeds potential harm especially for high-risk patients.</td>
</tr>
<tr>
<td>Intentional vagueness</td>
<td>Frequency of evaluation, patient level of risk.</td>
</tr>
<tr>
<td>Role of patient preferences</td>
<td>Family history, families’ concern about the test, ease and accessibility for testing must be considered.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>&lt;=24 mo old.</td>
</tr>
<tr>
<td>Strengths</td>
<td>Strong recommendation.</td>
</tr>
<tr>
<td>Key references</td>
<td>80, 365</td>
</tr>
</tbody>
</table>

Help with obesity treatment (see algorithm in Appendix 1).

The early and accurate classification of overweight and obesity and identification of obesity-related comorbidities is fundamental to the provision of timely and appropriate treatment (see the Comorbidities section, below). The routine classification of weight status allows for early recognition of abnormal weight gain. This is particularly important because patients—including children and adolescents—often do not perceive overweight and obesity as a health problem. Caregivers, families, pediatricians, other pediatric health care providers, and other health care providers can also be slow to recognize abnormal weight status, even in the presence of severe obesity.

Patients and caregivers identify pediatricians and other PHCPs as trusted and preferred sources of information about weight status, starting with discussions of feeding practice in infancy and continuing with evaluation of healthy nutrition and activity into adulthood. Pediatricians and other PHCPs are also uniquely qualified to evaluate patients for overweight, obesity, and related comorbidities.

Routine well-child checks (WCCs) in the medical home are an opportune time for the evaluation of a child or adolescent with overweight and obesity, but this can occur during problem-focused visits as well. When the discussion of weight status is normalized and nonstigmatizing, the family and provider can exit a WCC or visit with a clear and practical plan to improve health and quality of life. Successfully and sensitively treating overweight and obesity can be highly rewarding for both the family and the pediatrician (or other pediatric health care provider), because families suffering from overweight and obesity often have experienced previous shaming or negative experiences with treatment.

Shaming of children with regard to their weight may happen at school and even at home in misguided efforts to “motivate” the child to adopt healthier behavior. Overt or subtle and unintended bias in health care leads to adverse health, behavioral, and psychological outcomes. In addition, when feeding practices are identified as unhealthy, parents may feel blame. It is important, although challenging, for pediatricians and other PHCPs to communicate support and alliance with children, adolescents, and parents as they diagnose and guide obesity treatment.

In the AAP statement on obesity bias, steps to provide supportive and nonbiased behavior include recognition of the complex genetic and environmental influences on obesity. Recommendations include use of neutral words like “BMI” or “excess weight” rather than “fat” or “chubby,” use of people-first language (ie, “a child with high weight” or “a child with obesity” rather than “an overweight child” or “an obese child”), an office set-up that accommodates different body sizes, and a private weighing station. Ongoing successful communication of support and empathy during obesity treatment is essential to reduce the effect of weight bias, because families will not continue to seek help if they experience stigma.

B. Medical History

Both a complete medical history and physical examination are necessary to evaluate any patient with a chronic disease. Obesity is no exception and, like other chronic diseases, requires comprehensive evaluation in certain areas of both the history and physical examination, which may require additional time to that which is allocated in a routine visit. The medical history includes the chief complaint, history of the present illness, and family history.

- The chief complaint is notable for determining whether overweight and obesity is a concern for the
patient and family. An open-ended question such as "What concerns, if any, do you have about your child’s growth and health?" can provide a wealth of insight on this issue.

- The history of the present illness provides a more comprehensive picture of the trajectory of overweight and obesity. Starting with an inquiry about maternal weight gain during pregnancy and prenatal factors that predispose to obesity, and then moving on to childhood and later adolescent factors that predispose to obesity, the pediatrician or other pediatric health care provider can glean valuable information on causes and therefore management for a particular patient’s obesity. These prenatal and postnatal causes are described in detail in the Risk Factors section. Information about the onset of excess weight gain and consistency of weight status over time (including a review of the growth curve and previous weight control attempts) can provide an understanding of what weight status represents for the patient. It can also offer clues as to root causes, necessary diagnostic evaluation, and potential therapeutic targets.

- The family history focuses on obesity-related comorbidities and potential genetic causes of obesity in addition to other family health problems. A family history of obesity and obesity-related comorbidities may influence both evaluation and treatment. Although shared environment, SDoHs, and stress can contribute to obesity within the same family, a family history of obesity can also provide a clue to genetic susceptibility to obesity—especially if the family history includes severe obesity resulting in metabolic and bariatric surgery or severe obesity present in multiple family members and generations.

- The medication history should be complete and should include medications associated with weight gain, such as antipsychotics, especially atypical antipsychotics; antidepressants including selective serotonin reuptake inhibitors;

### TABLE 4: Special Considerations in the Review of Systems for the Patient With Overweight or Obesity

<table>
<thead>
<tr>
<th>System</th>
<th>Symptom</th>
<th>Possible Obesity-Related Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>General</td>
<td>Poor or slowed linear growth velocity</td>
<td>Endocrinologic contributor (eg, hypothyroidism, Cushing syndrome)</td>
</tr>
<tr>
<td></td>
<td>Hyperphagia from early childhood, developmental delay, obesity onset under age 5 y, or syndromic features</td>
<td>Various genetic etiologies (see Table 2, genetic syndromes associated with obesity)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Shortness of breath</td>
<td>Obesity-related asthma phenotype, deconditioning</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Snoring, apnea, disordered sleep</td>
<td>Obstructive sleep apnea (OSA)</td>
</tr>
<tr>
<td></td>
<td>Asymptomatic vague abdominal pain</td>
<td>NAFLD, NASH</td>
</tr>
<tr>
<td></td>
<td>Heartburn, dysphagia, chest pain, regurgitation</td>
<td>Gastroesophageal reflux disease</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Right upper quadrant pain</td>
<td>Constipation</td>
</tr>
<tr>
<td>Orthopedic</td>
<td>Hyperphagia</td>
<td>Gall bladder disease</td>
</tr>
<tr>
<td></td>
<td>Polyuria, polydipsia</td>
<td>Prader-Willi, other genetic causes</td>
</tr>
<tr>
<td>GYN</td>
<td>Oligomenorrhea, dysfunctional uterine bleeding</td>
<td>Diabetes mellitus (DM) type 1 or 2</td>
</tr>
<tr>
<td>Mental health</td>
<td>Hip, thigh, or groin pain, painful or uneven gait</td>
<td>Polycystic ovarian syndrome</td>
</tr>
<tr>
<td></td>
<td>Knee pain</td>
<td>Slipped capital femoral epiphysis (SCFE)</td>
</tr>
<tr>
<td></td>
<td>Foot pain</td>
<td>SCFE, Blunt disease</td>
</tr>
<tr>
<td></td>
<td>Back pain</td>
<td>Increased weight bearing</td>
</tr>
<tr>
<td></td>
<td>Proximal muscle wasting</td>
<td>Increased weight</td>
</tr>
<tr>
<td>Mental health</td>
<td>Sadness, depression, anhedonia, body dissatisfaction, school avoidance, poor self-image</td>
<td>Cushing syndrome</td>
</tr>
<tr>
<td></td>
<td>Impulsive eating, distractibility, hyperactivity</td>
<td>Depression or anxiety, bullying, sexual, physical, or emotional abuse</td>
</tr>
<tr>
<td>Urinary</td>
<td>Purging, restricting intake, binge-eating, night eating</td>
<td>Disordered eating or eating disorders</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Flat affect</td>
<td>Depression or anxiety</td>
</tr>
<tr>
<td>Dermatologic</td>
<td>Nocturia, enuresis</td>
<td>DM, OSA</td>
</tr>
<tr>
<td></td>
<td>Rash</td>
<td>Intertrigo</td>
</tr>
<tr>
<td></td>
<td>Darkened skin on flexural surfaces</td>
<td>Acanthosis nigricans</td>
</tr>
<tr>
<td></td>
<td>Pustules, abscesses</td>
<td>Hidradenitis suppurativa</td>
</tr>
<tr>
<td></td>
<td>Hirsutism in females</td>
<td>PCOS</td>
</tr>
<tr>
<td></td>
<td>Flesh-colored striae</td>
<td>Rapid weight gain</td>
</tr>
<tr>
<td></td>
<td>Purplefry striae</td>
<td>Cushing syndrome</td>
</tr>
<tr>
<td></td>
<td>Skin fold irritation</td>
<td>Candida</td>
</tr>
<tr>
<td>Neurologic</td>
<td>Morning headaches</td>
<td>OSA</td>
</tr>
<tr>
<td></td>
<td>Daytime sleepiness</td>
<td>OSA</td>
</tr>
<tr>
<td></td>
<td>Persistent headache</td>
<td>Idiopathic intracranial hypertension (IIH)</td>
</tr>
</tbody>
</table>

Adapted from Krebs et al.14
stereoids; anticonvulsants; antihypertensives; birth control agents, including injected forms; and medications used in diabetes mellitus.

Table 4 summarizes the RoS and provides a valuable framework for investigating a variety of obesity-related conditions.

B.1. Social History

A thorough social history is helpful in the evaluation of the child or adolescent with overweight and obesity. An understanding of family living arrangement will identify resources and barriers that are unique to the patient and their family. Factors such as eating routines and schedules; eating at multiple households; and eating environments, such as family meals, eating at a table, eating with or without screens, are all important elements in assessing contributors to and potential treatment targets for excess weight gain. Determining a family’s relationship with food is also important (eg. Is food a common reward? How is food used in celebrations? Is there pressure for the child to eat?).

Because overweight and obesity tends to cluster in social groups as well as families, discussions of neighborhood, school, and friend groups can guide pediatricians, other PHCPs, and families to productive areas for treatment. Social history can heighten an awareness of, and provide insight into, patients who are most exposed to negative SDoHs. Given that inequities exist in obesity risk factors, an SDoH evaluation is important to increase awareness and provide insight in identifying patients who are more vulnerable to obesity. Assessment of SDoHs is also important to contextualize the patient’s and family’s treatment challenges. Standardized tools for use in primary care exist and include the Safe Environment for Every Kid model375 and the Accountable Health Communities Health-Related Social Needs Screening Tool.376

Because of the greater burden of overweight and obesity on people of certain race and ethnicities, these differences should be acknowledged and any limitations should be

TABLE 5 Assessment Components

<table>
<thead>
<tr>
<th>Dietary Intake Can Be Addressed by Assessing the Following</th>
<th>Physical Activity Can Be Addressed by Assessing Physical Literacy379.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eating outside the home</td>
<td>Physical literacy: The motivation, confidence, physical competence, knowledge, and understanding to engage in age-appropriate physical activity for a lifetime. Routine ambient activity is built into daily living.</td>
</tr>
<tr>
<td>Consumption of sweet drinks</td>
<td>Sedentary time, especially recreational screen time. Moderate activity levels, characterized by a mild increase in pulse and respiratory rate but still able to talk. Vigorous activity levels, characterized by increased breathing, elevated heart rate, or sweating.</td>
</tr>
<tr>
<td>Portion size</td>
<td></td>
</tr>
<tr>
<td>Meal habits, including skipping meals</td>
<td></td>
</tr>
<tr>
<td>Snack habits</td>
<td></td>
</tr>
<tr>
<td>Fruit and vegetable consumption</td>
<td></td>
</tr>
</tbody>
</table>
mitigated. An example of a healthy habit survey can be found at https://mainehealth.org/-/media/lets-go/files/childrens-program/pediatric-family-practices/full-healthcare-toolkit.pdf. Sensitivity to cultural, economic, and literacy barriers is necessary with the nutrition history and physical activity history, as with other assessments. Furthermore, the presence of eating disorders, obsessive-compulsive disorder, and other mental health conditions may preclude the use of certain tools that require intensive tracking.

B.3. Assessments for Behavioral Health and Disordered Eating Concerns

Because rates of behavioral health illnesses are greater in patients with obesity than other patients, it is important for pediatricians and other PHCPs to evaluate the emotional health of children with overweight and obesity. A common comorbidity of obesity in children is weight-based bullying and teasing. If a patient responds affirmatively when asked if they have ever been teased or bullied about their weight, pediatricians and other PHCPs can consider provision of resources (such as those found at stopbullying.gov) to the child and parent as well as local counseling referral.

Various in-office tools can be used to address behavioral health disorders seen in greater prevalence in patients with obesity. Overall behavioral functioning can be assessed through the Pediatric Symptom Checklist’s parent or teen versions. Evaluation for depression can be conducted through the teen version of the Patient Health Questionnaire 2- or 9- question version. Assessment of anxiety by tests such as the General Anxiety Disorder assessment or the Screen for Child Anxiety Related Disorders assessment. In addition, ADHD can be assessed by the Vanderbilt ADHD Rating Scales.

As discussed in the AAP clinical reports, “Preventing Obesity and Eating Disorders in Adolescents” and “Identification and Management of Eating Disorders in Children and Adolescents,” adolescents with obesity may engage in unhealthy practices to lose weight. These practices include skipping meals, using diet pills or laxatives, and inducing vomiting. Therefore, it is important for pediatricians and other PHCPs to evaluate the adolescent with overweight or obesity for these and other related behaviors, and to examine the growth chart for evidence of more rapid than expected decline in BMI.

As noted in the clinical reports above, pediatricians “should be knowledgeable about the variety of risk factors and early signs and symptoms of eating disorders in both male and female children and adolescents. Pediatricians should evaluate patients for disordered eating and unhealthy weight-control behaviors at annual health supervision visits. Pediatricians should evaluate weight, height, and BMI by using age- and sex-appropriate charts, assess menstrual status in girls, and recognize the changes in vital signs that may signal the presence of an eating disorder.” For more information on this evaluation, please see the AAP clinical report.

B.3.a. Physical Evaluation

A complete physical examination is necessary in the patient with overweight and obesity because of the disease’s complex and multisystem effects. The 2015 article “Physical Examination Findings Among Children and Adolescents with Obesity: An Evidence-Based Review,” by Armstrong et al provides a thorough explanation of special considerations for patients with or at-risk for weight-related illness. Pediatricians and other PHCPs are encouraged to reference this AAP-published review. The physical exam also requires focused attention to certain obesity-related findings related to physical evaluation (Table 6). These include:

- **Vital signs** such as heart rate, pulse, and blood pressure should be taken; blood pressure should be measured accurately with an appropriately sized cuff.
- **Other important signs:** short stature may be a sign of a genetic or endocrinologic cause for overweight and obesity. Flat affect may indicate depression, and anxious mood may indicate anxiety. Attention-seeking may be a signal for underlying distress over overweight and obesity. Syndromic features may also offer indications of the presence of an underlying genetic cause for obesity.
- **Skin examination** should be performed to look for intertrigo and hirudinensis suppurativa associated with excess skin folds as well as acanthosis nigricans associated with insulin resistance. Flesh-colored striae may be seen on the abdominal wall and/or thighs as an indication of rapid weight gain. The combination of purplish abdominal striae, slowed linear growth, cervicodorsal fat accumulation, proximal muscle wasting, full facies, and hypertension should prompt evaluation for Cushing syndrome.
- **Examination of the head, ears, eyes, nose, and throat** should occur to look for papilledema associated with pseudotumor cerebri, tonsillar hypertrophy associated with sleep
<table>
<thead>
<tr>
<th>Physical Examination Finding</th>
<th>Definition</th>
<th>Other Causes and Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vital signs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>SBP or DBP ≥ 95th percentile on at least 3 readings</td>
<td>Numerous, including essential, stress-induced, renal parenchymal or vascular disease, cardiovascular disorders, obstructive sleep apnea syndrome, substance abuse or medication side effect, pheochromocytoma, anemia, hyperthyroidism, Cushing syndrome, Williams syndrome, Turner syndrome</td>
</tr>
<tr>
<td>Increased HR</td>
<td>Heart rate above upper limit of normal for age</td>
<td>Numerous, including fever, anemia, drugs, anxiety, pain, arrhythmia, myocarditis, substrate deficiency, hypovolemic shock, sepsis, anaphylaxis, toxic exposure, hyperthyroidism, Kawasaki disease, acute rheumatic fever, pheochromocytoma</td>
</tr>
<tr>
<td><strong>Anthropometric</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Changes in height velocity</td>
<td>Early height velocity increase</td>
<td>True pattern characteristic of obesity, but early height increases can also be: familial tall stature, precocious puberty, gigantism, pituitary gland tumor</td>
</tr>
<tr>
<td>Changes in weight gain</td>
<td>Early weight gain before age 5 y</td>
<td>Genetic causes, overfeeding</td>
</tr>
<tr>
<td></td>
<td>Earlier onset of peak height velocity</td>
<td>Slowing of height can be attributable to medications, inflammatory bowel disease, hypothyroidism, hypercortisolism, dysplastic or genetic syndrome, constitutional delay, growth hormone deficiency</td>
</tr>
<tr>
<td><strong>HEENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papilledema</td>
<td>Edema of the optic disc secondary to increased intracranial pressure (Frisen scale)</td>
<td>Intracranial mass lesion, hydrocephalus, cerebral venous thrombosis, medications, autoimmune disorders, anemia, and cranial venous outflow abnormalities</td>
</tr>
<tr>
<td>Dental caries</td>
<td>White, brown, or black spots (noncavitary) or eroded areas of enamel or dentin (cavitary)</td>
<td>Developmental disease of the tooth and gum, trauma, infection</td>
</tr>
<tr>
<td>Tonsillar hypertrophy</td>
<td>Tonsils occupy at least 50% of the oropharynx (Brodsky classification 3+ and 4+).</td>
<td>Infectious causes</td>
</tr>
<tr>
<td><strong>Chest</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>&gt;2 cm of breast tissue in biological males</td>
<td>Hyperaromatase syndrome, hypogonadism, hyperprolactinemia, chronic liver disease, and medications, particularly H2 antagonists</td>
</tr>
<tr>
<td>Cervicodorsal hump</td>
<td>Fibrous fatty tissue over the upper back and lower neck</td>
<td>Endogenous (Cushing syndrome) or exogenous corticosteroid exposure, adrenal carcinoma, adrenal adenoma, HIV with secondary hyperinsulinemia</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver enlargement (hepatomegaly)</td>
<td>Liver span &gt;5 cm in 5-yr-olds and 15 cm in adults or liver edge palpable below the right costal margin by &gt;3.5 cm in adults or &gt;2 cm in children</td>
<td>Multiple, including hepatitis, storage disorders, infiltrative, impaired outflow, and biliary tract disorders</td>
</tr>
<tr>
<td><strong>Genitourinary</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buried penis</td>
<td>Suprapubic fat accumulation leading to the appearance of a shortened penile shaft</td>
<td>Trapped penis, webbed penis, and micropenis</td>
</tr>
</tbody>
</table>
A cardiopulmonary examination should be performed to look for a spectrum of impairment that can be associated with overweight and obesity. Simple deconditioning may present with tachypnea, dyspnea, or tachycardia. Wheezing may be suggestive of intrinsic or exercise-induced asthma. Tonsillar hypertrophy may be a sign that increases...
the likelihood of sleep apnea. In more severe obesity, congestive heart failure may present with basilar rales or other signs of more significant cardiac disease.

- **Liver size** should be assessed by palpation and auscultation. If present, right upper quadrant tenderness should be noted.

- **Genito-urinary examination** should be performed to assess pubertal status and genital appearance looking for signs of endocrine or genetic abnormality. Hypogonadism may be present in certain syndromes associated with obesity or be a result of obesity. More commonly, biological males with abdominal obesity may have a suprapubic fat pad obscuring the penis, a so-called "vanishing penis," and need instruction on proper voiding and genital hygiene to avoid development of skin breakdown.

- **Neurologic evaluation** may reveal papilledema, as described above, as well as paresthesia.

- **Orthopedic findings** associated with obesity include abnormal gait, knee tenderness, pes planus, genu valgum ("knock knees"), genu varum (leg bowing), foot pain, back tenderness, and hip pain. Obesity may also make detection of scoliosis more difficult.

- **Neuromuscular evaluation** of obesity, as with the orthopedic evaluation of obesity, includes assessment of bone structure, gait and pain, but also includes assessment for balance, coordination, lower limb muscle strength, flexibility and motor skill proficiency. Patients with obesity frequently experience impairment in these areas. Such limitations can result in further reduction of ability to engage in physical activity.

### C. Assessment of Patient Readiness to Change

"Readiness to change" refers to a patient’s interest in changing a behavior (Importance) and their belief that they can bring about this change (Confidence). This evaluation is important when discussing healthy nutrition and activity with patients who have BMI in the healthy range; it assumes even greater importance with a patient and family who are struggling with overweight, obesity, or severe obesity where health concerns are elevated. This evaluation of readiness to change is central to deciding how and when to embark on obesity treatment. Motivational interviewing (MI), discussed in the Treatment section, provides a useful framework for evaluating and discussing a patient’s readiness to change.

Readiness to change, perceptions of weight status, health challenges, nutrition habits, and access to physical activity are influenced by familial, cultural, and socioeconomic factors. For this reason, understanding these factors is beneficial in forging a productive relationship with children and their families. It is also important to remember that patients and families care about their health and their child’s health regardless of race, ethnicity, and/or SES. Caregivers should be reminded that the presence of overweight or obesity is NOT an indication of poor parenting.

### D. Laboratory Evaluation

Based on BMI classification—and augmented by findings in the history, physical examination, and patient readiness to change assessments—laboratory evaluation of the patient represents the next important step in evaluation. This laboratory evaluation and its connection to the delineation of more common comorbid illnesses is described in the Comorbidities section. Other laboratory evaluations can be performed as clinically indicated.

### X. COMORBIDITIES OF PEDIATRIC OVERWEIGHT AND OBESITY

#### Introduction to Comorbidities

Children and adolescents with obesity have increased prevalence of comorbidities, and a greater risk for obesity in adulthood, morbidity, and premature death. The risk for obesity-related comorbidities increases with age and severity of obesity and prevalence varies by ethnicity and race. For example, there is a higher prevalence of NAFLD in Hispanic children and a lower prevalence in Black children. Al/AN, Black, and Hispanic youth have higher prevalence of prediabetes and diabetes, compared with white youth. Pediatricians and other PHCPs need to recognize that the association between ethnicity and race and obesity and related comorbidities in both children and adults likely reflects the impact of epigenetic, social, and environmental factors, such as SDoHs, low SES, exposure to structural racism, neighborhood deprivation, and inadequate built environment in these subpopulations.

Obesity and related comorbidities should be evaluated concurrently with an obesity-specific history and review of systems, family and social history, physical examination, and laboratory testing. This evaluation provides pediatricians and other PHCPs with an opportunity to assess for both the etiology and complications of obesity (see the Evaluation section). Pediatricians and other PHCPs need to take into consideration patient-specific factors that may increase the risk for comorbidities. For example, prediabetes and diabetes occur more frequently among children who are 10 years and older, are in early pubertal stages, or have a family history of T2DM.

There is compelling evidence that obesity increases the risk for comorbidities and that weight loss
interventions can improve comorbidities. Thus, the recommendations for comorbidity evaluation uses input from the technical report on comorbidities for the prevalence, age, and weight category associated with comorbidities, and the technical report on treatment of obesity intervention outcomes on dyslipidemia, prediabetes and diabetes, HTN, and NAFLD. Studies on optimal age, frequency, benefits, and harms of evaluating for comorbidities for children with obesity remain limited. To address when to begin evaluation, what tests to obtain, and frequency of testing, input from other clinical practice guidelines was also considered.

The KASs in this section are limited to comorbidities addressed in the technical reports and/or guidelines from professional organizations or societies. Consensus recommendations are included to cover the breadth of relevant comorbidities associated with pediatric overweight and obesity and to provide context for implementation. Each KAS or consensus recommendation is drawn from the technical reports, an extensive review of the literature, and clinical guidelines or position statements from premier organizations or professional societies in the field. The inclusion criteria for the guidelines and position statements are in Table 7. When there was more than 1 guideline from the same organization or professional society, the most recent guideline was given precedence. Other considerations for inclusion were guidelines supported by a technical report or endorsed by the AAP.

The following section is divided into 3 sections:

- Overall KASs for Laboratory Evaluation of Obesity-Related Comorbidities for children with overweight and obesity (KASs 3–3.1);
- Concurrent Treatment of Obesity and Obesity-Related Comorbidities (KAS 4); and
- Specific Recommendations for Evaluation for Common Comorbidities (KASs 5–8) and Guidelines for Other Comorbidities.

Recommendations for reevaluation and initial management of common comorbidities are in Appendix 3.

### A. Laboratory Evaluation of Obesity-Related Comorbidities for Children With Overweight and Obesity

The 2007 AAP Expert Committee on Child Obesity recommended laboratory evaluation for children with obesity for dyslipidemia, prediabetes, and NAFLD starting at 10 years by obtaining a fasting lipid panel, fasting glucose, alanine transaminase, and aspartate transaminase levels every 2 years. For children with overweight, the recommendation was only for a fasting lipid panel unless additional risk factors were present (such as family history of obesity-related diseases, elevated BP, elevated lipid levels, or tobacco use). KASs 3 and 3.1 build on the 2007 recommendations—taking into account recent studies, guidelines, and pediatrician and other PHCP behaviors—while balancing the harm versus benefit of evaluation at the individual and population levels.

#### TABLE 7 Inclusion Criteria for Guidelines or Position Statements Reviewed for Comorbidities

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Clinical guideline or position statement was published in the last 15 y.</td>
</tr>
<tr>
<td>- The organization or professional society is recognized as the leading scientific expert in the field.</td>
</tr>
<tr>
<td>- The clinical guideline or position statement uses an established grading matrix to assess the evidence.</td>
</tr>
</tbody>
</table>

**KAS 3.** In children 10 y and older, pediatricians and other PHCPs should evaluate for lipid abnormalities, abnormal glucose metabolism, and abnormal liver function in children and adolescents with obesity (BMI ≥ 95th percentile) and for lipid abnormalities in children and adolescents with overweight (BMI ≥ 85th percentile to <95th percentile).

<table>
<thead>
<tr>
<th>Aggregate Evidence Quality</th>
<th>Grade B.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefits</td>
<td>Allows for early detection and management to reduce risk factors for future cardiometabolic disease. Result will guide treatment. May motivate treatment engagement.</td>
</tr>
<tr>
<td>Risks, harm, costs</td>
<td>Cost, access, patient anxiety, labeling with chronic medical condition, stress, and time of undergoing treatment.</td>
</tr>
<tr>
<td>Benefit-harm assessment</td>
<td>Identification and management of cardiometabolic comorbidities in childhood and adolescence exceeds potential harm, especially for high-risk patients.</td>
</tr>
<tr>
<td>Intentional vagueness</td>
<td>Age.</td>
</tr>
<tr>
<td>Role of patient preferences</td>
<td>Parent and patient knowledge, family history, families’ concern about the test, ease and accessibility of testing should be considered.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>&lt;24 mo old.</td>
</tr>
<tr>
<td>Strengths</td>
<td>Strong.</td>
</tr>
<tr>
<td>Key references</td>
<td>80, 86, 88, 90, 398, 397, 413–416</td>
</tr>
</tbody>
</table>
Children ≥ 10 Years

To encourage a pragmatic and efficient evaluation strategy, KAS 3 and 3.1 recommend that, for children with obesity, evaluation for lipid abnormalities, abnormal glucose metabolism, and liver dysfunction be obtained at the same time and begin at age 10 years. The expectation is that pediatricians and other PHCPs will find it easier to adhere to recommendations when all tests are obtained at the same time. They may order fasting laboratory tests for the evaluation, because a fasting lipid panel is still the recommended test to evaluate for dyslipidemia for children and adolescents with overweight and obesity (see the dyslipidemia section, below, for additional information).

Children 2–9 Years

For children 2 to 9 years of age with obesity, evaluation for lipid abnormalities may be considered (KAS 3.1). This recommendation aligns with the 2011 National Heart Lung Blood Institute (NHLBI) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents.86 In population-based studies, lipid abnormalities occur in children younger than 10 years, with higher rates among children with obesity.395,417 High triglycerides (TG) and low high-density lipoprotein (HDL) levels (the typical pattern of dyslipidemia that occurs with obesity) have been reported in children with obesity as young as 3 years.395

As the risk profile for NAFLD and diabetes mellitus in children younger than 10 years is lower (especially in the absence of severe obesity), obtaining tests for abnormal glucose metabolism or liver function is not universally recommended for this population.88,90,415,418

Detailed and specific recommendations are provided in the following sections on dyslipidemia, prediabetes and diabetes mellitus, and NAFLD.

Children With Overweight

For children 10 years and older with overweight, evaluating for lipid abnormalities is recommended in the absence of additional risk factors (KAS 3).86,412 For evaluation of type 2 diabetes mellitus (T2DM), additional risk factors need to be considered, which include: family history, history of gestational diabetes, signs of insulin resistance (such as acanthosis nigricans), and use of obesogenic psychotropic medication.90,358,419 For NAFLD, additional risk factors include family history of NAFLD, central adiposity, signs of insulin resistance, prediabetes or diabetes mellitus, dyslipidemia, and sleep apnea.88

Considerations for Testing

Among children with obesity, there is clustering of comorbidities, a higher risk profile for more severe disease and/or progression than may be commonly or previously recognized.396,421–423 For example, regardless of the definition used for metabolic syndrome, the prevalence is 0% to 4.7% among children with healthy weight and increases to 14.5% to 35% among children and adolescents with obesity.396 In a cohort of 675 children with NAFLD from 12 clinical centers across the United States, one-third had T2DM or prediabetes,422 2 conditions that have significant morbidity in childhood. Adolescents with severe obesity—who have comparable BMI and metabolic profiles as adults—are more likely to present with advanced liver damage and severe systemic inflammation, suggesting that pediatric NAFLD may be more aggressive.424 Similarly, in T2DM, children have a more rapid rate of progression of islet β cell failure and dysglycemia compared with adults.425–427

Concerns about overtesting and cost are warranted but are balanced by the significant impact of obesity and...
comorbidities on morbidity and mortality. Almost half (43%) of children and adolescents with obesity have at least 1 abnormal lipid level, and 1 in 5 US adolescents have prediabetes, which are both precursors for future cardiometabolic disease. Although the prevalence of T2DM in children is low, at approximately 1%, the incidence has increased from 9 in 100 000 in 2002 to 13.8 in 100 000 in 2015, a worrisome annual percentage change of 4.6%. NAFLD is considered one of the most common chronic liver diseases in children and occurs more frequently in male children, older children, and Hispanic children.

Finally, although obesity prevalence rates continue to rise, the rate of evaluating for obesity or comorbidities in practice is low—suggesting that any concerns about overtesting are likely to be more theoretical than real.

See Appendix 3 for information on frequency of testing for comorbidities.

**B. Concurrent Treatment of Obesity and Obesity-Related Comorbidities**

There is substantial evidence to support concurrent treatment of obesity and comorbidities to achieve weight loss, avoid further weight gain, and improve obesity-related comorbidities. The majority of studies reviewed in the technical report on comorbidities demonstrate an association between overweight and/or obesity, severity of obesity, and higher prevalence of comorbidities. Studies also report improvement in comorbidities with intensive lifestyle treatment, weight loss medication, and/or bariatric surgery. Specifically, cardiometabolic markers improved significantly in children with obesity who underwent intensive pediatric obesity treatment of 3 to 6 months, which provides an opportunity for clinicians to emphasize health outcomes of lifestyle management. Interventions that meet the intensity or “dose” threshold of 26 hours or more over 2 to 12 months can lead to clinically significant improvements in BMI, and decreases in BMI can lead to clinically meaningful improvements in comorbidities.

Guidelines for dyslipidemia, T2DM, NAFLD, and HTN all recommend lifestyle treatment of the primary management of the comorbidity. Although the specific dietary recommendation may differ slightly (eg, CHILD-1 and 2 for dyslipidemia, low-glycemic diet for prediabetes, limiting sugary beverages for NAFLD, and a Dietary Approaches to Stop Hypertension [DASH] Diet for elevated BP), there is overlap between the dietary recommendations and all comorbidities improve with weight stabilization and reduction.

Children are often seen at least once a year for WCCs, at which the pediatrician or other pediatric health care provider reviews the growth chart, provides anticipatory guidance on growth, feeding, nutrition, sedentary screen time, and participation in physical activity. At a minimum, the WCC can include evaluation for comorbidities for children with overweight and obesity, and anticipatory guidance on risk for comorbidities with increasing BMI or obesity. It may be helpful for pediatricians and other PHCPs to include the diagnosis of obesity to the problem list to heighten awareness and remind providers to address weight concerns at subsequent clinic encounters. In a large adult study, documentation of an obesity diagnosis on a problem list was independently predictive of at least 5% weight loss. To avoid any harmful effects related to potential weight bias and stigma, however, pediatricians and other PHCPs need to be mindful of how this diagnosis is conveyed to the child and/or caregiver.

There may also be a potential benefit for improved weight outcomes with comorbidity evaluation. In adult studies, identifying obesity-related comorbidities has been shown to be a motivating factor to address weight concerns. The evidence in pediatrics is, however,

<table>
<thead>
<tr>
<th>Aggregate Evidence Quality</th>
<th>Grade A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benefits</strong></td>
<td>Awareness of relationship between comorbidities and weight status, treating weight improves comorbidities. Improved continuity of care and outcomes. Provides an opportunity to discuss health.</td>
</tr>
<tr>
<td><strong>Risks, harms, costs</strong></td>
<td>Anxiety about weight or comorbidities, time needed for education counseling, potential for disordered eating. Health care costs.</td>
</tr>
<tr>
<td><strong>Benefit-harm assessment</strong></td>
<td>Benefits exceed potential harm.</td>
</tr>
<tr>
<td><strong>Intentional vagueness</strong></td>
<td>Pediatricians and other PHCPs may not have access to appropriate subspecialists.</td>
</tr>
<tr>
<td><strong>Role of patient preference</strong></td>
<td>Increased visit time, patient or parent experience with prior weight-related counseling.</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>&lt;24 mo.</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>Strong.</td>
</tr>
<tr>
<td><strong>Key references</strong></td>
<td>80, 86–88, 90, 396, 410, 414, 415, 419, 420, 433–437</td>
</tr>
</tbody>
</table>
Adolescents identify a desire for improved health as a primary motivation for change. Another study analyzed clinic records of 4000 youth aged 10 to 18 years with overweight or obesity in an academic primary care network and found that youth who were evaluated ($n = 2815$) with a glycosylated hemoglobin ($HbA1c$) had a decrease in BMI-z slope per year after the $HbA1c$ test compared with similar peers ($n = 2087$) who had not been evaluated. Among those who had an $HbA1c$ test, the decline in BMI-z slope per year was greater for youth with $HbA1c$ in the prediabetes-range. An earlier study with a similar pediatric clinic population but a smaller sample size ($n = 128$) did not find a positive effect on BMI change following cholesterol evaluation. There is a need for more studies before definitive conclusions can be reached about whether evaluating families for comorbidities increases engagement, adoption of healthy choices, and weight loss or has unintended negative effects.

### C. Specific Guidelines for Initial Evaluation for Comorbidities

The following sections provide specific recommendations on initial comorbidity evaluation. Guidance on repeat evaluation and initial comorbidity management may be found in Appendix 3.

#### C1. Dyslipidemia

Children and adolescents with overweight and obesity have increased prevalence of abnormal lipid levels. The combination of hypertriglyceridemia and low high-density lipoprotein (HDL) levels, driven largely by underlying insulin resistance, is the most common type of dyslipidemia seen with overweight and obesity. Children and adolescents with overweight and obesity can also have elevated total cholesterol and low-density lipoprotein (LDL) levels. NHANES data from 2011 to 2014 showed that prevalence of abnormal lipid level was 3 times higher among children and adolescents with obesity, compared with those with a healthy BMI (43% vs 14%).

Studies indicate that cardiovascular risk factors track from childhood into adult life and that lifestyle treatments can improve outcomes with respect to these risk factors. Being aware of the association of these “silent” cardiovascular comorbidities with overweight and obesity—as well as their persistence into adulthood with potential serious health consequences—obliges pediatricians and other PHCPs to perform laboratory testing, educate patients and families about the long-term risks of cardiovascular disease and provide nutrition and activity counseling.

This KAS is supported by both the 2011 NHLBI Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents and 2018 American Heart Association and American College of Cardiology Guidelines, which recommend evaluation for early risk of atherosclerotic cardiovascular disease and counseling on risk-reduction behaviors in children and adolescents. Evaluation for dyslipidemia with obesity is recommended for younger children, as well as for children 10 years and older. Although data are limited in young children, 1 population-based study showed that 10% of children with obesity aged 3 to 5 years have elevated TG and low HDL levels.

In addition to obesity, other risk factors for dyslipidemia include cigarette use, HTN, diabetes, and a family history of cardiovascular disease in a first- or second-degree relative ($\leq 55$ years for males and $\leq 65$ years for females) with a history of myocardial infarction, sudden death, or HTN. All of these conditions...
warrant laboratory evaluation and may help guide clinical decisions for assessment of dyslipidemia in younger children. Additionally, awareness of an association of social factors, specifically ACEs, with cardiovascular risk factors is important.\(^{455}\)

### C.1.a. Laboratory Tests for Diagnosis of Dyslipidemia

The NHLBI expert panel recommends a fasting lipid panel for evaluation of dyslipidemia for children with overweight and obesity.\(^{86}\) Because dietary fats and carbohydrates (particularly simple sugars) increase serum TG concentrations, 8 to 12 hours of fasting before testing is recommended.\(^{456}\) Given that a combination of high TG and low HDL cholesterol is the most common pattern of dyslipidemia observed in children with overweight and obesity, the recommendation to obtain a fasting lipid panel is important, because nonfasting TG levels will not be accurate.\(^{86}\)

For practical purposes, a nonfasting lipid panel using the non-HDL level may be easier to obtain for routine evaluation in the primary care setting. The non-HDL level is the total cholesterol minus the HDL cholesterol level. If the non-HDL cholesterol level is abnormal (non-HDL \(\geq 145\) mg/dL) and/or the HDL level is < 40 mg/dL, a fasting lipid panel needs to be obtained for diagnosis.\(^{412}\) The nonfasting lipid panel is recommended for all children 9 to 11 years of age to evaluate for familial hypercholesterolemia.\(^{86}\) Estimates are that approximately 25% of children would be referred for a fasting lipid panel because of elevated non-HDL lipid evaluation.\(^{86}\) Because of the elevated risk of lipid abnormality among youth with overweight and obesity, a fasting lipid panel is recommended. See the implementation guide for additional information.

The cut-off criteria for lipids in the 2011 NHLBI guidelines are the same across different age groups, except for triglycerides, as indicated in Table 8.

### TABLE 8 NHLBI Criteria for Lipid Testing Results

<table>
<thead>
<tr>
<th>Lipid Category</th>
<th>Low (mg/dL)</th>
<th>Acceptable (mg/dL)</th>
<th>Borderline High (mg/dL)</th>
<th>High (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol</td>
<td>—</td>
<td>&lt;170</td>
<td>170–199</td>
<td>(\geq 200)</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>—</td>
<td>&lt;110</td>
<td>110–129</td>
<td>(\geq 130)</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>&lt;40</td>
<td>—</td>
<td>75–98</td>
<td>(\geq 100)</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>0–8 y</td>
<td>&lt;75</td>
<td>90–129</td>
<td>(\geq 130)</td>
</tr>
<tr>
<td>10–19 y</td>
<td>—</td>
<td>&lt;90</td>
<td>120–144</td>
<td>(\geq 145)</td>
</tr>
<tr>
<td>Non-HDL cholesterol</td>
<td>—</td>
<td>&lt;120</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Adapted from the Expert Panel on Integrated Guidelines for Cardiovascular Health.\(^{86}\) —, not applicable.

### C.2. Prediabetes and Type 2 Diabetes Mellitus

T2DM is now increasingly diagnosed in the pediatric population. Between 2002 and 2015, the incidence of T2DM among 10- to 19-year-olds in the United States increased from 9.0 to 13.8 per 100 000.\(^{290,399,458}\) Based on the 2005 to 2016 NHANES, 1 in 5 adolescents (12–18 years) have prediabetes.\(^{423}\) Although uncommon, T2DM has been diagnosed in children younger than 10 years, some as young as 4 years of age.\(^{459,460}\) For this reason, pediatricians and other PHCPs should consider risk factors and symptoms of altered glucose metabolism in all ages (eg, polydipsia, polyphagia, polyuria, blurred vision, unexplained weight loss).

Because obesity is a strong predictor for developing prediabetes and T2DM,\(^{423,461,462}\) pediatricians and other PHCPs need to have an increased index of suspicion when caring for children with obesity, especially in the presence of other risk factors (Table 9).\(^{90,408,414,415,463}\) Both genetics and SDoHs account for some of the racial and ethnic disparities observed in the incidence of T2DM.\(^{401,408}\)

The pathogenesis of prediabetes and T2DM is a peripheral and hepatic resistance to insulin accompanied by progressive loss of islet cell function.

### TABLE 9 Other Risk Factors for Prediabetes and T2DM\(^{90,358,415,419}\)

<table>
<thead>
<tr>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal history of diabetes or gestational diabetes</td>
</tr>
<tr>
<td>Family history of diabetes in first- or second-degree relative</td>
</tr>
<tr>
<td>Signs of insulin resistance or conditions associated with insulin resistance (acanthosis puberty nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight)</td>
</tr>
<tr>
<td>Use of obesogenic psychotropic medications</td>
</tr>
</tbody>
</table>
Insulin resistance, when assessed by the homeostatic model assessment of insulin resistance test, varies across weight categories, with highest levels observed among children with severe obesity. Some children with T2DM have rapidly progressive disease, which underscores the need for early identification and intensive treatment in collaboration with a pediatric endocrinologist.

C.2.a. Laboratory Tests for the Diagnosis of Prediabetes and T2DM

Testing for T2DM should always be performed if there is suspicion of hyperglycemia in a patient with symptoms and signs of hyperglycemia, such as new onset thirst (polydipsia), frequent urination (polyuria) or new onset bedwetting, excessive hunger and eating (polyphagia), blurred vision, unexplained or unexpected weight loss, or fatigue.

Diagnostic tests for prediabetes and T2DM are fasting plasma glucose (FPG), 2-hour plasma glucose after oral glucose tolerance test (OGTT), and HbA1c. There are several clinical guidelines that do not recommend one test over the other for evaluation. However, the OGTT is highly reproducible; the OGTT, which does not fare as well on reproducibility, is effective in identifying dysglycemia. This is a good reason to use the OGTT as a confirmation test if the initial test result is equivocal. The OGTT, however, may not be readily available at some medical settings, requires fasting before the test, lasts at least 2 hours, and includes an unpalatable glucose drink—all of which are factors that can limit its use in pediatric outpatient settings as an evaluation test.

The HbA1c test is easy to obtain as fasting is not required. It provides a measure of chronic hyperglycemia, and use of the test has been shown to increase evaluation for T2DM in primary care settings. It is also the recommended test for monitoring prediabetes. The sensitivity of HbA1c for diagnosing diabetes is lower in children when compared with adults. Pediatricians and other PHCPs also need to be aware that HbA1c levels can be 0.1% to 0.2% higher in individuals with iron deficiency anemia.

Fasting insulin is not recommended for diagnosis of prediabetes or T2DM because the levels are highly variable.

---

**TABLE 10 Criteria for Diagnosing Prediabetes and T2DM**

<table>
<thead>
<tr>
<th>Fasting plasma glucose (FBG)</th>
<th>2-h plasma glucose (OGTT)</th>
<th>Random plasma glucose (RBG)</th>
<th>HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>100–125 mg/dL</td>
<td>140–199 mg/dL</td>
<td>Not applicable</td>
<td>5.7% to 6.4%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prediabetes or Impaired Glucose Tolerance</th>
<th>Diabetes Mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td>126 mg/dL</td>
<td>≥126 mg/dL</td>
</tr>
<tr>
<td>200 mg/dL</td>
<td>≥200 mg/dL</td>
</tr>
<tr>
<td>6.5% to 6.4%</td>
<td>6.5%</td>
</tr>
</tbody>
</table>

*In the absence of unequivocal hyperglycemia, diagnosis is confirmed if 2 different tests are above threshold or a single test is above threshold on 2 separate occasions.

*Fasting for at least 8 h with no calorie intake.

*Oral glucose tolerance test (OGTT) using a load 1.75 g/kg of body weight of glucose with a maximum of 75 g.

*In patients with hyperglycemic crises or classic symptoms of hyperglycemia (e.g., polyuria, polydipsia).

*Glycosylated hemoglobin (HbA1c) is the preferred test for monitoring prediabetes.
and do not reliably correlate with the level of insulin resistance.\textsuperscript{268,477} The cut-off values are similar for pediatric and adult populations, as illustrated in Table 10, above. If the results are unequivocally high and indicative of T2DM, obtaining a second or repeat confirmatory test is not recommended; instead, treatment should be initiated.\textsuperscript{90,415} Guideline recommendations for tracking glycemic control over time use the HbA1c test; however, the FPG can be substituted using the cut-off criteria in Table 10. See the implementation guide for further discussion on use of OGTT or FBG tests.\textsuperscript{90,414,415,419,464}

See Appendix 3 for more information on frequency of evaluation and on initial management of prediabetes and T2DM.

C.3. Nonalcoholic Fatty Liver Disease

NAFLD is a chronic liver disease marked by steatosis (fat accumulation), inflammation, and fibrosis. The underlying pathogenesis is insulin resistance, which alters the process of fat oxidation in the liver, increasing oxidative stress and inflammation— with resultant liver damage. Among children with obesity, rates as high as 34% have been reported.\textsuperscript{429} Three diagnostic terms are used to describe the histology of the disease progression: NAFLD, nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). NAFLD refers to the whole spectrum of the disorder, from mild steatosis to cirrhosis of the liver. NAFLD is divided into steatosis (NAFL) and steatohepatitis (NASH). In NAFL, the milder form of the condition, there is fatty infiltration in \( \geq 5\% \) of the liver, with or without fibrosis. In NASH, there is inflammation, steatosis, and fibrosis with ballooning injury to the hepatocytes.\textsuperscript{433}

The risk profile and natural history of the disorder in the pediatric population are still evolving, given that there are limited long-term studies in children. Pediatric NAFLD may reflect the early onset of a chronic disease with a more aggressive course, particularly once NASH has occurred.\textsuperscript{424,479} Preadolescent children with NAFLD have higher rates of mortality over 20 years, compared with their peers without NAFLD.\textsuperscript{479} Children with increasing weight gain; higher levels of alanine transaminase (ALT), \( \gamma \) glutamyl transferase (GGT), and cholesterol at baseline; worsening levels of HbA1c; and an incident diagnosis of T2DM are more likely to have severe disease or progression (Table 11).\textsuperscript{433,479} However, in a recent study of children 8 to 17 years of age with biopsy-confirmed NAFLD who received standardized nutrition and exercise counseling consistent with the 2007 AAP Expert Recommendations at 12-week intervals over 1 to 2 years, about half demonstrated any improvement in resolution of NASH or regression of fibrosis. Among children with borderline or definite NASH, resolution occurred in about one-third. Adolescents were more likely to develop worsening steatosis and less likely to experience any resolution of NASH or regression in fibrosis than younger children.\textsuperscript{433}

C.3.a. Laboratory Tests for Diagnosis of NAFLD

The 2017 North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) clinical practice guidelines recommend ALT as the preferred test for NAFLD.\textsuperscript{88} ALT is more specific for liver disease than aspartate transaminase (AST), easily accessible at laboratory centers, minimally invasive relative to other testing modalities for NAFLD, and has been used most often in pediatric NAFLD studies. Higher levels of ALT correlate

\begin{table}[h]
\centering
\begin{tabular}{|c|c|}
\hline
\textbf{NAFLD} & \textbf{Risk Factors}\textsuperscript{a} \\
\hline
\textbf{Diagnosis} & Male sex, \( \geq 10 \) y, obesity, sibling with NAFLD, prediabetes or diabetes mellitus, obstructive sleep apnea, dyslipidemia \\
\textbf{Progression} & Adolescent \( \geq 14 \) y; higher or increasing alanine transaminase; elevated baseline aspartate transaminase, \( \gamma \) glutamyl transferase (GGT), and LDL cholesterol; prediabetes or diabetes mellitus, obstructive sleep apnea; increasing wt or waist circumference \\
\hline
\end{tabular}
\end{table}

\textsuperscript{a} Consideration should be given to groups of certain races/ethnicities with higher rates of NAFLD (e.g., Hispanic, Asian), for which higher prevalence can be attributed to genetic, socioeconomic, and environmental factors.\textsuperscript{160}
with more advanced liver disease with steatosis and fibrosis; however, a normal ALT does not definitively exclude NAFLD. In a population of children older than 10 years with overweight and obesity who were referred from a primary care clinic, an ALT level \( \geq 80 \) IU/L had a sensitivity of 57% and a specificity of 71% for NASH. Elevations in AST and GGT, especially at baseline, can be indicative of severe disease or rapid progression.

NAFLD is less common in children younger than 10 years. In an autopsy study of 742 children, 3.3% of 5- to 9-year-old children had fatty liver, compared with 11.3% in 10- to 14-year-olds and 17.3% in 15- to 17-year-olds. There is a higher risk for NAFLD in young children 2 to 9 years of age who have severe obesity, however. Thus, pediatricians and other PHCPs may consider evaluating NAFLD by obtaining an ALT level every 2 years in these children.

See Appendix 3 for more information on the frequency of evaluation for NAFLD and on managing NAFLD.

C.4. Hypertension

The prevalence of HTN among children and adolescents with overweight and obesity ranges from 5% to 30%, with higher prevalence with increasing BMI percentile. Children with excess weight also have abnormal diurnal variation in BP. One-third of children with obesity have a decreased nocturnal BP dip, increasing the potential risk for end-organ damage. Among children with obesity, additional cardiometabolic risk factors—such as insulin resistance or dyslipidemia—may affect BP, independent of obesity.

Studies indicate that HTN during childhood and adolescence increases the risk for adult HTN and cardiovascular disease. More concerning, studies have shown that, among children with obesity, HTN is associated with vascular changes, increased left ventricular mass, and carotid intima media thickness during childhood. These findings support the importance of evaluating for HTN early and consistently throughout childhood and adolescence among individuals with overweight and obesity.

C.4.a. Evaluation for HTN

Obesity is the strongest risk factor for HTN in childhood. Elevated BP is observed in early childhood and prevalence increases with age and BMI category. A large study conducted in primary care settings found that 8% of children 3 to 5 years of age with obesity had elevated BP levels; the percentage increased to 20% among children 11 to 15 years of age. HTN prevalence varies by race and ethnicity, with highest prevalence occurring among non-Hispanic Black and Hispanic youth. SES is also a risk factor for HTN, as are adverse childhood experiences, both prenatally and during childhood. These factors may contribute to the higher prevalence of hypertension observed among non-Hispanic Black and Hispanic youth.

Pediatricians and other PHCPs should obtain a history of salt intake (eg, addition of salt while cooking and/or at meals) and sources of sodium from processed, frozen, and fast foods, because high sodium intake is associated with childhood HTN. Obtaining a history of physical activity and inactivity levels is also recommended, because decreased activity levels are associated with childhood HTN. Finally, evaluation of sleep duration and disordered breathing are recommended because of the association between abnormal sleep duration and OSA and elevated BP.

This KAS aligns with the 2017 AAP’s “Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents,” which recommends evaluation of elevated BP and HTN for children with obesity at every clinic visit beginning at 3 years of age. Frequent monitoring of BP among children with overweight and
obesity fosters earlier detection of elevated BP.

**C.4.b. Diagnosis of HTN**

In 2017, the AAP published a CPG on HTN that included recommendations for evaluation for elevated BP and updated HTN

definitions of “elevation,” “stage 1 BP,” and “stage 2 BP” (see Table 12).

This CPG recommended that an elevated initial BP measurement (≥90th percentile), taken either by oscillimetry or auscultation, should be repeated twice with auscultation and averaged, at the same visit, to determine accurate BP measurement and category. For diagnosis, BP by auscultation should be repeated with confirmed elevated BP measurements on 3 separate clinic visits for elevated BP and stage 1 HTN, and on 2 separate visits for stage 2 HTN.87

### TABLE 12 BP Categories by Age and Number of Visits Needed for Diagnosis

<table>
<thead>
<tr>
<th>BP Category</th>
<th>Children 1–13 Years of Age</th>
<th>Children ≥13 Years of Age</th>
<th>Number of Visits to Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>BP &lt; 90th percentile</td>
<td>BP &lt;120/80 mm Hg</td>
<td>NA</td>
</tr>
<tr>
<td>Elevated</td>
<td>BP ≥ 95th percentile to &lt;95th percentile</td>
<td>120/80 to 129/89 mm Hg</td>
<td>3</td>
</tr>
<tr>
<td>Stage 1</td>
<td>BP ≥ 95th percentile to &lt;95th percentile + 12 mmHg</td>
<td>130/80 to 139/89 mm Hg</td>
<td>3</td>
</tr>
<tr>
<td>Stage 2</td>
<td>BP ≥ 95th percentile + 12 mm Hg</td>
<td>≥140/90 mm Hg</td>
<td>2</td>
</tr>
</tbody>
</table>

Used with permission and adapted from the AAP HTN CPG,87 Fig 2, and AAP Pediatric Obesity Clinical Decision Support Chart.494 NA, not applicable.

### TABLE 13 Summary of KASs for Evaluation of Comorbidities Among Children and Adolescents With Overweight and Obesity

<table>
<thead>
<tr>
<th>KAS #</th>
<th>Key Action Statement (KAS)</th>
<th>Evidence Quality, Recommendation Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>In children 10 y and older, pediatricians and other PHCPs should evaluate for lipid abnormalities, abnormal glucose metabolism, and abnormal liver function in children and adolescents with obesity (BMI ≥ 95th percentile) and for lipid abnormalities in children and adolescents with overweight (BMI ≥ 95th percentile to &lt;95th percentile)</td>
<td>B, Strong</td>
</tr>
<tr>
<td>3.1</td>
<td>In children 10 y and older with overweight (BMI ≥ 85th percentile to &lt;95th percentile), pediatricians and other PHCPs may evaluate for abnormal glucose metabolism and liver function in the presence of risk factors for T2DM or NAFLD. In children 2 to 9 y of age with obesity (BMI ≥ 95th percentile), pediatricians and other PHCPs may evaluate for lipid abnormalities.</td>
<td>C, Moderate</td>
</tr>
<tr>
<td>4</td>
<td>Pediatricians and other PHCPs should treat children and adolescents for overweight (BMI ≥ 85th percentile to &lt;95th percentile) or obesity (BMI ≥ 95th percentile) and comorbidities concurrently.</td>
<td>A, Strong</td>
</tr>
<tr>
<td>5</td>
<td>Pediatricians and other PHCPs should evaluate for dyslipidemia by obtaining a fasting lipid panel in children 10 y and older with overweight (BMI ≥ 85th percentile to &lt;95th percentile) and obesity (BMI ≥ 95th percentile) and may evaluate for dyslipidemia in children 2 through 9 y of age with obesity.</td>
<td>B, Strong (10 y and older); C, moderate (2–9 y of age)</td>
</tr>
<tr>
<td>6</td>
<td>KAS 6. Pediatricians and other PHCPs should evaluate for prediabetes and/or diabetes mellitus with fasting plasma glucose, 2-h plasma glucose after 75-g oral glucose tolerance test (OGTT), or glycosylated hemoglobin (HbA1c).a</td>
<td>B, Moderate</td>
</tr>
<tr>
<td>7</td>
<td>KAS 7. Pediatricians and other PHCPs should evaluate for NAFLD by obtaining an alanine transaminase (ALT) test.b</td>
<td>A, Strong</td>
</tr>
<tr>
<td>8</td>
<td>Pediatricians and other PHCPs should evaluate for hypertension by measuring blood pressure at every visit starting at 3 y of age in children and adolescents with overweight (BMI ≥ 85 percentile to &lt;95th percentile) and obesity (BMI ≥ 95th percentile).</td>
<td>C, Moderate</td>
</tr>
</tbody>
</table>

---

8. Per KAS 3 and 3.1: pediatricians and other PHCPs should evaluate children 10 y and older with obesity (BMI ≥ 95th percentile) for abnormal glucose metabolism and may evaluate children 10 y and older with overweight (BMI ≥ 85th percentile to <95th percentile) with risk factors for T2DM or NAFLD for abnormal glucose metabolism. (Refer to evidence tables for KAS 3 and 3.1)

9. Per KAS 3 and 3.1: pediatricians and other PHCPs should evaluate children 10 y and older with obesity (BMI ≥ 95th percentile) for abnormal liver function and may evaluate children 10 y and older with overweight (BMI ≥ 85th percentile to <95th percentile) with risk factors for T2DM or NAFLD for abnormal liver function. (Refer to evidence tables for KAS 3 and 3.1)
BP measurements should be taken with an appropriately sized cuff; the bladder length should be 80% to 100% of the circumference of the arm, and the width should be at least 40% of the arm circumference. (See https://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/manual_an.pdf)

For children and adolescents with excess weight, a larger cuff size may be required to obtain accurate measurements. For children and adolescents with severe obesity, a thigh cuff may be needed. Additionally, for children and adolescents with obesity, ambulatory blood pressure monitoring (ABPM) is recommended to assess HTN severity and identify possible abnormal circadian BP patterns, which increases risk for end-organ damage. ABPM also helps to identify masked HTN and/or “white coat” HTN.

Elevated BP in the office setting is unrecognized in approximately 25% of cases. The AAP’s CPG on HTN provides pediatricians and other PHCPs with practical tools to assist with identification of elevated BP and HTN. Improved identification of children at high risk and youth allows for a thorough evaluation, treatment, and follow-up, with the goal of decreasing long-term cardiovascular morbidity and mortality.

See Appendix 3 for more information on repeat evaluation for HTN and on management of HTN.

Table 13 lists the KASs for the comorbidities covered in the TR.

D. Other Comorbidities

D.1. Obstructive Sleep Apnea

OSA is a sleep disorder characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction that disrupts normal ventilation during sleep. The condition is associated with cardiovascular complications, neurocognitive impairment, and decreased quality of life. Children with obesity have a higher prevalence of OSA: 45% among children obesity compared with 9% among children with healthy weight. One study indicated that a 1-unit increase in the BMI SD score increased the odds of having OSA by a factor of 1.9 independent of age, sex, tonsillar hypertrophy, and asthma.

Evaluation for OSA is based on history of symptoms and examination. Children with obesity, tonsillar hypertrophy, craniofacial anomalies, trisomy 21, and neuromuscular disorders are at higher risk for OSA. Common symptoms include frequent snoring, gasps or labored breathing during sleep, disturbed sleep, daytime sleepiness, inattention and/or learning problems, nocturnal enuresis, and headaches. Examination findings may include tonsillar hypertrophy, adenoidal facies, micro- or retrognathia, high-arched palate, and elevated BP. Diagnosis is made by obtaining a polysomnography, the gold standard test, with an apnea-hypopnea index of 1 or more episodes per hour in children.

Because of limited availability of sleep centers with pediatric expertise, referral to a pediatric otolaryngologist for further evaluation, diagnosis, and management may be needed.

Consensus Recommendations

The CPG authors recommend pediatricians and other PHCPs obtain:

- A sleep history, including symptoms of snoring, daytime somnolence, nocturnal enuresis, morning headaches, and inattention, among children and adolescents with obesity to evaluate for OSA.
- A polysomnogram for children and adolescents with obesity and at least 1 symptom of disordered breathing.

See Appendix 3 for more information on the initial management of OSA.

---

TABLE 14 Definitions and Criteria for PCOS

<table>
<thead>
<tr>
<th>Definition</th>
<th>Diagnostic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health</td>
<td>Requires the presence of: 1. Hyperandrogenism (clinical and/or biochemical) 2. Ovarian dysfunction</td>
</tr>
<tr>
<td>American Society of Reproductive Medicine (Rotterdam)</td>
<td>Requires the presence of at least 2 criteria: 1. Hyperandrogenism (clinical and/or biochemical) 2. Ovulatory dysfunction 3. Polycystic ovarian morphology</td>
</tr>
<tr>
<td>American Endocrine Society</td>
<td>Requires the presence of hyperandrogenism (clinical and/or biochemical) and either: 1. Ovulatory dysfunction 2. Polycystic ovarian morphology</td>
</tr>
<tr>
<td>Androgen Excess and Polycystic Ovary Syndrome Society</td>
<td>Requires the simultaneous presence of: 1. Hyperandrogenism (clinical and/or biochemical) 2. Ovarian dysfunction (ovulatory dysfunction and/or polycystic ovarian morphology)</td>
</tr>
</tbody>
</table>

All of the diagnostic criteria for PCOS require the exclusion of other disorders of adrenal excess, such as nonclassic or late-onset congenital adrenal hyperplasia, Cushing syndrome, hyperprolactinemia, hypothyroidism, acromegaly, premature ovarian failure, a virilizing adrenal or ovarian neoplasm, or a drug-related condition.
D3. Polycystic Ovarian Syndrome

Polycystic ovarian syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and disordered ovulatory function and is often associated with obesity and insulin resistance. The condition increases risk for infertility, T2DM, cardiovascular disease, and cancer.497

Four different sets of criteria have been published for diagnosis of PCOS in adults as outlined by differing professional organizations (Table 14).498 Establishment of diagnostic criteria for PCOS in adolescence has been difficult, because characteristic features of PCOS can be normal physiologic events during early adolescence.499 International pediatric and adolescent specialty societies have made recommendations for diagnosis specific to adolescents, which include the following: (1) evidence of clinical or biochemical hyperandrogenism, and (2) persistent irregular menstrual cycles (<20 days or >45 days) 2 years after menarche.500 Limited data are available on prevalence of PCOS in adolescents. Estimates range from 3% to 11%, depending on the criteria for diagnosis.501

Evaluation for PCOS in an adolescent requires first excluding other medical conditions that may cause menstrual dysfunction (oligomenorrhea or amenorrhea) and/or signs of androgen excess (acne, hirsutism, or alopecia). Additionally, for adolescents, evaluation should occur 2 years after menarche, because irregular menstrual cycles are not uncommon during this timeframe. Laboratory testing may include: 17-hydroxyprogesterone, total testosterone, free testosterone, sex hormone-binding globulin, dehydroepiandrosterone sulfate, androstenedione, luteinizing hormone, follicle-stimulating hormone, estradiol, prolactin, free thyroxine, thyroid stimulating hormone, and insulin. Interpretation of laboratory results should be made in the context of age-appropriate reference ranges; therefore, referral to a laboratory that can perform ultrasensitive pediatric assays is recommended. Routine ovarian imaging is not indicated for the diagnosis of PCOS in adolescents.498,502 An algorithm for evaluation is provided in the implementation materials from previously published consensus recommendations.503

See Appendix 3 for more information on the initial management of PCOS.

Consensus Recommendation

The CPG authors recommend pediatricians and other PHCPs:

- Evaluate for menstrual irregularities and signs of hyperandrogenism (ie, hirsutism, acne) among female adolescents with obesity to assess risk for PCOS.

D4. Depression

The relationship between pediatric obesity and depression is less well understood than the physical comorbidities; however, identification of depression is an important component of the assessment and management of pediatric obesity, given its potential impact on treatment outcomes. A systematic review and meta-analyses conducted in 2019 showed that children 18 years and younger with obesity have a 32% increased odds of having or developing depression compared with children of healthy weight, with the highest odds (44%) among females with obesity.504

Studies are limited on the effect of treatment of pediatric obesity on depression. A recent meta-analysis of 36 studies found a small but significant reduction in depressive symptoms following structured pediatric obesity treatment. Notably, no adverse mental health outcomes were reported.505 Additionally, the interventions technical report indicates that obesity treatment may improve psychosocial outcomes for youth with obesity, including quality of life.80 Further research in this area is needed; however, pediatricians and other PHCPs should be aware that obesity treatment interventions have not been associated with increased symptoms of depression.80

Evaluation for depression includes awareness of symptoms and risk factors. Symptoms include irritability, fatigue, insomnia, excessive sleeping, decline in academic performance, family conflict, and weight changes. Risk factors include personal or family history of depression, substance use, trauma, frequent psychosomatic complaints, psychosocial stressors, and other mental health conditions. The AAP CPG for depression recommends evaluating adolescents 12 years and older for depression annually using a formal self-report tool, such as the Patient Health Questionnaire-9.506 Additionally, routine monitoring of psychosocial function and using an evaluation tool when a patient presents with symptoms of depression is recommended.

If initial evaluation for depression is positive, evaluation with a standardized depression tool should be conducted. Assessment for depression should also include direct, separate interviews with the patient and family members to include functional impairment at home, school, and peer settings and safety and/or suicide risk.506 The implementation materials include additional information and resources, including tools for pediatricians and other PHCPs, in...
addition to an assessment and management algorithm.  

See Appendix 3 for more information on the initial management of depression.

**Consensus Recommendation**

The CPG authors recommend pediatricians and other PHCPs:

- Monitor for symptoms of depression in children and adolescents with obesity and conduct annual evaluation for depression for adolescents 12 years and older with a formal self-report tool.

**D5. Orthopedic Comorbidities**

**D5.a. Slipped Capital Femoral Epiphysis**

Slipped capital femoral epiphysis (SCFE) is the most common hip disorder in the adolescent period. It occurs between 9 and 16 years of age, spanning periods of rapid linear growth. There is a 1.5:1 male-to-female ratio, and SCFE occurs more often in Black, Hispanic, and AI/AN children. SCFE is bilateral in 25% to 80% of cases. Weakening of the proximal femoral physis (growth plate) causes a slip in the physis, with a corresponding displacement of the epiphysis (femoral head). Risks such as obesity exert mechanical stress on the physis, whereas metabolic conditions (eg, hypothyroidism, hypopituitarism) weaken the physis, creating the ideal setup for a slip.

The common presentation is hip pain, although many children may present with knee pain alone or in addition to hip pain. The pain can happen only with weight bearing or be constant. On physical examination, there is external rotation with passive hip flexion, limitation of internal rotation and antalgic gait. Pain can also be elicited passively with internal rotation of the hip. SCFE is characterized as stable if the child can bear weight with or without crutches and as unstable when weight-bearing is not possible. Because SCFE can be bilateral, the pediatrician or other pediatric health care provider needs to remember to obtain a history and exam for the contralateral leg. The history and examination should also exclude differential diagnoses for hip pain (eg, infections, inflammation or autoimmune conditions, neoplasms, and trauma).

As the pathophysiologic process continues, the child is at greater risk for increased morbidity, including avascular necrosis. Thus, the importance of early diagnosis cannot be overemphasized. Once SCFE is suspected, pediatricians and other PHCPs should confirm the diagnosis and place an emergent referral to the orthopedic surgeon. The mainstay for diagnosis is plain radiographs of the hip and pelvis (Table 15). Ultrasonography and computerized tomography are not useful. In cases with equivocal radiography results and a high index of suspicion, MRI, which is more sensitive at assessing the physis, can be obtained.

Table 15 Recommended Imaging for Slipped Capital Femoral Epiphysis and Blount Disease

<table>
<thead>
<tr>
<th>Condition</th>
<th>First-Line Imaging</th>
<th>Additional Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCFE</td>
<td>Bilateral hip (anteroposterior and lateral), frog-leg radiographs</td>
<td>If SCFE is unstable, cross-table lateral radiograph. MRI for equivocal imaging results, or assess blood supply to femoral head.</td>
</tr>
<tr>
<td>Blount</td>
<td>Long leg (anteroposterior and lateral), knee (anteroposterior and lateral) radiographs</td>
<td>MRI of the knee to delineate level and extent of deformity, assess blood supply to physis.</td>
</tr>
</tbody>
</table>

See Appendix 3 for more information on the initial management of SCFE.

**D5.b. Blount Disease**

Blount disease is a growth disorder that primarily affects the proximal medial tibial physis and epiphysis. It often presents as a triad of asymmetric tibia vara, tibial torsion, and precurvatum. As with SCFE, excess weight is a risk factor, because it increases mechanical stress on the physis. Blount disease disproportionately affects non-Hispanic Black or Hispanic children. The reason for this predilection is unclear, but it may reflect epigenetic, social, or cultural factors that affect early ambulation, growth, or obesity. Other risk factors include a family history of Blount disease and ambulation before 12 months of age. Symptoms and signs include leg pain, abnormal gait with bowing of the lower legs, and leg-length discrepancy.

Blount disease is classified into 2 categories: (1) infantile or early-onset, and (2) late-onset or adolescent Blount disease, based whether the onset occurred before or after age 10 years, respectively. Infantile Blount disease is bilateral but asymmetric, occurs more often in males, and often includes a preceding history of early ambulation. For young children, pediatricians and other PHCPs should exclude physiologic bowing typically seen during toddlerhood, which is bilateral but symmetrical and resolves by age 3 or 4 years. In...
the adolescent subtype, the tibia vara deformity is milder, unilateral, and predominantly associated with severe obesity.\textsuperscript{510-513}

Plain radiographs are the initial imaging of choice (Table 15). When used, MRI provides a more sensitive investigation of the deformity.

See Appendix 3 for more information on the initial management of Blount disease.

**Consensus Recommendations**

The CPG authors recommend pediatricians and other PHCPs:

- Perform a musculoskeletal review of systems and physical examination (eg, internal hip rotation in growing child, gait) as part of their evaluation for obesity.
- Recommend immediate and complete activity restriction, nonweight-bearing with use of crutches, and refer to an orthopedic surgeon for emergent evaluation, if SCFE is suspected. PHCPs may consider sending the child to an emergency department if an orthopedic surgeon is not available.

**D.5.c. Idiopathic Intracranial Hypertension**

Idiopathic intracranial hypertension (IIH) (previously known as pseudotumor cerebri) is a neurologic condition with serious long-term morbidity.\textsuperscript{514,515} It occurs most often in females of childbearing age, and obesity is a well-established risk factor.\textsuperscript{516-518} In a population-based study in Olmstead County, Minnesota, the incidence of IIH among adult females aged 15 to 44 years with obesity was 3.5-fold higher than that of all females in that age group.\textsuperscript{517}

The pathogenesis is unclear, hence the name; however, 3 hypothesized mechanisms are increased venous pressure, decreased cerebrospinal fluid (CSF) drainage, and increased CSF production. Other factors associated with for IIH include medications (eg, doxycycline, tetracyclines, retinoic acid, sulfonamides), autoimmune disorders (eg, systemic lupus erythematosus), and hormonal disorders (eg, Cushing disease, Addison disease). A higher prevalence of IIH has also been reported in females with PCOS.\textsuperscript{519}

Typical symptoms are persistent headaches, pulsatile synchronous tinnitus, and visual changes or loss, although the history can be variable. Physical examination includes a fundoscopy for papilledema and a thorough neurologic evaluation for cranial nerve deficits such as sixth nerve palsy. The presence of altered consciousness or neurologic deficit with localized peripheral findings should prompt pediatricians and other PHCPs to consider another etiology. The serious sequelae for IIH is vision loss. Thus, a review of system should be obtained to evaluate any child with obesity who has significant or progressive headaches. There should also be a high index of suspicion for IIH with new-onset headaches and significant weight gain (5% to 15% of body weight), particularly when it occurs in the prior 12 to 18 months.\textsuperscript{518,520}

Initial evaluation for IIH involves conducting comprehensive evaluation by the neurologist and ophthalmologist or at an integrated IIH clinic.

See Appendix 3 for more information on the initial management of IIH.

**Consensus Recommendation**

The CPG authors recommend pediatricians and other PHCPs:

- Maintain a high index of suspicion for IIH with new-onset or progressive headaches in the context of significant weight gain, especially for females.

**D.6. Summary**

In summary, a thorough history and physical examination is invaluable in guiding pediatricians’ and other PHCPs’ assessment for comorbidities. This section of the CPG, the algorithm in Appendix 1, Appendix 3, and the accompanying implementation resources provide a framework for evaluation, reevaluation, and initial management. Obesity is a linchpin disorder with attendant comorbidities, some of which are not covered in this section or in the technical report (eg, pes planus). For these comorbidities,
pediatricians and other PHCPs are encouraged to seek resources available through the AAP and other professional societies.

**XI. TREATMENT OF CHILD AND ADOLESCENT OVERWEIGHT AND OBESITY**

**A. Obesity is a Chronic Disease**

Obesity is a chronic disease and should be treated with intensive and long-term care strategies, provision of ongoing medical monitoring and treatment of associated comorbidities and ongoing access to obesity treatment. As noted previously, obesity is associated with increased prevalence of comorbidities, including abnormal lipids, glucose dysregulation and other endocrinopathies, abnormal liver enzymes, and elevated BP. A key component of treating obesity is to concurrently monitor and treat the comorbidities (see Comorbidities section).

The chronic care model requires care to be delivered within the context of individual patient factors, taking into consideration the child’s household and familial influences, access to healthy food and activity spaces, and other SDoHs.522 Recommendations for obesity treatment should be integrated within existing community and social systems.521 The medical home model is the preferred standard of care for children who have chronic conditions.522 and the child’s medical home should serve as a care coordinator in the treatment of children with obesity, coordinating with subspecialists, including obesity treatment specialists, and community resources.

Treatment of obesity varies based on individual-level factors. No specific studies were found that compare different treatments by a patient’s underlying condition, special needs, or developmental status. Nonetheless, it is important to recognize that the following recommendations will require adaptation based on the patient’s unique medical, family, developmental, social, and environmental factors. No evidence exists, however, to exclude children with special health care needs, complex disease, or developmental limitations from the treatment options outlined below, except where specifically noted.

The evidence for pediatric obesity treatment that is presented in this CPG shows that several treatments are effective in treating both obesity and related comorbidities. It is important to note, however, that in all of these studies, if the treatment is discontinued, children tend to regain weight and lose the attendant health benefits. There is limited longitudinal evidence about durability of weight change after treatment. The natural course of obesity across the lifespan is characterized by responses to treatment and relapse when treatment ends.77 Therefore, continuous coordinated care is required to support ongoing obesity treatment throughout childhood and adolescence into young adulthood.503

**B. Evidence-based Pediatric Obesity Treatment Reduces Risks for Disordered Eating**

In the field of pediatric nutrition, in the treatment of both obesity and eating disorders, concerns have been raised as to whether diagnosis and treatment of obesity may inadvertently place excess attention on eating habits, body shape, and body size and lead to disordered eating patterns as children grow into adulthood. The literature refutes this relationship, however. Cardel et al refer to multiple studies that have demonstrated that, although obesity and self-guided dieting consistently place children at high risk for weight fluctuation and disordered eating patterns, participation in structured, supervised weight management programs decreases current and future eating disorder symptoms (including bulimic symptoms, emotional eating, binge eating, and drive for thinness) up to 6 years after treatment.578,505,523 The structure and underlying principles of the primary care-based and intensive health behavior and lifestyle programs described here share multiple similarities with eating disorder programs. These include a focus on increasing healthful food consumption, participating in physical activity for enjoyment and self-care reasons, and improving overall self-esteem and self-concept. Structured and professionally run pediatric obesity treatment is associated with reduced eating disorder prevalence, risk, and symptoms.505,523

**C. Motivational Interviewing**

MI (also discussed in the Evaluation section) is a patient-centered counseling style that identifies and reinforces a patient’s own motivation for change—in contrast to the more traditional approach in which a provider prescribes behavior change. MI guides families to identify a behavior to change, based on what the parent(s) or child feels is important and can be accomplished.524

MI does not impose a particular goal but is successful when the family changes the selected behavior—which could be nutritional, such as reducing sugar-sweetened beverages; increasing physical activity; or engaging in other behaviors, such as eating meals together or improving sleep hygiene. The target of MI is the person who is responsible for the behavior change. Pediatricians and other PHCPs focus on parent motivation...
when patients are preadolescent or younger, and transition to patient motivation, usually combined with parent motivation, when patients reach adolescence.

MI consists of 4 processes: engaging, focusing, evoking, and planning. These processes, described below, are particularly salient when discussing weight status and devising a change plan.\textsuperscript{524}

The MI process of engaging is facilitated by the existing medical pediatrician-patient relationship. Through engaging, MI can help answer the question of whether to attempt behavior change. Attempts at obesity treatment often fail because of a disconnect between pediatricians and other PHCPs who see impending health problems with regard to weight status and a caregiver who sees a thriving, growing child. The presence of other challenges—such as financial constraints and other SDOHs, mental illness, or competing health considerations—may make obesity treatment a low priority.

An evaluation of these factors is necessary before any action. The longitudinal nature of many pediatrician-family relationships can enable ongoing monitoring of weight, health status, and family challenges. More focused obesity treatment efforts can ensue when families are ready. And regardless of their readiness to engage in more “active” obesity treatment, all patients need follow-up, encouragement, and monitoring of health status.

The MI process of focusing furthers respect for the autonomy of the patient and family. Behavior change is the patient’s and family’s decision, not the pediatrician’s or other PHCP’s. Identifying behaviors to change is a collaborative process. Caregivers and pediatricians (or other pediatric health care providers) tend to feel that the locus of control for pediatric behavior change resides with the caregiver longer than it actually does, however. Between 6 and 12 years of age, a steady shift of control occurs from caregiver to patient. By the early teen years, the vast majority of behavioral decisions reside in the patient—not the caregiver.

Therefore, the patient should increasingly be the target of the readiness to change assessment and focusing as they age.

The MI principle of evocation advances the autonomy of the patient and family. Pediatricians and other PHCPs can evaluate values that are important to the patient and family. Speaking to an adolescent patient who is more concerned about athletic performance than health, pediatricians and other PHCPs may have better traction discussing what the patient hopes to accomplish physically than attempting to incite concern about potential future disease. Likewise, encouraging a very self-conscious patient to exercise in a public setting may come across poorly. Taking time to evaluate individuals’ values, goals, and barriers is a critical piece of assessing readiness to change.

With regard to the MI process of planning, pediatricians and other PHCPs can evaluate a patient’s knowledge of what is necessary for a particular strategy and what resources and support are available to them. As a consultant, pediatricians and other PHCPs play a crucial role providing support and guidance for the patient’s collaboratively chosen course of action. Because obesity treatment is characterized by frequent setbacks and relapses, pediatricians and other PHCPs can also serve as valuable experts who can assess why behaviors may have reverted and what strategies might be appropriate for patients who seek to “get back on track.”

Table 16 summarizes MI processes as a way of evaluating and responding to patient readiness to change. Note that the MI tools are suggestions; in practice, each tool

<table>
<thead>
<tr>
<th>MI Process</th>
<th>Phase of Evaluation</th>
<th>Goal</th>
<th>Possible MI Tool</th>
</tr>
</thead>
<tbody>
<tr>
<td>Engaging</td>
<td>Early, getting to know patient</td>
<td>Establishing collaborative role, understanding patient issues</td>
<td>Open-ended questions, affirmations, nonjudgmental graphics, empathic reflections</td>
</tr>
<tr>
<td>Focusing</td>
<td>Early and when desire to change weight status is expressed</td>
<td>Identifying appropriate and productive strategies to change weight status</td>
<td>Readiness ruler, elicit-provide-elicit, healthy habits survey, identifying and responding to change talk and sustain talk</td>
</tr>
<tr>
<td>Evoking</td>
<td>When behavior change is desired</td>
<td>Triggering internal motivation, empowering change</td>
<td>Values statement, double-sided and amplified reflections</td>
</tr>
<tr>
<td>Planning</td>
<td>When embarking on change</td>
<td>Carrying out effective change plan, dealing with relapse</td>
<td>Readiness ruler, action reflections, summarization, teach back, SMART goals (specific, measurable, achievable, realistic, and timely)</td>
</tr>
</tbody>
</table>
may find utility in every phase of evaluation.

### C.1. Motivational Interviewing and Weight Status

Prospective studies specifically examining MI have demonstrated that the approach has positive effect on weight status, compared with controls.525-528 The outcomes included greater decline in BMI percentile or BMI SD score (also known as z-score), and less of an increase in BMI. These studies were all low-intensity treatments (ie, less than 5 hours) that were delivered in pediatric primary care practices by medical providers and dietitians who successfully learned and used MI.

MI is a tool used with many different strategies aimed at encouraging nutrition and physical activity change, and so the use of MI does not guarantee effect. Tables 2 and 3 in the technical report on interventions (https://doi.org/10.1542/peds.2022-060642) provide an overview of all the programs, including impact and use of MI. Of the 2 additional effective low-intensity studies (not aimed at MI evaluation), 1 included MI in both arms529 and 1 did not use MI.530

Approximately 23 low-intensity studies were ineffective, of which 14 included MI.531-551 These programs varied in participant age, sample size, duration, and other components.

Among moderate-intensity interventions (5–25 hours), about one-third of the approximately 20 effective interventions used MI.552-574

Conversely, approximately one-quarter of the ineffective programs used MI.552-574

Use of MI in high-intensity programs is more difficult to interpret, because many of these studies resulted in several publications at different outcomes points, with discrepant effects. Some used MI in both study arms,439,610,612-614 An estimated one-quarter of the effective high-intensity programs used MI, however.439,612,613,615-622

Although much more work is needed to examine the optimal characteristics that might moderate MI’s impact, like training, fidelity to the MI process, potential patient characteristics, as well as target behaviors, the success of the studies in which MI was the core treatment supports this KAS.

### D. Intensive Health Behavior and Lifestyle Treatment

IHBLT is the foundational approach to achieve body mass reduction or the attenuation of excessive weight gain in children. It involves visits of sufficient frequency and intensity to facilitate sustained healthier eating and physical activity habits.79 IHBLT typically involves engagement with, and participation of, families in discussions of necessary treatment based on the severity of disease. It also involves interaction with pediatricians and other PHCPs who are trained in lifestyle-related fields and requires significantly more time and resources than are typically allocated to routine well-child care.623

### TABLE 17 Treatment Intensity and BMI Reduction in Randomized Controlled Trials

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study Population</th>
<th>BMI Outcomes</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilfey (2017)</td>
<td>US, ages 7–11, OW/OB, n = 172</td>
<td>Not reported; “&gt;6.71 percent overweight” at 8 mo</td>
<td>26–51 h per 8 mo</td>
</tr>
<tr>
<td>Butte (2017)</td>
<td>US; ages 2–12, OW/OB, n = 548</td>
<td>−0.42 at 12 mo; only effective in ages 6–8</td>
<td>&gt;52 h per 12 mo</td>
</tr>
<tr>
<td>Nemet (2005)</td>
<td>Israeli; ages 6–16, OB, n = 46</td>
<td>−2.2 at 12 mo</td>
<td>26–51 h per 3 mo</td>
</tr>
<tr>
<td>Savoye (2007)</td>
<td>US, ages 8–16, OB, n = 174</td>
<td>−3.3 at 12 mo, −2.8 at 24 mo</td>
<td>&gt;52 h per 12 mo</td>
</tr>
<tr>
<td>Vos (2011)</td>
<td>Germany; ages 7–15, OB, n = 73</td>
<td>−0.2 (BMIz) at 12 mo</td>
<td>26–51 h per 3 mo</td>
</tr>
<tr>
<td>Weigel (2009)</td>
<td>Germany; ages 7–15, OB, n = 73</td>
<td>−4.3 at 12 mo</td>
<td>&gt;52 h per 12 mo</td>
</tr>
<tr>
<td>Reinehr (2010)</td>
<td>Germany; ages 7–15, OW/OB, n = 66</td>
<td>−1.5 at 6 mo</td>
<td>&gt;52 h per 6 mo</td>
</tr>
</tbody>
</table>

OW, overweight; OB, obese.
There are known limitations for families to access and participate in IHBLT. These limitations include the relative scarcity and distribution of such treatment programs and pediatricians or other pediatric health care providers with experience and/or training in pediatric obesity treatment, family transportation challenges, loss of school or work time to attend multiple recurring appointments during what are typically working hours, SDoHs, competing health issues for children or family members, and mismatched expectations between the family (who may expect significant weight loss) and pediatricians or other pediatric health care providers. IHBLT is appropriate for typically developing children and adolescents as well as CYSHCN, although will require modification based on the patient’s unique health conditions and developmental factors.

The most consistently effective IHBLT programs deliver 26 or more hours of face-to-face, family-based counseling on nutrition and physical activity over at least a 3- to 12-month period, for children aged for 2 to 5 years of age. Although not universally available, treatment programs that provide engaging, group-based physical activity and nutrition programming are currently available in various forms across the United States. Some IHBLT are housed in academic medical centers or community hospitals, some are in primary care offices or obesity treatment specialty clinics (ie, weight management clinics), and others are delivered through partnerships with local community entities such as the YMCA or parks and recreation departments. Clinic-community partnerships in particular have demonstrated implementation feasibility and are engaging to low-income and racially diverse populations. Pediatricians and other PHCPs should investigate local programs in the area and become familiar with the referral requirements and processes to connect patients with this treatment option (Fig 3).

Each of the components of the KAS below are supported by evidence that is detailed in the technical report on interventions and summarized here:

- **26 or more hours**: The major factor driving the effectiveness of IHBLT is the intensity (or dose) of the intervention, measured in hours of face-to-face patient contact. The number of hours, or “dose,” delivered is directly proportional to the likelihood a child will experience a reduction in BMI (Table 17). Although a threshold effect was observed at 26 or more hours over a 3- to 12-month period, interventions that delivered ≥52 hours of contact over the same duration demonstrated the most consistent and significant reduction in BMI and cardiometabolic comorbidity improvement. As described in the technical report, 28% of treatments <5 hours, 525–527,529, 531–535,537–540,546–549,630 38% of treatments 5 to 25 hours, 527,537,554, 555,557,559,560,563,567,568,570,572,573, 575–583,602 and 75% of treatments ≥26 hours290,554,555,557,559, 560,563,567,568,570,572,573,575–583,602, 604–606,612,617,618,621,631 led to significant improvements in BMI among pediatric participants. Hence, pediatricians and other PHCPs should look for programs that engage families often and frequently. No studies directly compare the same intervention

| WHO: | Patient and family in partnership with a multidisciplinary treatment team* |
| WHEN: | Promptly for child or adolescent with overweight or obesity |
| WHAT: | Health education and skill building on multiple topics |
| WHERE: | Community-based setting with linkage to medical home |
| DOSSAGE: | Longitudinal treatment across 3-12 months with ideally ≥ 26 contact hours |
| FORMAT: | Group, Individual, or Both |
| CHANNEL: | Face-to-face (strongest evidence) |

* PCPs and/or PHCPs with training in obesity as well as other professionals trained in behavior and lifestyle fields such as dietitians, exercise specialists and behavioral health practitioners

**Fig 3** Intensive health behavior and lifestyle treatment.
over a shorter versus longer period of time, however.

- **Face-to-face**: Most of the studies included interventions where 
  IHBLT occurred in group settings where families gathered together 
  in a health care or community location, or in a family’s home as 
  part of a home visit. Sessions were led by a variety of individuals 
  or combinations of individuals, including community health 
  workers, nutritionists, exercise physiologists, physical therapists, 
  and social workers. Fewer studies evaluated the effectiveness of treatment 
  that did not take place in a face-to-face setting, including 
  mobile health tools for parents or adolescents, telemedicine-
  delivered counseling sessions, or guided self-help for families. 
  Although there is promising evidence that these strategies may 
  be successful, more research is needed to understand the target 
  population, effectiveness on health outcomes, and implementation 
  potential.

- **Family-based**: In all effective studies, the parent or the family 
  unit was included in the treatment. Prior evidence has demonstrated 
  that parent involvement is associated with early success in child obesity treatment 
  and that family-based interventions are more effective in achieving 
  and sustaining child BMI reduction than interventions that target the child without including the family (ie, school-based, 
  summer camp, after school). 
  For adolescent populations, the evidence and best practices for 
  including parents in obesity treatment is less clear. Several studies measure parental BMI as a treatment outcome, along with 
  adolescent BMI, although none included in the technical report 
  have demonstrated significant reduction in parent BMI. 
  Obesity tends to affect families; thus, family-based treatment has the potential 
  to improve the health and weight status of other household members, 
  including siblings, although no data are available to support 
  this outcome.

- **Multicomponent**: Nearly all of the evidence for effective treatment 

![Facilitators for Successful Health Behavior Lifestyle Treatment](image-url)
of childhood obesity includes components that focus on healthy eating and physical activity. The specific nutritional and exercise content varies widely among studies, and is delivered in different combinations, so no one unified approach has demonstrated superiority over another.

The physical activity component is more effective when children are engaged in a combination of aerobic and nonaerobic physical activity, compared with physical activity counseling. Noncompetitive, cooperative, fun activities that build motor skills as well as self-confidence are more engaging for children. Several studies have noted adaptations for children with obesity, including a preference for water-based activities and nonweight-bearing activities (ie, cycling) and considerations for physical therapy or conditioning or training if a child has a low level of fitness.

Nutrition skill-building sessions that involve direct meal preparation or tasting are more effective in increasing children’s acceptance of new foods and increasing parent confidence to prepare meals at home, compared with nutrition education. Specific nutritional content included in treatment varies as well. Several studies relied on published guidelines (ie, NHLBI-supported CHILD-1diet), whereas others used specific dietary approaches, such as the reduced-glycemic load diet or using meal replacements.

Several of the more-intensive programs that demonstrate effectiveness also included a focus on mental health and parenting skills; thus, evidence exists to support the addition of these components to increase effectiveness.

Programs often address other components of health as well, including getting enough sleep, reducing sedentary screen time, and addressing stigma and weight bias. Although these additional elements are generally recognized as positive and are consistent with anticipatory guidance, they do not have evidence for additional benefit in the context of IHBLT.

- Over a 3- to 12-month period: The criteria for the evidence review required a weight-specific outcome at least 3 months after the intervention started. The rationale for excluding shorter-term lifestyle treatments was to ensure that pediatricians and other PHCPs focus on treatments that have a more-sustained treatment effect and that reinforce with parents that obesity does not have a “quick fix,” but requires long-term and ongoing attention. Treatments with duration longer than 12 months are likely to have additional and sustained treatment benefit. There is limited evidence, however, to evaluate the durability of effectiveness and the ability of long-term treatments to retain family engagement.

- For children 2 to 18 years of age with overweight and obesity: The USPSTF identified evidence for intensive “lifestyle” treatments starting at age 6 years. This KAS includes children down to age 2, recognizing that several recent studies show treatment effectiveness in preschoolers 2 to 5 years of age. Treatment studies delivered care differently depending on the child’s age. For example, studies targeting preschoolers more often included home visits and focused on parental skills training. Studies targeting adolescents more often focused on the teen’s autonomy, preferences, and self-image.

Intensive behavioral interventions should be tailored to the child’s developmental abilities and learning skills.

D.1. Evidence for Effectiveness

The 2017 USPSTF recommendation for pediatric obesity treatment is based on high-quality randomized and nonrandomized studies that demonstrate a significant BMI reduction and were published through January 2016 (n = 42). The evidence review to inform this CPG additionally included a systematic evidence review of randomized and nonrandomized interventions leading to BMI reduction (March 2020; 214 total intervention studies of all types; of these, 126 were randomized lifestyle studies).

The evidence review is additive to the USPSTF review, as it includes new studies since January 2016 as well as studies with a comparative effectiveness design. Dose is clearly the factor most strongly correlated with treatment outcomes, as evidenced by a selection of trials that deliver “high intensity” and “comprehensive” contact over a 2- to 12-month or 3- to 12-month time period.

In research settings simulating clinical practice, intensive behavioral intervention has evidence for effectiveness in lowering child BMI, reducing comorbidities, and improving quality of life. Interventions that provide more than 12 months of treatment are associated with a reduction in BMI z-score between −0.10 and −0.50 or a range of −1.6 to −8.1 kg (3.5 to 18 lb) weight loss over 1 year. Interventions that meet the intensity or “dose” threshold of 26 hours or more over 3 to 12 months can lead to clinically significant
improvements in BMI, systolic and diastolic BP, insulin, and glucose levels and to clinically meaningful improvements in comorbidities such as asthma, obstructive sleep apnea, and NAFLD.\textsuperscript{440-444} Interventions lasting less than 3 months did not demonstrate effectiveness.

- **High-intensity:** Greater contact hours lead to greater treatment effect. In all of the studies, intervention dose is most strongly associated with weight outcomes. Although weight management interventions above a threshold of 26 contact hours are generally effective in reducing excess weight (mean BMI z-score reduction 0.2), higher-dose interventions with contact time $\geq 52$ hours demonstrate a stronger and more consistent BMI reduction effect.\textsuperscript{625} The mean difference in change of BMI z-score between controls and interventions with $\geq 52$ hours of contact is $-0.31$ (95% CI, $-0.16$ to $-0.46$), and absolute BMI z-score reductions in the pooled intervention groups is 0.05 to 0.34.\textsuperscript{625} This treatment effect is observed in children 2 to 16 years of age but most consistently in children 6 to 12 years of age.\textsuperscript{642} Savoye showed effective treatment in those 8 to 16 years of age but less effectiveness among those 13 to 16 years of age.\textsuperscript{439} and BMI reduction is driven by the younger age groups in the Weigel\textsuperscript{612} and Reinehr\textsuperscript{643} studies. A high dropout rate in obesity treatment is a known threat to delivering actual treatment hours. In research settings, attrition rates of 40\% are common;\textsuperscript{439} in real-world settings working with low-income families, attrition rates can be as high as 60\%.\textsuperscript{644}

- **Comprehensive:** Interventions that include behavior, physical activity, and nutrition components are associated with child BMI reduction. In randomized studies, effective behavior change uses a family-focused approach.\textsuperscript{515} Parents are taught self-management for their own behaviors (eg, role modeling), as well as positive parenting strategies and contingency management. Children learn goal-setting, body acceptance, and strategies to manage bullying. Effective interventions, for example, deliver moderate-to-vigorous physical activity for at least 50 minutes twice a week for 6 months and 40 minutes of nutrition counseling weekly for 6 months.\textsuperscript{439,645} Nutrition content includes a nondiet, lifestyle modification approach that teaches families to set goals for meal preparation, grocery shopping, and learning skills including portion size and label reading.\textsuperscript{439,612,643}

There is no evidence that obesity treatments harm patients’ quality of life. Among the studies that included quality of life measures, none showed worsening; about one-third showed improvement to quality of life.\textsuperscript{535,555,615,642} More study on treatments’ impact on mental health is needed, however. Few studies examined mental health impact; although none showed worsening mental health, all of the studies examined excluded subjects who had established mental health disorders at baseline.\textsuperscript{553,579,646}

The prevalence of eating disorders is not well-characterized in patients participating in obesity treatment;\textsuperscript{647} but disordered eating patterns may be more common among youth with obesity compared with youth at a healthy weight.\textsuperscript{387} Therefore, pediatricians and other PHCPs should evaluate patients before, during, and after intensive behavioral intervention for the presence of disordered eating (as discussed in the evaluation section) as well as for greater-than-expected weight change.

### D.2. Referral Strategies

Limiting factors to IHBLT effectiveness include lack of engagement or participation by families and high attrition rates. Thus, when referring to more intensive treatment, pediatricians and other PHCPs should inform patients and their family members about the reason for the referral, encourage families to actively participate in the treatment, and schedule follow-up visits to monitor progress in the treatment.

One factor in early attrition may be mismatched expectations for weight loss.\textsuperscript{648} Families can best make decisions about IHBLT participation after providers inform them of commitment and likely outcomes. Pediatricians and other PHCPs are encouraged to help set reasonable expectations for these outcomes among families, as there is a significant heterogeneity to treatment response and there is currently no evidence to predict how individual children will respond. Many children will not experience BMI improvement, particularly if their participation falls below the treatment threshold. As described in the Health Behavior and Lifestyle Treatment section, those who do experience BMI improvement will likely note a modest improvement of 1\% to 3\% BMI percentile decline.\textsuperscript{396}

### D.3. Prompt IHBLT

A key distinction from prior recommendations is for pediatricians and other PHCPs to refer as soon as possible to IHBLT. Current practice patterns involve counseling in primary care practices, often for months to years, before referring to more intensive programs. Although providing patient-centered and nonstigmatizing nutrition and activity counseling is important for children of all weight classifications,
there is no evidence to support either watchful waiting or unnecessary delay of appropriate treatment of children who have already developed obesity. Many children are only referred to treatment programs when their obesity has become more severe. A delay in care ultimately reduces the likelihood of treatment success for the child.

Similarly, no evidence supports selectively referring patients to obesity treatment programs based on those who meet certain criteria, such as obesity severity, presence of comorbidities, and/or readiness or motivation to change. Although there is currently limited evidence for obesity treatment in children 2 through 5 years of age, excess weight gain in early life predicts future obesity; therefore, future studies should examine treatment in this age group. Pediatricians and other PHCPs are advised to prioritize the most effective treatment available for patients with obesity and encourage patients and families to use these programs at the time of obesity diagnosis.

It is necessary to provide IHBLT within various sites of health care delivery. Face-to-face time with pediatricians and other PHCPs cannot realistically achieve the intensity that is most effective. Thus, RDNs, health behavior specialists, and exercise professionals should be part of the health care team and have critical skills for IHBLT. They can work within a multidisciplinary obesity treatment clinic, be embedded within a medical home organization so that they coordinate with pediatricians and other PHCPs, and participate in care through referrals. Given the number of children who meet criteria for treatment, and the current limitations on number of pediatricians and other PHCPs who deliver IHBLT, a significant effort toward medical home capacity-building will be needed to achieve equitable access for all children. Current programs are generally located in cities, and often in academic centers. An individual center may or may not offer the entire range of intensive treatment, including intensive lifestyle, pharmacotherapy, and surgery. Providers should be familiar with the treatment programs at local centers; their knowledge of the child and family, along with awareness of available options, can guide treatment direction. Rural communities need resources and programs, especially ones that accommodate the distinct challenges of rural living, including transportation and economic and cultural factors.

On the strength of the literature, the USPSTF gives the evidence for intensive "lifestyle" treatment of childhood obesity a "B" rating, which means that health plans should cover this care. The USPSTF is authorized by Congress to assign grades to the state of the evidence regarding treatment options for diseases. Under the Affordable Care Act, grades of "A" or "B" are mandated to be covered with no deductibles, copayments, or cost-sharing. A large gap currently exists, however, between this expectation and the actual policies in state Medicaid and commercial health plans. Health care systems should build the capacity necessary to deliver this evidence-based level of care (see the Implementation Barriers section for more discussion).

E. When Intensive Programs Are Not Available

Pediatricians and other PHCPs are on the frontline of identifying overweight and obesity. Consistent success in behavior-based obesity treatment is highly related to treatment intensity. Both individual and systemic barriers may, however, keep many families from receiving the recommended moderate- to high-intensity multicomponent obesity treatment. In addition, pediatricians and other PHCPs...
should be aware that pediatric patients who seek bariatric surgical treatment may encounter significant disparities in access to care based on demographics, SES, and insurance type.\textsuperscript{654}

Availability of IHBLT or other treatments is generally poor, as described in a Children’s Hospital Association report in 2013.\textsuperscript{655} Differences in access based on demographics and similar factors have not been well studied. A consortium of academic centers with pediatric weight management programs reported a high proportion of publicly insured patients and racial and ethnic diversity\textsuperscript{656}; however, these sites are safety-net medical centers in larger cities and, as such, are a small sample of the children in the United States with obesity. Pediatricians and other PHCPs should familiarize themselves with resources and actively collaborate with other specialists and community programs.

For example, pediatricians and other PHCPs should assess the availability and pediatric expertise of local diétitians and offer referrals to patients where possible. RDNs can assess a child’s nutritional needs, including appropriate food groups and portion sizes, and provide guidance for specific diet needs and preferences, including cultural patterns. Some RDNs have received special certification in pediatric and adolescent obesity, and the Academy of Nutrition and Dietetics offers RDNs additional learning opportunities in pediatric and adolescent obesity and encourages training in patient-centered counseling techniques. RDNs can complement the care of medical providers and may be the most widely available specialist with whom pediatricians and other PHCPs can work to provide more intensive behavioral intervention. Behavioral health specialists, ideally integrated into primary care, can focus on the process of behavior change, including parenting skills, role modeling, and consistent reinforcement techniques.

Implementation tools can help address actions in low-resourced settings. Exercise specialists can provide counseling and training to engage children and families in noncompetitive, cooperative, fun, aerobic and nonaerobic activities. Behavior goals related to physical activity include aiming for the physical activity guidelines of 60 minutes per day of moderate to vigorous physical activity\textsuperscript{635,642} and reducing time spent in sedentary behavior.\textsuperscript{656} Physical activity limitations, such as joint pain related to musculoskeletal comorbidities or increased work of breathing related to severe obesity, should be considered, and a stepped care plan for a gradual increase in physical activity can be made. Medicaid and other insurance plans may restrict coverage to specific medical conditions which do not include obesity or risk factor reduction. Providers can search for community programs that follow a philosophy of noncompetitive, fun activities, ideally engaging the whole family. See Figure 4 for facilitators of successful health behavior lifestyle treatment.

**Consensus Recommendations**

The CPG authors recommend that pediatricians and other PHCPs:

- Deliver the best available intensive treatment to all children with overweight and obesity.
- Build collaborations with other specialists and programs in their communities.

**F. Specific Health Behavior Recommendations**

Many pediatricians and other PHCPs, especially those in primary care, have an important role in recommending specific health behaviors to improve energy balance. The following specific health behavior recommendations do not form a KAS, because randomized controlled trial (RCTs) that test each in isolation do not exist and are unlikely to be performed.
Effective programs described in the technical report incorporated many nutrition, physical activity, and behavior change strategies simultaneously, an approach that is responsive to the multiple behaviors that contribute to energy imbalance. Single-component interventions, such as physical activity alone, were generally not successful, and the multicomponent studies were not designed to isolate the impact of one component over another. If the study target were too narrow (for example, consumption of 5 fruits and vegetables a day), any impact on weight or BMI would likely be too small to detect.

Most of the successful interventions described in the technical report described nutrition counseling without a structured diet. (Exceptions were a small study that found both low and modified carbohydrate diets were better than control, and a study that found a focus on only beverages and a focus on multiple nutrition changes were both superior to control but not different from each other.) Two effective studies of adolescents implemented caloric restriction of 1300 to 1550 calories per day, but the interventions also included additional components, such as physical activity promotion and behavior change strategies. Two small studies found benefit from interventions that reduced glycemic load.

Despite the lack of evidence for specific strategies on weight outcomes, many of these strategies have clear health benefits and were components in RCTs of intensive behavioral intervention. Many strategies are endorsed by major professional or public health organizations. Therefore, pediatricians and other PHCPs can appropriately encourage families to adopt these strategies.

Pediatricians and other PHCPs should present these specific strategies in the context of MI, helping families to identify their own goals and to determine steps to overcome barriers in making change. The AAP’s Next Steps: A Practitioner’s Guide of Themed Follow-up Visits to Help Patients Achieve a Healthy Weight provides step-by-step strategies for the pediatrician or other PHCP on content and delivery of each theme, including portion sizes, screen time and sleep, meal patterns and snacks, and bullying and teasing.

Table 18 lists specific behavior strategies endorsed by major professional and public health organizations. Some systematic reviews are cited, which include many association studies, but a comprehensive search for studies and reviews was not performed.

Table 19 presents strategies that are common but have not at this time been addressed by the AAP or other major health organizations. For some, rigorous systematic reviews provide information about potential benefit as well as harm or lack of harm. Brief mention of existing literature is included, but extensive searches for publications were not performed.

When actively intervening to treat overweight and obesity in the primary care setting, pediatricians and other PHCPs should also evaluate and address the modifiable risk factors for obesity that are described in the Risk Factors section. These include parenting feeding styles, frequency of dining out and eating fast food, and ACEs, among other household risk factors. Awareness of supports and barriers in the patient’s community will also help guide the family to resources outside the home, such as parks and recreation programs, community gardens, and school wellness policies.

Parents and caregivers have a crucial role to play in obesity treatment through strategies such as parental monitoring, limit setting, reducing barriers, managing family conflict, and modifying the home environment. A systematic review of parental involvement in childhood obesity treatment studies found that medium- to high-intensity parental involvement was associated with weight-related measures of treatment effectiveness. Parents can serve as role models and provide support in obesity treatment. In addition, an enhanced parent-child relationship functions as a mediator in development of healthier behaviors and further weight control. Parents themselves and family relationships may also benefit from children’s obesity treatment.

A recent systematic review found that certain common features involving parents in obesity treatment interventions with their preadolescent children were successful in producing nutrition and physical activity behavior change. These features include promotion of intrinsic motivation and self-efficacy through empowerment of parents and children and fostering shared value and whole-family ownership. The activities most commonly associated with positive behavior change included parental leadership in goal setting, problem solving, social support, demonstrating desired behaviors, and restructuring the home environment. It is encouraging that the majority of studies that included low-income populations in this review found favorable results.

Adolescence can present substantial challenges to family-based care, because this period is marked by a developmentally normative period of...
TABLE 18 Behavior Strategies

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Description</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction of sugar-sweetened beverages (SSBs)</td>
<td>Higher intake of sugar-sweetened beverages (carbonated beverages, sweetened beverages, soda, sports drinks, and fruit drinks) is associated with greater wt gain in adults and children. The American Heart Association (AHA) recommends not more than 25 g (6 tsp) each day of added sugar and not more than 1, 8-oz serving of SSB per week. The AAP discourages the consumption of sports drinks and energy drinks for children and adolescents. The AAPT statement on fruit juice notes that it is a poor substitute for whole fruit because of its high sugar and calorie content and pediatricians should advocate for elimination of fruit juice in children with excessive wt gain.</td>
<td>Systematic review, AHA SSB, AAP sports and energy drinks, AAP fruit juice</td>
</tr>
<tr>
<td>Choose My Plate</td>
<td>MyPlate is the US Department of Agriculture's (USDA) broad set of recommendations for healthy eating for Americans. These recommendations include multiple healthy diet goals: low in added sugar, low in concentrated fat, nutrient dense but not calorie dense, within an appropriate calorie range without defined calorie restriction, and with balanced protein and carbohydrate. The principles can be adapted to different food cultures. There is a surprising dearth of literature on the impact of these guidelines on health and BMI outcomes and on the most effective education practices.</td>
<td>USDA choosemyplate.gov</td>
</tr>
<tr>
<td>60 min daily of moderate to vigorous physical activity</td>
<td>Aerobic exercise, especially for 60 min at a time, is associated with improved body weight in youth although its effect may be small and variable. It is also associated with better glucose metabolism profiles. High-intensity interval training in youth with obesity may improve body fat, weight, and cardiometabolic risk factors, although the effect is variable. The Physical Activity Guidelines for Americans recommends 60 min per day for children and adolescents.</td>
<td>Systematic reviews, AAP physical activity; Guidelines for Americans</td>
</tr>
<tr>
<td>Reduction in sedentary behavior</td>
<td>Reduction in sedentary behavior, generally defined as reduced screen time, has consistently shown improvement in BMI measures, although impact is small. Early studies focused on reduced television, a discrete activity that is simpler than current multifunctional electronic devices. The AAP recommends no media use under age 18 mo, a 1-h limit for ages 2–5 y, and a parent-monitored plan for media use in older children, with a goal of appropriate, not-excessive use but without a defined upper limit.</td>
<td>AAP media and young minds, systematic review</td>
</tr>
</tbody>
</table>

increased desire for independence and autonomy, despite continued reliance on parents for many needs. Given these challenges, the research investigating specific clinical paradigms for parent involvement in adolescent obesity treatment demonstrates mixed findings regarding the ideal level of involvement and the specific parenting strategies that can optimize treatment. Further research and detailed reporting are needed to inform clinical guidelines for optimizing the role of parents in adolescent obesity treatment.
Obesity is a complex chronic disease with biologic, environmental, and other causative factors that are systemic and operate at the local, regional, and global level. As with all chronic disease, the patient and family have to manage the demands of the disease and evidence-based treatment in the context of these factors. This means that individual patients and their families will have unique challenges to overcome based on the severity of their disease and the adversity of their environments. Effective obesity treatment helps patients and families develop self-management.

### TABLE 19 Common Strategies

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Description</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoidance of breakfast skipping</td>
<td>Breakfast skipping among children is associated with overweight and obesity and with lower quality of dietary intake throughout the day.</td>
<td>Systematic review668</td>
</tr>
<tr>
<td>Traffic Light Diet</td>
<td>This approach to teaching healthy eating has shown consistent success within the context of moderate- to high-intensive multicomponent programs, in which experienced providers help families learn and use the diet.</td>
<td>Evidence summary can be found on the Academy of Nutrition and Dietetics Web site: <a href="https://www.andeal.org/topic.cfm?cat=1429&amp;highlight=traffic%20light%20diet&amp;home=1">https://www.andeal.org/topic.cfm?cat=1429&amp;highlight=traffic%20light%20diet&amp;home=1</a>.</td>
</tr>
<tr>
<td>5 2 1 0</td>
<td>This messaging emerged from a consortium of primary care pediatricians as simple, memorable, and feasible (<a href="http://www.mainhealth.org/Lets-Go/Childrens-Prog">www.mainhealth.org/Lets-Go/Childrens-Prog</a>). Each component of 5-2-1-0 messaging aligns with a major recommendation or guideline: 5 fruits and vegetables a day is consistent with the USDA ChooseMyPlate recommendations, 2 h or less of screen time is consistent with earlier versions of AAP policy, 1 h or more of moderate to vigorous physical activity is consistent with Physical Activity Recommendations for Americans, and 0 (or nearly no) sugar-sweetened beverages aligns with USDA, AHA, and AAP.</td>
<td></td>
</tr>
<tr>
<td>Use of screen-based physical activity (exergames)</td>
<td>Video games that require physical activity can reduce children’s body wt. Players can reach levels of light-to-moderate intensity physical activity during exergame play, especially games that involve whole-body movement. Systematic reviews have shown that children can lose body weight or attenuate weight gain when playing exergames over a sustained period of time. Specific setting in which exergaming resulted in weight, adiposity, or BMI z-score improvement included home, part of a structured physical activity program, and part of a multicomponent obesity treatment program. Children experienced modest reductions in weight, adiposity, or BMI z-score when exergames were provided in the home, within a structured physical activity program, and within an obesity treatment program. There is less evidence to date for newer technologies like smartphone apps and wearables, but these are promising tools to engage and sustain youths’ interest in healthy behaviors.</td>
<td>Scant literature on weight or BMI impact.669,670 Attainment of 5-2-1-0 behaviors is low.671</td>
</tr>
<tr>
<td>Appropriate amount of sleep for age</td>
<td>Obesity is associated with shorter sleep duration, and the association appears to be driven by increased calorie consumption, decreased physical activity from fatigue, and potential hormonal and metabolic alterations such as increased ghrelin and decreased leptin leading to hunger.</td>
<td>Systematic review243–247</td>
</tr>
</tbody>
</table>
strategies that are critical for chronic disease management in this context.

Self-management has been defined as “the development of a range of attitudes, health behaviours and skills to help minimize the impact of their condition on all aspects of life for themselves and their families and caregivers.” Self-management has also been described as “a dynamic, interactive, and daily process in which individuals engage to manage a chronic illness,” and “the ability of the individual, in conjunction with family, community, and health care professionals, to manage symptoms; treatments; lifestyle changes; and psychosocial, cultural, and spiritual consequences of health conditions.” For example, dietary change is an important treatment strategy in the self-management of many chronic diseases and is about “tailoring support to improve knowledge, skills and confidence” by promoting facilitators such as “location, language, incentive and tailored resources” while mitigating barriers, such as inadequate knowledge or skills or lack of time. For young children and children with disabilities, “self-management” may apply to caregivers on behalf of or in conjunction with the patient.

The complex environment in which children and adolescents with obesity and their families live needs to be acknowledged in the way providers individualize and tailor self-management supports.

H. Treatment Considerations for Children and Youth With Special Health Care Needs

CYSHCN are those who have, or who are at increased risk for, a chronic physical, developmental, behavioral, or emotional condition and who also require health and related services of a type or amount beyond that required by children generally. It is important that management of obesity for CYSHCN includes similar protocols and processes as those for children with typical development. This includes assessing health behaviors, identifying community resources and policies, sharing appropriate resources, and promoting healthy behaviors. Pediatricians and other PHCPs are encouraged to assess risks contributing to obesity in collaboration with families and interdisciplinary teams (specialists, psychologists, primary care providers, mental health professionals, social workers, physical therapists, and dietitians), providing their patients (CYSHCN) and their families with essential skills and resources to manage obesity.

In addition, it is critical to recognize that CYSHCN may have physical, emotional, and/or cognitive condition(s) preventing them from engaging in community or clinical activities that are available for their peers with typical development. Therefore, creative solutions for promoting physical activity and healthy nutrition and behavior change are vital for this special population. Solutions come from...
guidance and supervision from families, health care providers, and community recreation staff for appropriate physical activities and consumption of healthier food options.\textsuperscript{700–702}

It is essential to emphasize the numerous benefits of recreational activities for CYSHCN to include improve socialization, fitness level, and motor and movement skills.\textsuperscript{703,704} Additional nutrition, physical activity, and sedentary time recommendations can be found in a recent report from the Healthy Weight Research Network, an interdisciplinary group of clinical investigators and experts providing obesity treatment of children with autism and other intellectual and/or developmental disabilities.\textsuperscript{697}

The International Classification of Functioning (ICF), Disability, and Health model and AAP recommendations are appropriate frameworks related to assessing pertinent health conditions and contextual factors affecting CYSHCN to aid in planning to treat obesity, as seen in Fig 5. The ICF framework can be used to organize approaches in the management of childhood obesity.

Children with obesity-related genetic syndromes, behavioral difficulties, developmental disabilities, and hypothalamic disorders (Table 2) have added obesity risk and may need additional supports in obesity treatment.\textsuperscript{316}

Hyperphagia can be particularly challenging to manage in CYSHCN. A combination of specific behavioral techniques within the context of family-based behavioral treatment and the use of pharmacotherapy may be necessary.\textsuperscript{700}

Prader Willi syndrome is a complex genetic disorder affecting 1 in 15,000 to 1 in 30,000 people and is associated with obesity and hyperphagia.\textsuperscript{706,707} Specific recommendations for health supervision and multicomponent care can help pediatricians and other PHCPs institute a longitudinal treatment approach to care.

Hypothalamic obesity is a neuroendocrine disorder resulting from damage to the hypothalamus, disrupting the body’s energy regulatory system, which requires intensive multicomponent treatment.\textsuperscript{708}

ADHD is associated with obesity, and symptoms such as deficits in alertness and attention that are caused by sleep-disordered breathing attributable to obesity can overlap with those of ADHD. Impulsivity in ADHD may contribute to dysregulated eating and weight gain. Effective treatment of ADHD in children with obesity can be associated with attainment of healthier weight status.\textsuperscript{709}

I. Use of Pharmacotherapy

Consensus Recommendation

The CPG authors recommend pediatricians and other PHCPs:

- May offer children ages 8 through 11 years of age with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to health behavior and lifestyle treatment.

Although IHBLT has the largest body of evidence meeting the evidence review’s high-quality evidence for effectiveness criteria, it is important to consider the use of pharmacotherapy for children and adolescents who require an additional treatment option to manage their obesity. In particular, children with more immediate and life-threatening comorbidities, those who are older, and those affected by more severe obesity may require additional therapeutic options. For children younger than 12 years, there is insufficient evidence to provide a KAS for use of pharmacotherapy for the sole indication of obesity. There are, however, specific conditions outlined below for which use of medication may be indicated. Additionally, although the evidence is insufficient at the time of this

\textbf{Aggregate Evidence Quality}

<table>
<thead>
<tr>
<th>Benefit</th>
<th>Evidence Quality</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI reduction as an adjunct to lifestyle treatment.</td>
<td>Varies by pharmacotherapeutic agent.</td>
<td>B</td>
</tr>
<tr>
<td>Benefit and harm are individualized by patient, must weigh the side effects and potential benefit of the medication and patient-specific factors.</td>
<td>None.</td>
<td></td>
</tr>
<tr>
<td>Intentional vagueness</td>
<td>Significant; must determine appropriate timing and duration of treatment, monitor for side effects.</td>
<td></td>
</tr>
<tr>
<td>Role of patient preference</td>
<td>Medication-dependent exclusions.</td>
<td></td>
</tr>
<tr>
<td>Exclusions</td>
<td>Moderate.</td>
<td></td>
</tr>
<tr>
<td>Key references</td>
<td>710</td>
<td></td>
</tr>
</tbody>
</table>
evidence review, the use of pharmacotherapy to aid BMI reduction in children is a rapidly evolving field; new evidence may lead to additional options for children younger than 12 years in the future.

Studies Included
At the time of the evidence review for this CPG, 27 randomized studies met the inclusion criteria for review, and an additional 8 observational studies were also considered. The majority of the studies evaluated the efficacy of metformin either alone (n = 16 randomized, 7 observational) or in combination with other medications (n = 7 randomized). Other studies evaluated orlistat (n = 2 randomized), exenatide (n = 2 randomized), or other medications with only 1 study cited (phentermine, mixed carotenoids, topiramate, ephedrine, and recombinant human growth hormone). Since the evidence review, additional high-quality evidence has been published to define the safety and efficacy of novel agents (setmelanotide, liraglutide, and the combination phentermine or topiramate) and are included in this discussion.

Medication Use and Mechanisms of Action
Metformin is an antidiabetic agent used in T2DM among patients 10 years and older. Metformin also has several indications not approved by the US Food and Drug Administration (FDA), including prediabetes, PCOS, and prevention of weight gain when used with atypical antipsychotic medications. Metformin is a biguanide drug that reduces blood glucose levels by decreasing blood glucose production in the liver, decreasing intestinal absorption, and increasing insulin sensitivity. It comes in immediate- and extended-release formulations; the recommended starting dose is 500 mg, once or twice daily, with gradual increases up to a maximum total daily dose of 2500 mg. Adverse effects are dose-dependent, and include bloating, nausea, flatulence, and diarrhea. Lactic acidosis is a serious but very rare complication in pediatric populations.711

Metformin has not been approved as a weight-loss drug. A 2020 meta-analysis of metformin studies in adults with obesity showed modest (≤5%, or 1 BMI unit) weight reduction with metformin when used as an adjunct to lifestyle; however, the effectiveness is inconsistent across different populations.712 The evidence for effectiveness of metformin for weight loss in pediatric populations is similarly conflicting. One small study randomized 39 teens 13 to 18 years of age with obesity participating in a lifestyle modification program to either metformin hydrochloride XR 2000 mg, or placebo once daily for 48 weeks.713 Adolescents taking metformin reduced BMI by approximately 1 kg/m² as compared with a slight increase in BMI among teens in the lifestyle-only program.

Another well-designed randomized study of 100 children 6 to 12 years of age with severe obesity (mean BMI 34.6 kg/m²) showed a BMI reduction of approximately 1 kg/m² at a dose of 1000 mg twice daily for 6 months, also as an adjunct to lifestyle treatment.714 Gastrointestinal symptoms limited the tolerated maximum dose in nearly 20% of patients, however, and no additional BMI reduction was noted with treatment beyond 6 months. Of the 16 studies of metformin that met quality inclusion criteria for the evidence review, about two-thirds showed modest BMI reduction.713–724 One-third showed no benefit.725–728

The effective studies typically included higher metformin doses, more intensive lifestyle adjunct treatment, and use in children or adolescents with more severe obesity and/or a secondary diagnosis, such as prediabetes or PCOS. Given the modest and inconsistent effectiveness, metformin may be considered as an adjunct to intensive health behavior and lifestyle treatment and when other indications for use of metformin are present.

Orlistat is an intestinal lipase inhibitor that blocks fat absorption through inhibition of pancreatic and gastric lipase. It is currently approved for children 12 years and older at a dose of 120 mg, 3 times per day. Adverse effects include steatorrhea, fecal urgency, and flatulence; these adverse effects greatly limit tolerability, and thus, orlistat is uncommonly used in pediatric obesity treatment. Orlistat is FDA approved for long-term treatment of obesity in children 12 years and older.729,730

Glucagon-like peptide-1 receptor agonists, such as liraglutide, exenatide, dulaglutide, and semaglutide, decrease hunger by slowing gastric emptying and by acting on targets in the central nervous system. Depending on the medication, the formulation is either oral or a daily or weekly subcutaneous injection. Two small studies of exenatide (weekly injection) among children as young as 8 years showed BMI reduction ranging from 0.9 to 1.18 U but with significant adverse effects. Exenatide is currently approved in children 10 to 17 years of age with T2DM. A recent randomized controlled trial found liraglutide (daily injection) more effective than placebo in weight loss at 1 year among patients 12 years and older with obesity who did not respond to lifestyle treatment.710 The magnitude of the difference was approximately 4.5 kg body weight lost, or 5% BMI reduction. The starting dose is 0.6 mg
per day up to a maximum dose of 3.0 mg per day, by subcutaneous injection. Adverse effects include nausea and vomiting, and among patients with a family history of multiple endocrine neoplasia, a slightly increased risk of medullary thyroid cancer. Liraglutide is FDA approved for long-term treatment of obesity (with or without T2DM) in children 12 years and older.

**Melanocortin 4 receptor (MC4) agonists**, such as setmelanotide, act on the MC4R pathway to restore normal function for appetite regulation that has been disrupted because of genetic deficits upstream of the MC4 receptor. MC4 receptors in the brain regulate hunger, satiety, and energy expenditure. The daily dose is 1 to 3 mg daily, given subcutaneously, and results in weight loss of 12% to 25% over 1 year in a small, uncontrolled study of patients with these rare deficits. Common adverse effects include injection site reaction and nausea. Setmelanotide is FDA approved for patients 6 years and older with proopiomelanocortin (POMC) deficiency, proprotein subtilisin or kexin type 1 deficiency, and leptin receptor deficiency confirmed by genetic testing.

**Phentermine** is a central noradrenaline uptake inhibitor but also nonselectively inhibits serotonin and dopamine reuptake and reduces appetite. Recommended doses include 7.5 mg, 15 mg, 30 mg, or 37.5 mg, and adverse effects include elevated BP, dizziness, headache, tremor, dry mouth, and stomachache. Adverse effects are dose-dependent; however, effectiveness does not always increase with increasing dose. Phentermine is FDA approved for short-course therapy (3 months) for adolescents 16 years or older.

**Topiramate** is a carbonic anhydrase inhibitor and suppresses appetite centrally through largely unknown mechanisms. The major adverse effect is cognitive slowing, which can interfere with academic concentration or other activities of daily living. In addition, topiramate is a potential teratogen and requires counseling and reliable birth control for patients able to become pregnant. Typical dosing for headache prevention ranges from 25 mg a day to 100 mg a day in twice daily doses. Although topiramate has an indication for treatment of binge eating disorder in adults (age ≥ 18), only 1 study has evaluated the use of topiramate in children, and it did not differ from placebo. Topiramate is currently FDA approved for children 2 years and older with epilepsy and for headache prevention in children 12 years and older.

**Phentermine and topiramate** as a combination medication is approved for weight loss in adults. Recent data show that among adolescents 12 to 17 years of age with documented history of failure to lose sufficient weight or failure to maintain weight loss in a lifestyle modification program (mean age, 14 years; mean BMI, 37.8 kg/m²), BMI percent change at 56 weeks was -10.44 (high dose; 15 mg/92 mg) and -8.11 (mid dose; 7.5 mg/46 mg) as compared with placebo. Treatment also improved HDL and TG cholesterol profiles. Adverse events reported were not more common than placebo in the high- or mid-dose range.

**Lisdexamfetamine** is similar in mechanism to phentermine and is a stimulant-class medication approved for children 6 years and older with ADHD. It has an indication for treatment of binge eating disorder in patients 18 years and older; thus, it is used off-label for children with obesity. However, no evidence is available at the time of this review to demonstrate safety or efficacy for the indication of obesity in children.

**Prescriber Qualifications**

Weight loss medications require the same oversight and expertise in management as other medications used in pediatric care. To adequately inform patients and parents about the risks and benefits of off-label or experimental use of new therapies, pediatricians and other PHCPs who prescribe weight loss medications should have knowledge of the patient selection criteria, medication efficacy, adverse effects, and follow-up monitoring guidelines. In addition, injectable medications may require additional teaching for families that is not available in all primary care offices. Pediatricians and other PHCPs may choose to refer to pediatric obesity experts or treatment centers for prescribing weight loss medication.

No current evidence supports weight loss medication use as a monotherapy; thus, pediatricians and other PHCPs who prescribe weight loss medication to children should provide or refer to intensive behavioral interventions for patients and families as an adjunct to medication therapy.

**J. Pediatric Metabolic and Bariatric Surgery**

It is widely accepted that the most severe forms of pediatric obesity (ie, class 2 obesity; BMI ≥ 35 kg/m², or 120% of the 95th percentile for age and sex, whichever is lower) represent an "epidemic within an epidemic." Moreover, severe obesity is a harbinger of the establishment and cumulative progression of numerous related comorbidities, diminished long-term health status, and shortened life expectancy. For adults, the evidence supporting the clinical indications and associated recommendations on the use of metabolic and bariatric surgery are well documented.
surgery is founded on a body of literature that has been expanding since the early 1960s. Corresponding analyses related to the use of various surgical weight loss procedures in pediatric populations have been primarily established in the last 20 to 30 years. Large contemporary and well-designed prospective observational studies have compared adolescent cohorts undergoing bariatric surgical treatment versus intensive obesity treatment or nonsurgical controls. These studies suggest that weight loss surgery is safe and effective for pediatric patients in comprehensive metabolic and bariatric surgery settings that have experience working with youth and their families. Laparoscopic Roux-en-Y gastric bypass and vertical sleeve gastrectomy are both commonly performed in the pediatric age group and result in significant and sustained weight loss, accompanied by improvements and/or resolution of numerous related comorbid conditions. Laparoscopic adjustable gastric band procedures, approved by the FDA only for patients 18 years and older, have declined in use in both adults and youth because of worse long-term effects as well as higher-than-expected complication rates. Similar to the adult experience, an expanding body of data shows that pediatric bariatric patients also experience durable reduction in BMI, as well as significant improvement and/or complete amelioration of several obesity-related comorbid conditions. These include HTN, T2DM, dyslipidemia, cardiovascular disease risk factors, and weight-related quality of life. Furthermore, recent evidence showing that adolescents had a higher probability of remission of certain cardiometabolic risk factors (T2DM and HTN) compared with adults highlights the argument that earlier surgical intervention may impart specific advantages related to the cumulative impact of chronic obesity-related diseases. The significantly lower magnitude of efficacy of intensive behavioral interventions—compared with larger and more durable improvements in BMI and comorbidity resolution after metabolic and bariatric surgery—has led to a significant increase in pediatric bariatric surgical case volume since the early 2000s. The majority of complications following metabolic and bariatric surgery in the pediatric population are minor (15%), occur mostly in the early postoperative timeframe, and consist of a combination of postoperative nausea and/or dehydration, although major perioperative (30-day) complications have been reported in 8% of individuals. Subsequent related procedures may be required in 13% to 25% of patients up to 5 years following metabolic and bariatric surgery. In addition, recent data showing multiple micronutrient deficiencies following metabolic and bariatric surgery serve to highlight the need for routine and long-term monitoring.
TABLE 20 Criteria for Pediatric Metabolic and Bariatric Surgery

| Class 2 obesity, BMI ≥ 35 kg/m² or 120% of the 95th percentile for age and sex, whichever is lower | Clinically significant disease, examples include but are not limited to T2DM, IH, NASH, Blount disease, SCFE, GERD, obstructive sleep apnea (AHI >5), cardiovascular disease risks (HTN, hyperlipidemia, insulin resistance), depressed health-related quality of life. Not required but commonly present. |
| Class 3 obesity, BMI ≥ 40 kg/m² or 140% of the 95th percentile for age and sex, whichever is lower | |

AHI, apnea-hypopnea index.

Although the determination of eligibility for metabolic and bariatric surgery relies heavily on a multicomponent and individualized approach between members of the metabolic and bariatric surgery team, the patient, and the patient’s parents or guardians, initial steps toward consideration should be provided, when appropriate, within the medical home. Specifically, pediatricians and other PHCPs should be familiar with recent and clearly defined clinical and anthropometric benchmarks, which serve as a prompt for the initiation of these discussions with the patient and family and ongoing bilateral communication between the medical home and surgical center.

(Table 20). In addition to knowledge of indications for metabolic and bariatric surgery, pediatricians and other PHCPs should build and maintain skills in discussing this topic with families in a nonbiased and sensitive manner. Pediatricians and other PHCPs should also seek to establish a local and/or regional referral mechanism to qualified facilities that offer pediatric-focused metabolic and bariatric surgical services.

Individual determination of eligibility status at the time of referral to a center that offers metabolic and bariatric surgical intervention for the pediatric population involves a comprehensive and multidisciplinary assessment of longitudinal BMI and comorbidity status as well as physiologic and psychosocial assessment, including the determination of potential contraindications such as correctable causes of obesity, ongoing substance use disorder, and pregnancy. Important elements include the ability to determine the patient’s and family’s capacity to understand the risks and benefits of metabolic and bariatric surgery and adhere to required lifestyle modifications leading up to and following such intervention. The evaluative process is rooted in a framework of thoughtful, shared decision making between the patient, parents(s) and/or guardian(s), and medical and surgical providers and ideally includes coordinated and ongoing communication with the patient’s medical home.

A referral to a comprehensive metabolic and bariatric surgery center with experience and expertise in treatment of patients younger than 18 years does not necessarily mean the child will ultimately have surgery. This referral provides the family with important information and additional evaluation of risks and benefits for use in making an informed decision. In the case of younger children, recommendations for referral to a comprehensive multidisciplinary obesity treatment center with surgical capability should be considered on a case-by-case basis.

Although data addressing surgical intervention in the younger age group are limited, recent comparative analysis show sustained efficacy and similar safety profiles when compared with adolescents. Additional research is needed before broad recommendations can be made for children 12 years and younger.

Age is not the sole determinant of eligibility for metabolic and bariatric surgery. The pediatrician or other PHCP should take into account the patient’s physical and psychosocial needs. Evaluation for metabolic and bariatric surgery should include a holistic view of the patient and family, including individual and social risk factors. Families should be fully informed of the benefits and risks of metabolic and bariatric surgery, and their preferences are paramount. As highlighted in a recent AAP policy statement, the decision to continue care with a pediatrician or pediatric medical or surgical subspecialist should be made solely by the patient (and the family, as appropriate).

Insurance authorization is a key consideration for individuals considering metabolic and bariatric surgical intervention regardless of age; however, data highlight a significant disparity regarding benefit coverage when comparing pediatric versus adult populations. Efforts to determine coverage availability, including potential mitigation strategies designed to address coverage gaps, should be the focus of early discussions between the family, medical home, and metabolic and bariatric surgical specialty providers. Children and adolescents who are referred for evaluation for metabolic and bariatric surgery should have this referral visit covered, and those who are deemed eligible for metabolic and bariatric surgery...
should have their preparation visits, the surgery itself, hospitalization, postoperative visits, and ongoing care covered.

**K. Comprehensive Obesity Treatment (COT) for Children and Adolescents**

The essential components of COT of children and adolescents include treatment of the obesity as a chronic disease and evaluation and management of comorbidities. This treatment is delivered by primary care providers and their teams, in collaboration with pediatric obesity specialists, allied health providers, community partners, and metabolic and bariatric surgery teams.

**COT:** COT includes:

- Providing intensive, longitudinal treatment in the medical home
- Evaluating and monitoring child or adolescent for obesity-related medical and psychological comorbidities
- Identifying and addressing social drivers of health
- Using nonstigmatizing approaches to clinical treatment that honor unique individual qualities of each child and family
- Using MI that addresses nutrition, physical activity, and health behavior change using evidence-based targets for weight reduction and health promotion
- Setting collaborative treatment goals not limited to BMI stabilization or reduction, including goals that reflect improvement or resolution of comorbidities, quality of life, self-image, and other goals related to holistic care
- Integrating weight management components and strategies across appropriate disciplines, which can include intensive health behavior and lifestyle treatment, with pharmacotherapy and metabolic and bariatric surgery if indicated
- Tailoring treatment to the ongoing and changing needs of the individual child or adolescent and the family and community context

Who delivers COT? Ideally, primary care teams and pediatric weight management specialty teams will partner to provide COT for children and adolescents with obesity. Primary care providers evaluate for obesity, evaluate for comorbidities, and provide patient-centered and evidence-based nutrition and physical activity guidance, using MI. Some primary care practices may also be able to provide IHBLT and pharmacotherapeutic options. IHBLT, regardless of where it is delivered, requires the allocation of significantly more time and resources than are typical in the provision of routine well childcare. Coordination in the medical home with additional professionals, such as dietitians, exercise specialists and behavioral health practitioners, will depend on the child’s COT plan and available resources. Pediatric health care providers can augment COT with referral to community resources and programs (see algorithm in Appendix 1).

**XII. SYSTEMS OF CARE FOR CHILDREN WITH OVERWEIGHT AND OBESITY**

Obesity is a chronic disease—similar to asthma and diabetes. Children and adolescents with obesity have the potential to benefit from the foundational standards for systems of care designed for children and youth with special health care needs. CYSHCN are defined as “those who have or are at increased risk for a chronic physical, developmental, behavioral, or emotional condition and who also require health and related services of a type or amount beyond that required by children generally.” The principles of the chronic care model and the medical home that can also benefit children with obesity include the following:

**A. Provision of Evidence-based Care**

All care provided to children and youth with obesity and their families should be evidence based where possible; where evidence-based approaches do not exist, care should be evidence informed and/or based on promising practices.

As pediatric obesity becomes an increasing public health issue and recognizable chronic disease, it becomes critical to rely on evidence-based medicine and or expert recommendations to establish prevention, assessment, and treatment of obesity. To date, several guidelines have been developed and updated to address obesity in children. Examples include “Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline,” and “Expert Committee Recommendations Regarding the Prevention, Assessment, and Treatment of Child and Adolescent Overweight and Obesity.” These guidelines have been critical in moving forward with the prevention, assessment, and treatment of obesity in children as new research is conducted and more new evidence becomes available. This CPG adds to this body of knowledge.

**B. Partnership With Children and Families**

Children and families of children and youth with obesity should be active and core partners in decision making in all levels of care.

Patient-centered care involves not only an understanding of the family’s social and cultural context but also an appreciation for their desires as decisions are made about obesity treatment. Family desire for treatment should not be assumed despite attendance at primary care or
specialty weight management visits. Pediatricians’ and other PHCPs’ use of MI techniques can, however, reinforce the importance of family-driven treatment decisions and foster families’ internal motivation that can sustain treatment. As a relationship is built with the family, MI can form the foundation for shared decision making between pediatricians (and other PHCPs) and families about treatment continuation and intensification.751

The advent of parent and patient EHR portals has enabled bidirectional communication between families and health care teams and can facilitate shared decision making in obesity treatment. Additional facilitators may include tools featuring direct input from families, such as care plans and care coordination agreements.752 A patient decision aid to promote shared decision-making about options for adolescent severe obesity treatment was found to be feasible and acceptable by pediatricians (and other pediatric health care providers) and families.753

C. Provision of Health Care That Recognizes Cultural Values

All services and supports for children and youth with obesity and their families should be implemented and delivered in a linguistically appropriate and accessible manner that recognizes cultural values.

All written materials provided to children and youth with obesity and their families should be culturally appropriate and in a manner and format appropriate for children and their parents or caregivers who have limited English proficiency, lower levels of literacy, or sensory impairments. With families with limited English proficiency, vigilance is needed to also provide a trained interpreter and use growth charts in educating about obesity.754

D. Medical Home

**Children With Obesity Should be Cared for in a Medical Home**

The benefits of a medical home for children and youth with obesity include streamlined care, efficient use of resources (home-, school-, and community-based services), expanded expertise and competence for the involved providers, establishment of a forum for problem solving, and improved satisfaction for the patient, family, and provider. Primary care providers can help identify children early as obesity is developing and base intervention efforts on family dynamics and reduction in high-risk dietary and activity behaviors.755

Linkages should also be established between primary care practices and obesity treatment clinics to coordinate care with obesity specialists when necessary (eg, psychologist, dietitian, physician). The medical home also provides an effective model for implementing successful transitions to adult-oriented systems to treat obesity.

E. Transition to Adult Primary Care Providers

**Children and adolescents with obesity should have a plan for a transition of care to adult primary care providers.**

Transition of care for children with obesity to adult primary care providers is an important field for which evidence and recommendations have been developing. Generally, the concept of transition of care highlights the importance of the collaboration of the primary and/or subspecialty pediatric, adolescent, or family medicine care team, with the adult provider who is preparing to assume the role of primary care provider for a young adult. The importance of a formal transition plan has been shown in children with diabetes mellitus, sickle cell disease, and congenital heart disease.468,756–762 Specifically, transition of care plans have been shown to improve knowledge and self-efficacy and help to integrate the young adult into a new medical home or neighborhood.757,761,763,764

The transition of care literature for childhood obesity is limited but growing.752,765,766 In general, transition of care for obesity involves the development of specific goals and a timeline for the transition.759 This also includes the development of a registry type system to track and alert pediatricians and other PHCPs when a child reaches the age of 12 years so that outreach to the family to start the transition process can occur.468,762,763 It is generally understood that timing of these discussions and the actual transition of care to an adult primary care provider(s) or team depends on the individual needs of the patient and family as well as developmental and neurocognitive abilities. It is also understood that these discussions should be ongoing, at least annually. It is highly recommended that the providers and teams should be in direct communication with each other. Peer support groups are also highly recommended to assist the patient and family and to provide a peer network as part of the medical home.752,767

The complex nature of obesity management and care, including the structured changes involved in behavioral strategies, the connection with community-based programs, and the need for medication therapy and surgery for a number of children and adolescents with obesity highlights the importance of a coordinated transition plan, frequent communication with the
XIII. BARRIERS AND RECOMMENDATIONS FOR CPG IMPLEMENTATION

Pediatricians and other PHCPs and families face numerous barriers to promoting healthy, active lifestyles and to supporting obesity treatment among children. The successful implementation of this CPG into routine practice requires careful consideration of barriers and facilitators at the policy, community, practice, and provider level that can modify implementation, effectiveness, and sustainability.

A. Policy Level

At the forefront of the policy-level barriers to the implementation of these guidelines are both direct and indirect costs that are associated with recommended evaluation and effective treatment of obesity. In 2010 and again in 2017, the USPSTF designated a grade B classification for evidence of effectiveness of childhood obesity screening and high-intensity, family-based behavioral treatment.79 Although a grade B designation should secure reliable insurance payment under the statutes of the Affordable Care Act, the lack of payment by insurers remains a major barrier to childhood obesity treatment.769,770 There is currently no consistent coverage of other evidence-based treatment strategies not explicitly included in the USPSTF recommendation.

Direct costs to families include payment for obesity evaluation and treatment that insurers do not pay for, as well as insurance plans with high deductibles or copays. These cost barriers make it difficult for families to access care, obtain laboratory testing, attend follow-up visits, and initiate and/or complete treatment programs. Differences in payment policies between public and private insurers and restrictive provider networks can make it challenging for pediatricians and other PHCPs to achieve consistent management practices. The overall lack of financial support from either insurance companies or families’ inability to pay for treatment programs disincentivizes the expansion of their availability, and there have not been robust studies on best practices for scaling up and sustaining effective treatment programs.

For patients and families, efforts to implement the recommendations for behavior change are also associated with indirect costs (such as time and costs associated with healthier foods and exercise) and are heavily impacted by policies at the federal, state, and local level. These policies include agricultural subsidies, school nutrition, and physical activity standards and curricula, zoning and public spaces to promote safe physical activity, tax deductions for direct advertising of unhealthy foods to minors, and nutrition labeling.771–773 As the recent AAP policy statement on the role of structural racism that has plagued policies manifests in the form of limited access to high-quality education, safe neighborhoods for active play, healthy food, and health care for people of certain races and ethnicities.52,774

One simulation-based cost effectiveness analysis of multiple interventions for childhood obesity found that 3 policies were estimated to be cost-saving; in other words, they would save more in health care costs through reduction in obesity prevalence than it would cost to implement.771 The policies are: (1) implementing an excise tax on SSBs; (2) elimination of the tax deduction for companies advertising unhealthy foods to children; and (3) improving nutrition standards for food and beverages sold in schools outside of meals. Another simulation study projected that an excise tax on SSBs, banning child-directed advertising of fast food, and providing after-school physical activity programs would all reduce obesity prevalence while also reducing disparities.773

Implementation Consensus Recommendation 1: The subcommittee recommends that the AAP and its membership strongly promote supportive payment and public health policies that cover comprehensive obesity prevention, evaluation, and treatment. The medical costs of untreated childhood obesity are well-documented and add urgency to provide payment for treatment.122 There is a role for AAP policy and advocacy, in partnership with other organizations, to demand more of our government to accelerate progress in prevention and treatment of obesity for all children through policy change within and beyond the health care sector to improve the health and well-being of children. Furthermore, targeted policies are needed to purposefully address the structural racism in our society that drives the alarming and persistent disparities in childhood obesity and obesity-related comorbidities.

B. Community and Population Level

At the community and population level, SDoHs can limit the implementation and prioritization of health behavior recommendations (including counseling on nutrition, physical activity, sleep, and screen time) for both pediatricians (or other PHCPs) and families. These SDoHs include food security, safe neighborhoods and housing, health
literacy, weight-related parenting skills, household chaos, and access to transportation.

Many communities lack access to evidence-based, high-intensity weight management programs for treatment, either in clinical or community-based settings. Telehealth and mobile technologies are emerging as a potential means to close this access gap, but little is known about the effectiveness of pediatric weight management treatments via these modalities. The well-described digital divide may also limit their utility among populations disproportionately impacted by obesity. A failure to consider these factors could lead to worsening disparities.

The recent iteration of the Obesity Chronic Care Model proposes an integrated framework for the prevention and treatment of obesity. The framework discusses the importance of coordinating and integrating approaches to address obesity across clinical and community systems as well as stakeholders. In doing so, an integrated approach strives to identify and address barriers to equitable implementation, access to healthier options, and data sharing. An important part of integration includes the identification of an integrator or convener that brings stakeholders together in a collaborative effort to address population health. Integrators are essential to addressing social determinants of health and complex problems that no single stakeholder can address.

Implementation Consensus Recommendation 2: The subcommittee recommends that public health agencies, community organizations, health care systems, health care providers, and community members partner with each other to expand access to evidence-based pediatric obesity treatment programs and to increase community resources that address social determinants of health in promoting healthy, active lifestyles.

C. Practice and Provider Level

At the practice and provider level, classic barriers to implementation of guidelines include the lack of time, resources, knowledge, awareness, self-efficacy (confidence in one’s ability to perform a behavior), and outcome expectancy (the belief that a recommended behavior will lead to a specific effect). Evidence indicates that clinical decision support (CDS) can be delivered through EHR systems to help overcome some of these practice- and provider-level barriers and improve evaluation and effective management. Evidence-based CDS tools include assessment components (ie, flagging abnormal heights, weights, and BMIs) and provision of suggestions for obesity treatment, such as order sets for recommended laboratory tests or other follow-up actions.

Most pediatric providers currently use EHRs that calculate and plot BMI; however, limitations of EHR systems hinder rapid dissemination and implementation of innovations to support practice.

Implementation Consensus Recommendation 3: The subcommittee recommends that EHR vendors, health systems, and practices implement CDS systems broadly in EHRs to provide prompts and facilitate best practices for managing children and adolescents with obesity.

At the same time, EHRs can only do so much and are ineffective in the absence of a clinical workforce that is knowledgeable about evidence-based obesity treatment and skilled in delivering high-quality, patient-centered care that will yield improved health outcomes for children with obesity. The recent AAP policy statement on weight stigma highlights the detrimental effects of weight bias and ineffective approaches to the diagnosis and management of obesity.

Implementation Consensus Recommendation 4: The subcommittee recommends that medical and other health professions schools, training programs, boards, and professional societies improve education and training opportunities related to obesity for both practicing providers and in preprofessional schools and residency and fellowship programs. Such training includes the underlying physiologic basis for weight dysregulation, MI, weight bias, the social and emotional impact of obesity on patients, the need to tailor management to SDoHs that impact weight, and weight-related outcomes and other emerging science.

XIV. EVIDENCE GAPS AND FUTURE RESEARCH DIRECTIONS

Research in the field of pediatric overweight and obesity has rapidly increased over the past decade and supports the evidence-based recommendations and guidelines contained in this CPG on the assessment and management of pediatric overweight and obesity. Although research has progressed in these areas, significant gaps remain and are described in detail in the accompanying technical reports. The gaps and limitations that are most relevant to pediatricians and other PHCPs treating children with obesity include duration and heterogeneity of treatment effects and limits in our understanding of how specific treatment components interact.

- Duration of treatment effects.

Limited research with long-term follow-up exists to determine:
(1) whether treatment leads to sustained weight improvements, and (2) how comorbidities develop throughout childhood. Longer-term data are needed to establish sufficient weight loss or cardiovascular improvements influencing health into adulthood.

- **Heterogeneity of treatment effects and special populations.** Current research does not provide sufficient information about the heterogeneity of treatment effects for obesity interventions, limiting our ability to identify which treatment is most likely to be effective for a specific child. Many factors may increase obesity risk and impact treatment course but are poorly isolated in studies to date. These factors may include geographical region, food insecurity, poverty, ACEs, and other social drivers. Perhaps most importantly, severity of obesity has not been clearly considered in most interventions, and treatment is likely to have different effectiveness in children with greater severity of disease. Similar to obesity research, most research on treatment and comorbidities use relatively restrictive inclusion criteria, excluding children with comorbidities (including mental health conditions), children with physical activity limitations, children with disabilities, or those using medications. In clinical practice, these children often have the greatest need for support in addressing obesity.

- **Limited understanding of specific components, dose, and duration.** Published intervention studies often provided limited information about the dose, duration, and specifics of the intervention components. This limitation makes it difficult to provide detailed information about specific intervention content, behavior change techniques, and approaches to improve retention and family motivation. Further, the limited research on potential synergies among lifestyle intervention components as well as pharmaceutical and surgical interventions prevents the development of individualized treatment plans tailored to a child’s weight and health status, motivation, and readiness.

Despite these limitations, half of the lifestyle randomized-control trials reviewed were effective in reducing adiposity. Reports of future studies detailing specific treatment components, implementation of behavioral approaches, provider involvement in clinical practice, and the socioeconomic and cultural context of the family and community are needed to better understand which interventions work, for whom, and in what situations.

In addition to these critical areas for future research, there are other limitations that should be considered in the context of the guidelines.

For comorbidity assessment, studies were mostly cross-sectional, limiting the ability to assess within-individual changes in comorbidity prevalence across age and obesity class and, therefore, guidance on the appropriate age to begin laboratory evaluation for cardiometabolic comorbidities. Epidemiologic studies intended for specific age ranges and that examine comorbidity prevalence across different levels of overweight and obesity would help identify specific ages and BMI classes with increased prevalence of cardiometabolic comorbidities to focus further research. Longitudinal studies would also help identify the optimal age and BMI ranges to begin evaluation and are needed to monitor progression of comorbidity related to age and BMI level and provide guidance on the recommended frequency of comorbidity reevaluation. Consistent thresholds of laboratory values across studies are also needed.

Although many treatment studies examined change in biomedical outcomes as markers of secondary prevention of comorbidities, few studies in primary care evaluated outcomes other than BMI. Additionally, studies that assess if comorbidity assessment and/or diagnosis influences patient and family engagement in weight management treatment are lacking. The role of SDOHs and culture in the treatment of obesity comorbidities is also limited. Studies examining motivation for behavior change related to health outcomes and inclusion of SDOH factors in treatment outcomes are needed. Finally, most studies provided no or very limited assessment of harms or unintended consequences. In general, behavioral interventions carry low-risk of harms; this is not well-documented in the existing literature, however, as few studies report adverse events.

The scope of the evidence review for this CPG did not include primary prevention of obesity or assessment and treatment of children 0 to 2 years of age. Early prevention of obesity is important, as 1 in 7 preschool-aged children already have obesity, and disparities in obesity are evident in the first years of life. Identification and guidance on treatment strategies in this population are needed. Resources for primary prevention in children of all ages and treatment of children younger than 2 years can be found on the AAP Institute for Healthy Childhood Weight’s Web site (www.ihcw.aap.org) and are also provided in the implementation materials. Future CPGs should incorporate the voices of caregivers, children or adolescents, and organizations that represent families to lend important context.
TABLE 21 List of Gaps

<table>
<thead>
<tr>
<th>Type of Gap</th>
<th>Example of Gap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiology</td>
<td>- Key drivers of reducing obesity prevalence</td>
</tr>
<tr>
<td></td>
<td>- Predictors of severe obesity</td>
</tr>
<tr>
<td></td>
<td>- Factors associated with obesity among racial and ethnic groups, including impact of SDoHs on disparities</td>
</tr>
<tr>
<td></td>
<td>- Identification of medical costs associated with obesity and comorbidities</td>
</tr>
<tr>
<td>Definition or measurement</td>
<td>- Alternative, accurate measurements of adiposity in primary care;</td>
</tr>
<tr>
<td></td>
<td>- BMI trajectories in clinical practice and response to treatment over time;</td>
</tr>
<tr>
<td></td>
<td>- BMI trajectories and development of comorbid conditions;</td>
</tr>
<tr>
<td></td>
<td>- BMI status and trajectories among race/ethnic groups and the impact of social drivers on BMI status and trajectories</td>
</tr>
<tr>
<td>Risk factors</td>
<td>- Mechanism by which maternal obesity predisposes to adverse outcomes in the offspring</td>
</tr>
<tr>
<td></td>
<td>- Impact of sedentary behavior alone on BMI and comorbidities</td>
</tr>
<tr>
<td></td>
<td>- Improved understanding of associations between obesity and food insecurity</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>- Age to begin evaluation for cardiometabolic comorbidities</td>
</tr>
<tr>
<td></td>
<td>- Frequency of evaluation to monitor progression of comorbidity</td>
</tr>
<tr>
<td></td>
<td>- Comorbidity identification as motivation for behavior change</td>
</tr>
<tr>
<td></td>
<td>- Role of social determinants of health in obesity comorbidities, especially among minority populations</td>
</tr>
<tr>
<td></td>
<td>- Role of social determinants of health in obesity comorbidities</td>
</tr>
<tr>
<td>Treatment</td>
<td>- Tailored age-based treatment approaches</td>
</tr>
<tr>
<td></td>
<td>- Evidence-based treatment options for 0-5 year-olds</td>
</tr>
<tr>
<td></td>
<td>- Optimal level of parent involvement among adolescents in weight management</td>
</tr>
<tr>
<td></td>
<td>- Optimizing MI use with respect to training, fidelity to the MI process, and potential patient characteristics</td>
</tr>
<tr>
<td></td>
<td>- Evidence for specific components of intensive lifestyle intervention on BMI trajectory in clinical practice</td>
</tr>
<tr>
<td></td>
<td>- Approaches to intensive lifestyle intervention that are most effective, including clustering of behavioral recommendations, messaging, and implementation, especially in primary care</td>
</tr>
<tr>
<td></td>
<td>- Optimal duration of treatment, including strategies to address attrition and sustainability</td>
</tr>
<tr>
<td></td>
<td>- Adverse events of treatment</td>
</tr>
<tr>
<td></td>
<td>- Treatment outcomes by age, degree of obesity, and social determinants of health</td>
</tr>
<tr>
<td></td>
<td>- Studies reporting long term outcomes are limited</td>
</tr>
<tr>
<td></td>
<td>- Paucity of published studies reporting negative outcomes</td>
</tr>
<tr>
<td></td>
<td>- Evaluation of intervention on quality of life and mental health</td>
</tr>
<tr>
<td></td>
<td>- Studies of EHR tools, including clinical decision support, to improve attention to weight, counseling, and referral</td>
</tr>
<tr>
<td></td>
<td>- Telemedicine and electronic and mobile health approaches</td>
</tr>
<tr>
<td></td>
<td>- Robust community programs with clinical linkages</td>
</tr>
<tr>
<td></td>
<td>- Cultural considerations in wt management</td>
</tr>
<tr>
<td>Systems of care</td>
<td>- Feasibility of application and benefits of recommended systems of care for CYSHCN in obesity, including care transition strategies on the adolescents’ and young adult’s improvements in the treatment of obesity and health outcomes</td>
</tr>
<tr>
<td>Barriers to and facilitators of CPG implementation</td>
<td>- Evidence informing best practices for rapid, cost-effective, and sustainable scale up of effective treatment program for childhood obesity that balance fidelity with adaptability to unique contexts</td>
</tr>
<tr>
<td></td>
<td>- Research addressing the inconclusive evidence around technology-based interventions for obesity prevention?</td>
</tr>
</tbody>
</table>

CPG, clinical practice guideline; CYSHCN, children and youth with special health care needs; EHR, electronic health record; MI, motivational interviewing.

In addition to the above, a list of other gaps and considerations for further research are provided in Table 21.

**XV. CONCLUSION—PUTTING IT ALL TOGETHER**

Pediatricians and other PHCPs now have more evidence-based tools than ever before that support obesity treatment that is effective, provides ongoing health benefits, supports children and families longitudinally, and reduces potential harms for disordered eating. In contrast to previous recommendations, these clinical guidelines highlight the urgency of providing immediate, intensive obesity treatment to each patient as soon as they receive the diagnosis of obesity.

As highlighted in the previous sections, there are Key Action Statements (KASS) that, collectively, comprise a holistic patient-centered approach to COT that should be coordinated within the context of
the medical home. These strategies form the basis for applying evidence-based approaches that take the child’s health status, family system, community context, and resources for treatment into consideration to create the best evidence-based treatment plan for each individual child. Obesity is a complex chronic disease but societal stigma around obesity results in pervasive weight bias. This makes compassionate and sensitive communication with patients and families even more imperative (see the Communication of BMI and Weight Status to Children and Parents section).

It is important to recognize that treatment of obesity is integral to the treatment of its comorbidities and overweight or obesity and comorbidities should be treated concurrently (KAS 4). It is also important to consider that a child with overweight and obesity and their family require longitudinal and coordinated care in a medical home (KAS 9) (see algorithm in Appendix 1).

Measuring BMI and assessing weight classification (KAS 1) is a screening step that is applied to a practice population of children, which allows the pediatrician and other PHCP’s to initiate obesity evaluation. This evaluation is guided by a comprehensive history, physical examination, and diagnostic studies, including those for SDoHs, disordered eating, and mental and behavioral health (KAS 2). Overall guidance for evaluation of comorbidities is that in children 10 years and older, pediatricians and other PHCPs should evaluate for lipid abnormalities, abnormal glucose metabolism, and abnormal liver function in children and adolescents with obesity (BMI ≥ 95th percentile) and for lipid abnormalities in children and adolescents with overweight (BMI 85th to <95th percentile).

For younger children or children who are overweight, the recommendations are more conservative. In KAS 3.1, for children 10 years and older with overweight (BMI 85th to <95th percentile), pediatricians and other PHCPs may evaluate for abnormal glucose metabolism and liver function in the presence of risk factors for T2DM or NAFLD. In children 2 through 9 years of age with obesity (BMI ≥ 95th percentile), pediatricians and other PHCPs may evaluate for lipid abnormalities. In addition to laboratory evaluation, pediatricians and other PHCPs should evaluate for hypertension by measuring blood pressure at every visit starting at 3 years of age in children and adolescents with overweight and obesity (KAS 8). More specific guidance for further evaluation for each comorbidity is included in the Appendices, along with discussion of other obesity-related comorbidities.

The purpose of the evaluation is to determine the child’s individual health status, including the presence and extent of obesity related comorbidities, obesity risk factors present in the child’s history and environment, and the resources available to the family to conduct obesity treatment. Most importantly, comorbidities must be addressed concurrently with treatment of obesity (KAS 4).

MI is a collaborative approach to conversation about change that is a core component of delivering of COT, including engaging patients and families in addressing overweight and obesity (KAS 10), setting goals, and promoting participation in available resources and programs. Providing or referring to intensive IHBLT, as described in KAS 11, is a foundational aspect of COT. Pediatricians and other PHCPs should provide or refer children 6 years and older and may provide or refer children 2 through 5 years with overweight and obesity to IHBLT. IHBLT is more effective with greater contact hours; the most effective programs include 26 or more hours of face-to-face, family-based, multicomponent treatment over a 2- to 12-month period. IHBLT provides ongoing behavioral and lifestyle support to the child and family and treatment of obesity-related comorbidities.

Delivering IHBLT requires being able to address nutrition and activity in a holistic manner, using a family-centered and nonstigmatizing approach that acknowledges structural and contextual drivers of obesity and follows the principles of the chronic care model and medical home, in the same manner as other special health care needs (KAS 9). IHBLT should be delivered by primary care providers and their teams, in collaboration with pediatric obesity specialists, allied health providers, and community partners. If IHBLT is not available, the pediatrician or other PHCP should deliver the highest-intensity HBLT possible. In addition, the pediatrician or other PHCP serves as a medical home for the patient, coordinating care, advocating for the patient and family, and supporting transition to adult care.

Concurrent treatment of obesity and obesity-related comorbidities is crucial as is the provision of weight loss pharmacologic treatment and metabolic and bariatric surgery to patients according to indications, risks, and benefits of these modalities. Weight loss pharmacotherapy and metabolic bariatric surgery are evidence-based obesity treatment modalities that
should be available and offered to patients when indicated and should always occur along with IHBLT. Pediatricians and other PHCPs should offer adolescents 12 years and older with obesity weight loss pharmacotherapy, according to medication indications, risks, and benefits, as an adjunct to IHBLT (KAS 12). Pediatricians and other PHCPs should offer referral for adolescents 13 and older with severe obesity for evaluation for metabolic and bariatric surgery to local or regional comprehensive multidisciplinary pediatric metabolic and bariatric surgery centers (KAS 13; see Table 22).

Pediatricians and other PHCPs play a crucial role in providing COT as primary treatment providing COT as a first line of treatment in the management of obesity in children and adolescents. Obesity is a chronic disease with exacerbations and remissions, and children and adolescents need appropriate reassessments of medical and psychological risks and comorbidities with appropriate modifications to their treatment plan. COT also requires ongoing evaluation and capacity building of both practice and community resources that can aid the family in addressing SDoHs as needed.

O b e s i t y  i n  c h i l d r e n  a n d  a d o l e s c e n t s  i s  a  complex, multifactorial, and treatable disease. Evidence for successful treatment, despite stated gaps and complexities, gives hope to patients and families that pediatricians and PHCPs can successfully assess and address the disease of obesity with an individualized and compassionate approach. In contrast to earlier practices of watchful waiting or following a staged approach to intensifying treatment, this CPG supports early treatment at the highest level of intensity appropriate for and available to the child. It is TABLE 22 Role of the Pediatrician or PHCP

<table>
<thead>
<tr>
<th>Focus</th>
<th>Role of the Pediatrician or PHCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis and measurement</td>
<td>- Measure height and weight&lt;br&gt;- Calculate BMI and assess BMI Percentile&lt;br&gt;- Communicate BMI and weight status to patient and family</td>
</tr>
<tr>
<td>Risk factors</td>
<td>- Assess individual, structural, and contextual risk factors</td>
</tr>
<tr>
<td>Evaluation</td>
<td>- Perform comprehensive patient history&lt;br&gt;- Conduct physical exam&lt;br&gt;- Evaluate for comorbidities&lt;br&gt;- Order relevant diagnostic studies and laboratories&lt;br&gt;- Assess readiness to change</td>
</tr>
<tr>
<td>Treat comorbidities</td>
<td>- Treat obesity and comorbidities concurrently</td>
</tr>
<tr>
<td>Treat obesity</td>
<td>- Manage children with overweight &amp; obesity following principles of chronic care model and medical home&lt;br&gt;- Deliver nonstigmatizing care&lt;br&gt;- Use MI to engage patient and families in addressing overweight and obesity, set goals and promote participation or utilization of local resources or programs&lt;br&gt;- Promptly engage and refer children to intensive IHBLT treatment, if available. If intensive IHBLT treatment is not available in your area, deliver highest intensity IHBLT treatment possible.</td>
</tr>
</tbody>
</table>
hoped that pediatricians and other PHCPs, health systems, community partners, payers, and policy makers will recognize the significance and urgency outlined by this CPG to advance the equitable and universal provision of treatment of the chronic disease of obesity in children and adolescents.

SUBCOMMITTEE ON OBESITY
Sarah E. Hamp, MD, FAAP
Sandra G. Hassink, MD, FAAP
Ashley C. Skinner, PhD
Sarah C. Armstrong, MD, FAAP
Sarah E. Barlow, MD, MPH, FAAP
Christopher F. Bolling, MD, FAAP
Kimberly C. Avila Edwards, MD, FAAP
Ihuoma Eneli, MD, MS, FAAP
Robin Hamre, MPH
Madeline M. Joseph, MD, FAAP
Doug Lunsford, MD
Eneida Mendonca, MD, PhD, FAAP
Marc P. Michalsky, MD, MBA, FAAP
Nazarat Mirza, MD, ScD, FAAP
Eduardo R. Ochoa, Jr, MD, FAAP
Mona Sharifi, MD, MPH, FAAP
Amanda E. Staiano, PhD, MPP
Ashley E. Weedn, MD, MPH, FAAP
Susan K. Flinn, MA
Jeanne Lindros, MPH
Kymika Okechukwu, MPA

ACKNOWLEDGMENTS
We thank Pia Daniels, MPH, PPM, Program Manager, Evidence-Based Medicine Initiatives and Jeremiah Salmon, MPH, Manager, Clinical Initiatives, Institute for Healthy Childhood Weight. We also thank Brook Belay, MD, and Alyson B. Goodman, CDC liaisons to the writing committee, for their technical input.

REFERENCES


44. Kirk SFL, Ramos Salas X, Albergå A, Russell-Mayhew S. Canadian Adult Obese Clinical Practice Guidelines.
Reducing Weight Bias in Obesity Management, Practice and Policy.
Edmonton, Alberta: Canadian Association of Bariatric Physicians and Surgeons, Obesity Canada; 2020


71. Wiss DA, Brewerton TD. Adverse childhood experiences and adult obesity: a systematic review of plausible mechanisms and meta-analysis of cross-sectional studies. Physiol Behav. 2020;223:112964


73. Health Resources and Services Administration. National organizations of state and local officials: public health capacity. Available at: https://www.peds...


128. Racette SB, Yu L, DuPont NC, Clark BR. BMI-for-age graphs with severe obesity percentile curves: tools for plotting...
cross-sectional and longitudinal youth BMI data. BMC Pediatr. 2017;17(1):130


145. Freedman DS, Butte NF, Tavares EM, Goodman AB, Ogden CL, Biancik HM. The limitations of transforming very high body mass indexes into z-scores among 8.7 million 2- to 4-year-old children. J Pediatr. 2017;188:50–56.e1


158. American Medical Association. Person-first Language For Obesity. Policy H-


190. Burke MP, Martini LH, Çayır E, Hartline-Grafton HL, Meade RL. Severity of household food insecurity is
2016;146(10):2019–2026


223. Patrick H, Hennessy E, McSpadden K, Oh A. Parenting styles and practices in children’s obesogenic behaviors: scientific gaps and future research


253. Harvard University, Center on the Developing Child. Key concepts. Toxic stress. Available at: https://


349. Berkowitz RI, Moore RH, Faith MS, Stallings VA, Kral TV, Stunkard AJ. Identification of an obese eating style in 4-year-old children born at high and...
low risk for obesity. *Obesity (Silver Spring).* 2010;18(3):505–512


363. He M, Evans A. Are parents aware that their children are overweight or obese? Do they care? *Can Fam Physician.* 2007;53(8):1493–1499


375. Van Slyke J, Garber R, Crago K; Section on Foster Care, Adoption, and Neglect; Committee on Psychosocial Aspects of Child and Family Health. Trauma-informed care. *Pediatrics.* 2021;148(2):e2021052580


387. Golden NH, Schneider M, Wood C; Committee on Nutrition; Committee on Adolescence; Section on Obesity. Preventing obesity and eating disorders in adolescents. Pediatrics. 2016;138(3):e20161849.


407. Golden NH, Schneider M, Wood C; Committee on Nutrition; Committee on Adolescence; Section on Obesity. Preventing obesity and eating disorders in adolescents. Pediatrics. 2016;138(3):e20161849.


444. Reinehr T, Kleber M, Toschke AM. Life-events in adolescents with severe obesity (Silver Spring). 2020;28(3):534–540


463. Piccolo RS, Pearce N, Araujo AB, McKinlay JB. The contribution of biogeographical ancestry and socio-economic status to racial/ethnic disparities in type 2 diabetes mellitus: results from the Boston Area Community Health Survey. Ann Epidemiol. 2014;24(9):648–654, 654.e1


Ozkan B, Bereket A, Turan S, Keskin S. Addition of orlistat to conventional


75. Schultz AT, Smaldone A. Components of interventions that improve transitions to adult care for adolescents with type 1 diabetes. J Adolesc Health. 2017;60(2):133–146


